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ABSTRACT 
 
Brian Raymond Keppler:  Human Telomerase Holoenzyme Assemblage as an 
Anticancer Drug Target 
(Under the direction of Michael B. Jarstfer, Ph.D.) 
 
 
Telomerase is an RNA-dependent DNA polymerase that extends the 3’ ends of 
linear chromosomes.  Almost 90% of all cancers require telomerase activity in order to 
maintain their immortal phenotype.  This thesis describes a novel platform for human 
telomerase inhibition as an anticancer approach.  Preliminary studies included testing the 
feasibility of perturbing proper human telomerase assemblage as a means of inhibiting 
enzymatic activity.  This methodology was validated using oligonucleotides targeted at 
specific domains of the telomerase RNA subunit (hTR), which were found to inhibit 
telomerase activity in a direct assay by preventing the association of hTR with the 
telomerase protein subunit (hTERT) when added prior to assembly.  Following these 
proof-of-principle studies, this approach was further authenticated with the use of known 
nucleic acid-binding ligands.  Various compounds, including DNA minor groove binders 
and aminoglycoside antibiotics, were found to decrease telomerase activity to a greater 
extent when added prior to hTR/hTERT assembly as compared to their addition after 
hTR an hTERT were allowed to associate.   
A small library of compounds including various tanshinone natural products and 
some synthetic derivatives was tested for telomerase inhibition using the pre- and post-
assembly parallel screen.  Results indicate that the most potent inhibitor was tanshinone 
 iii
II-A.  This compound completely inhibited activity prior to assembly, however, could 
only partially inhibit activity after assembly indicating that its mode of action could be 
preventing telomerase assemblage.   
Studies here also further characterize and elucidate the roles of the telomerase-
associated protein Hsp90 and reveal that the presence of Hsp90 is unremittingly required 
in order to maintain telomerase in an active conformation.  Results show that the N-
terminus of Hsp90 may be involved in preparing telomerase for telomeric primer loading 
while the role of the C-terminus may be to stabilize the telomerase holoenzyme complex. 
This new technique of identifying novel telomerase inhibitors was converted into 
a high-throughput format.  Scintillation proximity assay technology was utilized in order 
to design and develop a screen capable of identifying compounds that perturb a specific 
interaction between hTR and hTERT.  The assay was optimized and validated using an 
oligonucleotide previously shown to preclude this interaction. 
 These studies indicate that human telomerase assemblage is a viable anticancer 
drug target.  The further development and optimization of telomerase assemblage 
exploitation methods could lead to a new class of clinically relevant telomerase 
inhibitors.   
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Chapter I.  Introduction 
 
 
A.  Telomerase 
 
1. Significance and background 
 
Cancer is a growing health problem for people all over the world.  Most cancer 
research focuses on curing or subduing a specific type of cancer (e.g. breast, prostate, lung, 
colon, etc.).  Recently, though, a large proportion of cancer cell types were found to share a 
common trait as approximately 90% of all human tumors express telomerase activity (Cong 
et al., 2002).  Telomerase, or telomere terminal transferase, is a ribonucleoprotein complex 
responsible for the maintenance of telomeric DNA.  Telomeres are DNA-protein complexes, 
which posses a 3' single-stranded overhang of short, repeated, guanosine-rich sequences (5'-
TTAGGG for humans).  Human telomerase is composed minimally of a protein (hTERT) 
and an RNA (hTR) subunit (Feng et al., 1995; Meyerson et al., 1997; Nakamura et al., 1997).  
The RNA subunit is used as a template for the G-rich sequence addition while the protein 
subunit employs its reverse transcriptase activity to extend telomeric DNA (Figure 1.1). 
Telomerase activity is extinguished in most human tissues during embryonic 
development (Wright et al., 1996b), however, certain cells in the human body express 
telomerase activity through all stages of life such as germline cells and some stem cells 
(Cong et al., 2002).  Most normal healthy human somatic cells, on the other hand, are 
deficient in telomerase activity.  The telomeres of these somatic cells therefore undergo 
telomere shortening after each cell cycle as the result of the end-replication problem 
(Olovnikov, 1971; Watson, 1972).  When a cell's telomeres get too short, the cell will either 
senesce or enter crisis and die.   The majority of  cancerous cells,  however,  can escape crisis 
5’- GGTTAGGGTTAGGGTTAG
3’- CCAAT UCCCAAUC
3’ 5’
5’- GGTTAGGGTTAGGGTTAGGGTTAG
3’- CCAAT UCCCAAUC
3’ 5’
5’- GGTTAGGGTTAGGGTTAGGGTTAG
3’- CCAAT UCCCAAUC
3’ 5’
5’- GGTTAGGGTTAGGGTTAGGGTTAGGGTTAG
3’- CCAAT UCCCAAUC
3’ 5’
Telomere with single-
stranded 3’ overhang
Telomerase RNA 
template
Telomerase Reverse 
Transcriptase
Telomere Extension
Translocation
Telomere
Extension
 
 
Figure 1.1 Mechanism of telomerase-mediated telomere extension. The telomerase reverse 
transcriptase (hTERT) and the telomerase RNA (hTR) work together to extend the 3’ end of the 
telomere.  Nucleotides added to the telomere by telomerase are bold.  This figure was adapted from 
White et al., 2001.   
 
 
 
 
 
by up-regulating telomerase expression (White et al., 2001) (Figure 1.2).  As a result, 
telomerase promotes tumorigenicity in part by helping maintain telomeric DNA length.  
Importantly, inhibiting telomerase activity in cancer cells causes telomere shortening and 
cessation of cell growth (Hahn et al., 1999).  The successful exploitation of this common trait 
could therefore lead to the development of a universal anticancer agent based on inhibiting 
telomerase activity.   
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Figure 1.2 Telomere length versus time for different cell types.  Germline cells constitutively express 
telomerase activity and thus their telomeres do not decrease in length over time.  Most normal somatic cells do 
not express telomerase and thus their telomeres decrease in length over time.  The telomeres of certain stem 
cells also decrease in length over time, but at a slower rate than that of most normal somatic cells because they 
express low levels of telomerase activity.  Though the administration of a telomerase inhibitor to the human 
body would affect all telomerase-positive cells, the cancerous cells would die off first before the healthy cell's 
telomeres get critically short.  This figure was adapted from White et al., 2001. 
 
  2. The catalytic subunit of human telomerase, hTERT (human Telomerase    
    Reverse Transcriptase 
 
The hTERT gene, discovered in 1997 (Harrington et al., 1997; Kilian et al., 1997; 
Meyerson et al., 1997; Nakamura et al., 1997), is found on the short arm of chromosome 5 
(5p15.33).  The hTERT protein is 1132 amino acids in length and contains a number of 
distinguishable features including reverse transcriptase motifs within the C-terminal half of 
the gene, a conserved telomerase-specific region (T-motif) located just 5' of the reverse 
transcriptase motifs, and a large N-terminal region (Cong et al., 2002; Harrington, 2003).  
The telomerase catalytic subunits from different organisms represent a distinct subgroup 
within the reverse transcriptase family (Cong et al., 2002).  Their reverse transcriptase motifs 
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are phylogenetically conserved with other reverse transcriptases, but are more closely related 
within their own subgroup than with other members of the reverse transcriptase family 
(Eickbush, 1997; Nakamura et al., 1997; Nakamura and Cech, 1998).   The T-motif has been 
found to be required for hTR binding in vitro (Bryan et al., 2000) and is also thought to be 
involved in the recruitment of hTERT to the nucleolus, which has been proposed to be an 
important step in telomerase biogenesis (Etheridge et al., 2002; Bosoy et al., 2003).  The 
large N-terminal region contains conserved residues that are functionally important for hTR 
binding, telomerase complex assemblage, and catalysis, as well as a number of other 
functions (Cong et al., 2002; Harrington, 2003). 
 Importantly, hTERT expression usually correlates closely with telomerase activity, 
cancer initiation, progression, and metastasis (Cong et al., 2002).  In fact, while hTR and 
other required subunits of the telomerase holoenzyme are ubiquitously expressed in most 
cells, many independent studies have shown that hTERT is the limiting determinant of 
telomerase activity (Meyerson et al., 1997; Weinrich et al., 1997; Ito et al., 1998; Kanaya et 
al., 1998; Nakayama, J. et al., 1998; Takakura et al., 1998).  Furthermore, elevated 
telomerase levels oftentimes directly correlate with poor tumor prognosis and vice versa, 
though this is not the case for all cancer cell types (Granger et al., 2002). 
 The hTERT gene contains 16 exons and 15 introns and can be differentially spliced 
(Kilian et al., 1997) to generate both the full-length protein as well as multiple splice 
variants, however, only the full-length transcript has been found to correlate with telomerase 
activity (Ulaner et al., 1998; Ulaner et al., 2000).  Although the expression of the variants is 
deliberate and may serve a dominant negative function, the role of the alternately spliced 
hTERT mRNAs remains unknown (Ulaner et al., 2001).   
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3. The RNA subunit of human telomerase, hTR (human Telomerase RNA) 
 
hTR was the first core component of human telomerase to be cloned (Blasco et al., 
1995; Feng et al., 1995).  Unlike hTERT, hTR is typically expressed ubiquitously in most 
tissues, even those lacking telomerase activity (Blasco et al., 1995; Avilion et al., 1996; 
Harrington, 2003).  The mature human transcript is 451 nucleotides long and is transcribed 
by RNA Polymerase II (Feng et al., 1995).   
Extensive comparative phylogenic analysis of the vertebrate telomerase RNA allowed 
a proposed secondary structure of hTR (Chen, J. L. et al., 2000).  Vertebrate telomerase 
RNAs contain several conserved regions including the template-containing pseudoknot 
domain  and  the  CR4-CR5  domain  (Figure 1.3).     Previous  studies  have  shown  that  the    
P6
P6.1 CR4-CR5 Domain
Hypervariable 
Paired Region
L6
Pseudoknot Domain
       (CR2/CR3)
P3
Template (CR1)
Box H/ACA Domain 
        (CR6/CR8)
CR7 Domain
P1
5’
3’
46
209
243  328
 301
 322
174 195
 
 
 
Figure 1.3 Human telomerase RNA.  Conserved regions (CR) of hTR are indicated.  Pairing regions (P) 
indicated include the P3 pairing region, which is part of the pseudoknot domain, and the P6.1 stem-loop, 
which is part of the CR4-CR5 domain.  Arrows indicate nucleotides that are referred to in the text.  This 
structure was adapted from Chen, J.L. et al., 2000 and 2002. 
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 pseudoknot and CR4-CR5 domains are essential for telomerase activity and interact 
separately with hTERT (Tesmer et al., 1999; Beattie et al., 2000; Mitchell and Collins, 2000; 
Bachand and Autexier, 2001; Martin-Rivera and Blasco, 2001; Chen, J. L. et al., 2002b; 
Chen, J. L. and Greider, 2003).  In addition, Chen et al. revealed the presence of an additional 
secondary structure within the CR4-CR5 domain of hTR, the P6.1 stem-loop (nucleotides 
302-314), which appears to be essential for telomerase activity as well as for binding to 
hTERT (Chen, J. L. et al., 2002b).  The roles of hTR were further extended by the work of 
Ly et al. (Ly et al., 2003) and Ren et al. (Ren et al., 2003).  Ly et al. showed that hTR can 
homo-dimerize via the P3 pairing region to form a trans-pseudoknot and that mutations 
preventing the P3-trans interaction led to loss of enzymatic activity but did not appear to 
prevent binding of hTR to hTERT (Ly et al., 2003).  Similarly, Ren et al. propose that hTR 
can homo-dimerize via the internal loop J7b/8a within the CR7 domain to form a "kissing 
complex," which may be functionally important for hTR accumulation and telomerase 
holoenzyme assemblage in vivo (Ren et al., 2003).  Theimer et al., however, reported 
evidence contradictory to the previously proposed hTR dimerization models (Theimer et al., 
2005).  Using NMR spectroscopy to solve the solution structure of a fragment of the human 
telomerase RNA pseudoknot they showed that telomerase activity actually correlates with the 
presence of a conserved pseudoknot tertiary structure and not with pseudoknot-mediated hTR 
dimerization (Theimer et al., 2005). 
 
4. Telomere structure and function  
The human telomere ranges in length from 5-15 kilobases (White et al., 2001) of the 
repeated sequence 5'-TTAGGG/AATCCC and 75-600 nucleotides of a 3' single-stranded 
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overhang (McElligott and Wellinger, 1997; Wright et al., 1997).  Telomeric DNA, which is 
not replicated efficiently by the normal DNA replication machinery, is lost at a rate of 50-100 
base pairs per cell cycle in cells with limited telomerase activity.  With the help of various 
specialized telomere-binding proteins, such as TRF1, TRF2 and Pot1, the single-stranded 
portion of the telomere can be inserted into the double-stranded portion to form what is 
called a t-loop (Griffith, J. D. et al., 1999).  The telomeric repeat binding factors, TRF1 and 
TRF2 (van Steensel and de Lange, 1997; van Steensel et al., 1998; Griffith, J. D. et al., 1999; 
Smogorzewska et al., 2000; Stansel et al., 2001), bind to the double-stranded region of the 
telomere while Pot1 (protection of telomeres) (Baumann and Cech, 2001; Colgin et al., 2003; 
Loayza and De Lange, 2003) binds to the single-stranded region and plays a critical role in 
both t-loop integrity and regulating telomere length.  The t-loop therefore appears to function 
as a protective "cap" to guard the telomere from degradation, chromosome end-to-end 
fusions and mistaken DNA repair (Griffith, J. D. et al., 1999; Cong et al., 2002).  Though 
telomere shortening has been found to induce cellular senescence, it is actually the disruption 
in the telomeric capping structure that alters the cell's replicative potential (Karlseder et al., 
2002).  In other words, when a cell's telomeres get too short the t-loop cannot form and a 
signal triggers the cell to enter senescence.  Therefore, telomere capping is extremely 
important for cell viability as loss of capping can lead to genetic instability and cell death 
(Rhodes et al., 2002).   
 
5.  Telomerase-associated proteins 
Though human telomerase is minimally composed of hTR and hTERT, there are 
other proteins that associate with the holoenzyme and are required for in vivo telomerase 
regulation and activity (Cong et al., 2002).  The active telomerase complex is actually a 
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multi-subunit holoenzyme containing hTERT, hTR, Hsp90, p23, Hsp70, p60 and Hsp40/ydj, 
Ku, TEP1 and dyskerin, as well as other telomerase-associated proteins (Forsythe et al., 
2001; Cong et al., 2002; Harrington, 2003).  The addition of these and other factors to in 
vitro experiments, however, is not necessary when expressing hTERT in reticulocyte lysate 
as the reticulocyte lysate already contains these factors (Holt et al., 1999; Cong et al., 2002).   
 
 a. Hsp90 
The molecular chaperone Hsp90, which directly associates with hTERT, has a 
demonstrable role in establishing telomerase activity both in vitro and in vivo, and previous 
reports indicate that Hsp90 is required for the reconstitution of telomerase activity from 
recombinant hTERT and hTR (Holt et al., 1999).  Hsp90, perhaps the most abundant 
housekeeping protein, is believed to account for almost 2% of all cytosolic proteins.  The 
human chaperone exists as two isoforms, Hsp90α and Hsp90β, which share 85% identity, 
however, no functional differences have been identified (Hickey et al., 1986).  The main 
function of Hsp90 is to stabilize its clients in denaturing environments and times of stress, 
however, the unwavering involvement of this heat shock protein in membrane translocation, 
turnover, folding and activation of numerous targets reveals a much larger responsibility.  
Hsp90 is highly conserved in both prokaryotes and eukaryotes, and its client list includes 
proteins involved in signal transduction (Richter and Buchner, 2001; Pratt and Toft, 2003), 
steroid receptors (Cheung and Smith, 2000; Kimmins and MacRae, 2000; Smith, 2000; 
Bledsoe et al., 2002), kinases (Rose et al., 1987; Matts and Hurst, 1989; Stancato et al., 1993; 
Palmquist et al., 1994; Wartmann and Davis, 1994; Jaiswal et al., 1996; Sato et al., 2000; 
Pratt and Toft, 2003) and reverse transcriptases (Hu and Seeger, 1996; Holt et al., 1999), as 
well as many others (Pratt and Toft, 2003).   
 8
 
i. Structure and function 
 
The Hsp90 protein consists of three main domains; the N-terminus, the C-terminus 
and a central charged region.  The N-terminal of Hsp90 is the most conserved and therefore 
the most studied domain in the chaperone (Prodromou et al., 1997).  Though the C-terminal 
portion of Hsp90 is less well understood, it has been shown to contain a dimerization domain 
that is required to achieve an active functional homodimer (Iannotti et al., 1988; Minami et 
al., 1991).  Both the N-terminal (Grenert et al., 1997; Prodromou et al., 1997; Stebbins et al., 
1997) and C-terminal (Marcu et al., 2000a; Garnier et al., 2002; Soti et al., 2002) contain 
ATP-binding pockets.  The central charged region acts as a flexible linker and is believed to 
mediate cross-talk between the two termini (Scheibel et al., 1999; Marcu et al., 2000a).  
There is also some evidence that this middle segment regulates access of nucleotides to the 
N- and C-termini by interacting with the γ-phosphate of ATP (Marcu et al., 2000a; Soti et al., 
2002; Meyer et al., 2003). 
The N-terminal pocket shares sequence homology with MutL proteins, histidine 
kinase and bacterial gyrase B, an ATP-dependent DNA topoisomerase (Dutta and Inouye, 
2000).  Hydrolyzable ATP must be able to bind to this domain in order to convert Hsp90 into 
its active conformation capable of binding client proteins and co-chaperones (Grenert et al., 
1997; Prodromou et al., 1997; Stebbins et al., 1997).  In fact, binding of a non-hydrolyzable 
ATP analog to Hsp90 or chaperone mutations resulting in the loss of ATP binding 
capabilities eradicates Hsp90 function both in vitro and in vivo (Obermann et al., 1998; 
Panaretou et al., 1998; Grenert et al., 1999).  When the N-terminal ATP binding site is 
unoccupied, the chaperone is “open” and able to bind clients.  As ATP binds, the chaperone 
changes conformation to a “closed” state and “clamps” down on its client (Prodromou et al., 
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2000; Richter et al., 2002).  In fact, it is believed that the two N-termini of the homodimer 
interact transiently upon ATP binding, and that this interaction is required for ATP 
hydrolysis (Maruya et al., 1999; Prodromou et al., 2000).  Furthermore, additional evidence 
suggests that the capturing of clients is also dependent on the participation of Hsp90-
associated co-chaperones (Wegele et al., 2004; Young et al., 2004). 
 The C-terminal of Hsp90 is responsible for holding the homodimer in an antiparallel 
arrangement (Maruya et al., 1999).  The dimer formation of this chaperone is required for 
functionality as C-terminal truncations have been shown to prevent ATP hydrolysis 
(Prodromou et al., 2000).  This terminus, like the N-terminal, is capable of binding ATP.  
Some data suggests that the C-terminal binding site only becomes available for nucleotide 
binding once the N-terminal ATP binding site is occupied (Chiosis et al., 2004).  Because 
Hsp90 exists as a dimer and both termini are capable of binding substrate, it is possible that 
the functional homodimer may be capable of binding four substrates simultaneously (Pratt 
and Toft, 2003). 
 
   ii.  Hsp90-associated proteins 
Although Hsp90 is typically the major player in chaperoning cellular activities it does 
not act alone, but rather functions in larger multi-protein complexes with accessory proteins 
and other chaperones.  One of the most important partners of Hsp90 is the acidic 
phosphoprotein p23 (Johnson and Toft, 1994).  This 23-kDa protein is known to bind to the 
N-terminal domain of ATP-bound Hsp90 (Sullivan et al., 1997; Fang et al., 1998; Chadli et 
al., 2000).  Studies have also provided evidence that additional p23 binding sites on Hsp90 
exist outside of the N-terminus though the precise locations have yet to be identified (Grenert 
et al., 1997; Chadli et al., 2000).  Like Hsp90, p23 is also required for the reconstitution of 
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active telomerase from recombinant sources (Holt et al., 1999).  The principal function of 
p23 is to suppress Hsp90’s ATPase activity and thus aid Hsp90 in binding and holding onto 
its clients by maintaining the chaperone in a closed state (McLaughlin et al., 2002; Panaretou 
et al., 2002).  The presence of p23, however, is not essential for functional assembly of 
Hsp90 complexes (Johnson and Toft, 1994; Bohen, 1998). 
 Hsp70, another cellular chaperone involved in protein folding and preventing protein 
aggregation, is another Hsp90-associated protein.  This heat shock protein binds to the C-
terminus of Hsp90 (Young et al., 1998; Carrello et al., 1999; Marcu et al., 2000a; Murphy, P. 
J. et al., 2001) and is necessary to run the ATP hydrolysis cycles of Hsp90 (Wegele et al., 
2004; Young et al., 2004).  In fact, both Hsp90 and Hsp70 are known to work in conjunction 
in order to prepare certain clients, such as steroid receptors, for ligand binding.  It is believed 
that, in the case of steroid receptors, Hsp70 first binds to the client in an ATP-dependent step 
to “prime” the receptor, followed by transfer of the client to Hsp90 in a second ATP-
dependent step, which fully activates the receptor (Morishima et al., 2001; Hernandez et al., 
2002; Kanelakis et al., 2002).  Furthermore, Hsp70 is released from the Hsp90 multi-protein 
chaperone complex during the assembly of steroid receptors (Smith, 1993).  Similarly, in the 
case of human telomerase, Hsp70 is only transiently associated while Hsp90 and p23 are 
stably associated with the holoenzyme (Forsythe et al., 2001).  As for p23, the precise 
binding site(s) for Hsp70 on Hsp90 have not been mapped out, however, recent studies are 
beginning to shed some light on this question (Young et al., 1997; Scheibel et al., 1998). 
 Evidence reveals that both Hsp70 and Hsp90 are essential components of the active 
chaperone complex while p23 is non-essential, though the presence of p23 has the potential 
to increase the kinetics of substrate binding.  There are a number of other Hsp90-associated 
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proteins that are involved in client maturation, however, they will not be discussed in detail 
here. 
 
iii.  Hsp90 and cancer 
Over-expression of Hsp90 and other heat shock proteins have been found to lead to 
poor prognosis in a variety of cancers (Jameel et al., 1992; Ciocca et al., 1993; Yano et al., 
1996; Conroy et al., 1998).  Targeting Hsp90 as an anticancer approach has therefore 
received much attention (Beliakoff and Whitesell, 2004; Chiosis et al., 2004; Workman, 
2004).  Because Hsp90 is ubiquitously expressed in all cell types, normal and cancerous, it is 
also the functions of Hsp90 and not only its presence that defines its involvement in cancer 
(Bagatell and Whitesell, 2004).  Hsp90 has been shown to stabilize mutated proteins found in 
cancer cells which contribute to apoptotic pathways.  For example, this heat shock protein 
chaperones Akt (Sato et al., 2000; Basso et al., 2002), NF-κB (Chen, G. et al., 2002a), 
survivin (Fortugno et al., 2003), Raf-MAPK (Schulte et al., 1995), Apaf-1 (Pandey et al., 
2000), IKKα/β (Lewis et al., 2000), TNF-α (Zhao and Wang, 2004) and many other clients 
to maintain transformed cells in an immortalized state.  By buffering these mutations, Hsp90 
acts as an anti-apoptotic and growth promoter contributing to tumor cell survival (Chiosis et 
al., 2004). 
Because of Hsp90’s role in so many different cancer progression pathways, it is 
hypothesized by some that inhibitors of this chaperone have the potential to induce a wide-
range of anticancer effects (Vilenchik et al., 2004).  The use of Hsp90 inhibitors as a means 
of cancer therapy, however, has revealed indiscriminate toxicity for normal and malignant 
cells as the chaperone is present in all cell types and is involved in so many cellular pathways 
(Supko et al., 1995).  Structure-activity relationship studies on Hsp90 inhibitors, combined 
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with the fact that transformed cells express higher levels of Hsp90 than normal cells, has led 
to the identification of new drugs that are selective for cancer cells and display little target-
associated toxicity (Schulte and Neckers, 1998).  It is also believed that cancer cells 
exercising Hsp90-mediated mutant protein stabilization may be more sensitive to toxicity 
than normal cells (Chiosis et al., 2004).  Furthermore, it was determined that some Hsp90 
inhibitors exhibit dose limiting toxicity (Goetz et al., 2003).  Inhibiting Hsp90 has been 
found to not only prevent stabilization, but also initiate ubiquitination of its clients, 
eventually leading to growth arrest (Xu, W. et al., 2002; McDonough and Patterson, 2003).  
Additionally, the signal transduction inhibitor hypericin causes ubiquitination of Hsp90 
leading to the release and proteasome-independent degradation of clients such as mutant p53 
(Blank et al., 2003). 
 
iv.  Hsp90 inhibition 
 
Functional activation of Hsp90 as well as substrate and client binding are not 
permanent but require multiple ATP hydrolysis cycles to maintain.  Therefore, targeting the 
ATP binding sites of Hsp90 is a widely accepted anticancer approach.   
 One class of compounds known to bind the N-terminus of Hsp90 is benzoquinone 
ansamycin antibiotics, including geldanamycin (GA) and herbimycin (Whitesell et al., 1994; 
Stebbins et al., 1997; Neckers et al., 1999; Roe et al., 1999).  The most studied of these 
compounds is GA.  Described as an ATP/ADP mimetic (Prodromou et al., 1997) or a 
competitive inhibitor of client-protein binding, GA interacts with the N-terminal ATP 
binding site, thus displacing the nucleotide (Grenert et al., 1997).  This release of ATP 
disrupts the Hsp90 chaperone complexes on steroid hormones and results in the down-
regulation of a number of oncogenic client proteins (Whitesell et al., 1994; Smith et al., 
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1995).  GA binding to Hsp90 also causes the release of p23 from the chaperone (Prodromou 
et al., 1997).  This is believed to occur because GA seizes Hsp90 in its ADP-dependent state, 
which is incapable of binding p23 (Johnson and Toft, 1995; Grenert et al., 1997; Sullivan et 
al., 1997).  In human telomerase, the same effect is seen as the Hsp90 interaction, but not the 
p23 interaction, is maintained with hTERT in the presence of GA (Holt et al., 1999).  GA has 
also been shown to promote degradation of the heat shock protein’s clientele prior to their 
complete activation by preventing Hsp90-client dissociation (Schneider et al., 1996; Schulte 
et al., 1997).  Specifically, GA treatment of H1299 cells resulted in the perturbation of Hsp90 
and the ubiquitination and degradation of hTERT in a proteasome-dependent fashion (Kim, J. 
H. et al., 2005).  Besides being used to elucidate the roles of Hsp90, GA has also been tested 
as a potential therapeutic drug.  In certain cell lines this ansamycin causes growth arrest, 
differentiation and apoptosis (Hostein et al., 2001; Munster et al., 2001).  However, despite 
being a potent inhibitor of cellular Hsp90, clinical testing of GA and related compound has 
revealed a significant toxicity profile (Supko et al., 1995).  Therefore, in terms of cancer 
therapy, new compounds had to be developed.  One such compound is the GA derivative 17-
allylamino-17-demethoxygeldanamycin (17-AAG) (Schulte and Neckers, 1998).  17-AAG, 
now in phase II of FDA clinical trials, exhibits potent anti-Hsp90 activity at sub-toxic doses 
in various animal models (Kelland et al., 1999; Solit et al., 2002). 
Aside from GA, another commonly used Hsp90 inhibitor employed to elucidate the 
cellular functions of Hsp90 is novobiocin (NB).  NB is a coumarin-type antibiotic and a 
known inhibitor of DNA gyrase B.  As opposed to GA, NB binds to the C-terminus of Hsp90 
(Marcu et al., 2000a; Marcu et al., 2000b; Soti et al., 2002).  Upon NB treatment, Hsp90 
releases its interactions with both Hsp70, whose binding site overlaps the NB binding site, 
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and p23 (Young et al., 1998; Carrello et al., 1999; Marcu et al., 2000a).  This fact had led to 
the hypothesis that NB may therefore provoke additional deleterious effects on Hsp90 
function as compared to GA (Marcu et al., 2000a), which only induces the release of p23 
from Hsp90 (Prodromou et al., 1997), though this premise has yet to be substantiated.  
Studies have also shown that NB binding to the carboxy terminus of Hsp90 prevents both 
nucleotide binding (Pratt and Toft, 2003) and GA binding (Marcu et al., 2000b) to the amino 
terminus, providing evidence for collaboration between the two termini.  In cells, NB 
undermines a number of Hsp90-associated client proteins including Her2, Raf-1, v-src and 
mutant p53 and downregulates multiple downstream targets, though it binds to Hsp90 with 
poor affinity (Marcu et al., 2000a; Marcu et al., 2000b). 
 
6. The secondary role of telomerase in tumorigenesis 
 
As previously discussed, telomerase aids in tumorigenesis by extending telomeric 
DNA and thus maintaining telomeric integrity (Masutomi and Hahn, 2003).  Interestingly, 
however, recent evidence suggests that telomerase is involved in a secondary, anti-apoptotic 
role in tumorigenesis (Cao et al., 2002; Stewart et al., 2002).  Cao et al. demonstrated that 
breast cancer cells undergoing apoptosis could be rescued by the expression of a mutant 
hTERT that lacked enzymatic activity and thus did not have the ability to elongate telomeres 
(Cao et al., 2002).  The work by Stewart et al. also suggests that telomerase plays at least two 
roles in tumorigenesis (Stewart et al., 2002).  Their research focused on an alternative 
mechanism of telomere maintenance (ALT – Alternative Lengthening of Telomeres) and its 
ability to substitute for telomerase expression.  The ALT pathway, which is found in 7-10% 
of human cancers, elongates telomeres by inter-chromosomal recombination (Stewart et al., 
2002; Reddel, 2003).  They showed that ALT could not fully replace telomerase function in a 
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cell transformation assay (Stewart et al., 2002).  Together, these independent reports suggest 
that telomerase has a secondary, anti-apoptotic role in tumorigenesis separate from its 
telomere-elongating activity (Saretzki, 2003).  One proposed explanation for these results is 
that telomerase is involved in telomere capping (Blackburn, E., 1999; Blackburn, E. H., 
2000; Blackburn, E. H., 2001; Masutomi et al., 2003).  Therefore, the mere presence of 
telomerase, whether it is active not, may elicit an anti-apoptotic effect as it interacts with and 
helps to maintain functional telomeres (Saretzki, 2003).  We predict that inducing telomerase 
misassemblage will alter these other roles of telomerase in cancer biology. 
 
 7. Regulation of telomerase 
 
 Telomerase regulation is a multi-faceted process taking place at the levels of 
transcription, hTERT maturation, subcellular localization and telomeric accessibility.  
Because hTERT expression is the rate-limiting factor in determining enzymatic activity, its 
regulation is of particular importance.  In most normal cells hTERT is transcriptionally 
repressed.  During immortalization, the gene is activated and upregulated allowing for 
unlimited cell proliferation. 
   
a. Transcriptional regulation 
 
      i. Positive regulators of hTERT transcription 
 
Transcriptional regulation of hTERT at its promoter is thought to be a major 
determinant in protein expression (Meyerson et al., 1997; Nakamura et al., 1997).  In fact, 
hTERT transient transfection with a promoter-luciferase reporter reveals that the hTERT 
promoter is active in immortalized cells, but inactive in normal cells  (Cong et al., 1999; 
Takakura et al., 1999).  The promoter contains many transcription factor binding sites that 
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have both positive and negative regulatory connotations (Cong et al., 1999).  One such 
binding site is that for Myc/Mad, which contains an E-box and is a transcriptional target of 
the oncogene c-myc (Wang, J. et al., 1998; Greenberg et al., 1999; Wu et al., 1999).  c-Myc 
has been linked to a number of different human cancers as it promotes proliferation, growth 
and apoptosis (DePinho et al., 1991; Grandori et al., 2000).  In normal human mammary 
epithelial cells and primary fibroblasts, as well as other cell types, c-myc induction has been 
shown to correlate with hTERT expression (Wang, J. et al., 1998).  Conversely, c-myc and 
hTERT are typically downregulated in non-proliferative cells.  Furthermore, over-expression 
of the c-Myc antagonist Mad1 results in the down-regulation of hTERT (Gunes et al., 2000; 
Oh, S. et al., 2000).  Although c-myc expression is an important aspect of hTERT regulation, 
additional transcription factors are usually required to account for the full transforming 
activity of c-Myc.   
 The general transcription factor Sp1 is also involved in hTERT up-regulation.  It does 
so by binding GC-boxes within the core of the hTERT promoter (Kyo et al., 2000).  In fact, 
these Sp1 binding sites are necessary components of the hTERT promoter as evidenced by 
the fact that mutations in the GC-boxes eradicate promoter activity (Cong and Bacchetti, 
2000; Kyo et al., 2000).  The reason for this requirement is because the hTERT promoter 
contains no TATA box.  Sp1 therefore helps to initiate transcription of the hTERT promoter, 
as well as other TATA-less promoters, by binding general transcription machinery such as 
the TATA-box binding protein (TBP) and associated factors (Pugh and Tjian, 1991; Hoey et 
al., 1993; Emili et al., 1994).  Sp1 has also been found to work in concert with c-myc in order 
to initiate hTERT transcription (Kyo et al., 2000). 
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 One factor known to activate hTERT transcription independent of c-myc induction is 
the human papillomavirus 16 E6 protein (Gewin and Galloway, 2001; Oh, S. T. et al., 2001; 
Veldman et al., 2001).  The protein’s oncogenic variants have been found to induce 
telomerase activity in primary human keratinocytes and mammary epithelial cells 
(Klingelhutz et al., 1996). 
 Several sex hormones have also been linked to telomerase activity regulation.  For 
example, estrogen activates telomerase through direct and indirect transcriptional activation 
of hTERT expression in hormone-sensitive tissues such as mammary epithelial cells that 
express the estrogen receptor (Kyo et al., 1999; Misiti et al., 2000).  Human ovary epithelial 
cells also show hTERT mRNA induction in the presence of the hormone, however, this 
transcriptional activation is dependent on the -950 estrogen response element of estrogen 
receptor α and not estrogen receptor β (Misiti et al., 2000).  The hTERT promoter can also 
be activated in MCF-7 breast cancer cells.  Estrogen in these cells has been found to have an 
indirect effect on hTERT activation via c-myc induction (Kyo et al., 1999).  Furthermore, the 
estrogen-specific initiation of hTERT transcription has also been confirmed by demonstrating 
that the anti-estrogen drug tamoxifen reduces telomerase activity in certain cell lines (Aldous 
et al., 1999; Nakayama, Y. et al., 2000).  Progesterone, another sex hormone, also has an 
antagonistic effect on estrogen-induced hTERT expression (Wang, Z. et al., 2000).  Though 
the mechanism of progesterone-mediated hTERT regulation is complex and still widely 
unknown, evidence suggests that progesterone targets the hTERT promoter and that the 
reversal of estrogen-mediated hTERT activation by progesterone may be indirect (Wang, Z. 
et al., 2000; Cong et al., 2002).  Androgens also possess regulatory capabilities over hTERT, 
though, as is the case for progesterone, the mechanism of telomerase activation has yet to be 
 18
fully elucidated.  Androgen depletion in androgen-dependent cell lines, but not androgen-
independent cell lines, has been found to reduce telomerase activity.  This activity in 
androgen-sensitive cells, however, can be restored by the addition of testosterone as 
androgen signaling upregulates hTERT expression (Guo et al., 2003).   
 
             ii. Negative regulators of hTERT transcription 
 
 Transcriptional repression of hTERT is thought to be the main reason that most 
normal somatic cells do not express telomerase activity.  Transformation of cancerous cells, 
therefore, is usually due to the loss of such repression.  This hypothesis is supported by 
results from cell fusion experiments in which normal somatic cells repress telomerase 
activity in telomerase-positive immortalized cells (Wright et al., 1996a; Ishii et al., 1999).  
These results suggest that normal somatic telomerase-negative cells may express 
transcriptional repressors of hTERT (Shay, 1999; Cong et al., 2002). 
 Some normal human chromosomes contain transcriptional repressors of hTERT.  
Transfer of chromosomes 3 (Oshimura and Barrett, 1997) 6 (Steenbergen et al., 2001) and 10 
(Nishimoto et al., 2001) into various human telomerase-positive cancer cell lines has been 
shown to downregulate telomerase activity and cause telomere shortening, suggesting the 
presence of alleged telomerase repressors on these chromosomes.  Aside from these as yet 
undiscovered transcriptional repressors of hTERT, many transcription factors have already 
been identified as negative regulators of hTERT transcription.   
 One negative regulator already mentioned above is Mad 1.  Mad, c-Myc and Max are 
transcription factors that dimerize in different combinations and bind to the E-box on the 
hTERT promoter to either upregulate or downregulate hTERT expression.  While Max is 
expressed ubiquitously, c-Myc is usually upregulated in cancer cell lines and tumor cells and 
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Mad is upregulated in telomerase-negative normal somatic cells.  The expression and 
dimerization of Myc and Mad with Max therefore results in increased or decreased hTERT 
transcription, respectively (Xu, D. et al., 2001). 
 Another negative regulator of hTERT transcription is the tumor suppressor p53.  This 
53-kDa protein is of central importance in terms of cellular transformation and immortality 
as over 50% of all human cancers contain dysfunctional p53 (Hollstein et al., 1994; Asker et 
al., 1999).  p53 functions in part by inducing cell cycle arrest or apoptosis in order to keep 
uncontrolled growth in check (Levine, 1997).  As a transcription factor, p53 perturbs 
telomerase activity by transcriptionally repressing hTERT, possibly independent of cell cycle 
arrest or apoptosis (Kusumoto et al., 1999; Kanaya et al., 2000; Xu, D. et al., 2000b).  
Counter intuitively, the transcription factor Sp1, an activator of hTERT transcription, is 
required for p53-dependent hTERT repression (Kanaya et al., 2000; Xu, D. et al., 2000b).  
Though it has been established that Sp1 binding to the hTERT promoter is impeded by p53 
binding to Sp1, the precise mechanism of p53-mediated transcriptional repression of hTERT 
remains a conundrum (Xu, D. et al., 2000b).  Several hypotheses have been proposed 
including the notion that p53 and Sp1 may impede the access of transcriptional activators 
(Avantaggiati et al., 1997) or recruit repressor complexes to the hTERT promoter (Murphy, 
M. et al., 1999).   
 p53 works closely with two other transcription factors during cell cycle regulation.  
pRB (Nguyen and Crowe, 1999; Crowe and Nguyen, 2001) and E2F (Henderson et al., 
2000), when over expressed, have the potential to repress hTERT transcription in partnership 
with one another and possibly even independently.  Despite the fact that there is no 
consensus mechanism of pRB/E2F-mediated hTERT repression, one established explanation 
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describes the involvement of histone deacetylase (HDAC) complexes (Harbour and Dean, 
2000).  Shown to be negative regulators of hTERT transcription (Cong and Bacchetti, 2000; 
Takakura et al., 2001; Xu, D. et al., 2001; Hou et al., 2002), histone deacetylases may be 
interacting with pRB and DNA-bound E2F at the promoter in order to stifle hTERT 
transcription.   
Another tumor suppressor involved in hTERT repression is Wilms’ tumor 1 (WT1).  
WT1 has been found to decrease levels of hTERT mRNA in 293 kidney cells as a result of 
direct interaction with the hTERT promoter (Oh, S. et al., 1999).  Menin (Lin, S. Y. and 
Elledge, 2003), Interferon-α (Xu, D. et al., 2000a) and TGF-β (Yang et al., 2001) are also 
negative regulators of telomerase activity, and the list continues.  Transcriptional control of 
hTERT is undoubtedly a complex and cell cycle-dependent process involving transcription 
factors, hormones, oncogenic proteins, viral proteins and tumor suppressors, as well as many 
other known and unknown cell cycle regulators. 
 
  b. Posttranslational regulation 
 
 The suggestion of posttranslational hTERT modifications as a means of telomerase 
regulation arose when various cells lacking telomerase activity were found to express both 
hTR and hTERT mRNA (Liu et al., 1999; Tahara et al., 1999; Rohde et al., 2000; Ulaner et 
al., 2000; Minamino et al., 2001).  This inconsistency supposes that telomerase activity does 
not always correlate with the presence of hTERT, but rather the presence of correctly 
modified and active hTERT.  The most prevalent modification responsible for 
posttranslational regulation of a great deal of proteins including hTERT is reversible 
phosphorylation.   
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 Activators and inhibitors of various kinases have been shown to be determinant 
factors in telomerase activity regulation.  Protein kinase C (PKC) is a phospholipid-
dependent kinase that functions to regulate growth, differentiation and carcinogenesis.  In 
certain cells types, the PKC inhibitor phorbol myristate acetate upregulates telomerase 
activity and the PKC inhibitor bisindolylmaeimide I downregulates telomerase activity 
(Bodnar et al., 1996).  Similarly, activators and inhibitors of phosphatases have the opposite 
effect on hTERT modification.  Phosphatase 2A has been shown to downregulate telomerase 
activity in a breast cancer cell line.  Conversely, okadaic acid upregulates telomerase activity 
in vivo by means of phosphatase 2A inhibition (Li et al., 1997).  These reports, as well as 
others, demonstrate that phosphorylation of hTERT is a common and effective means of 
telomerase activity regulation, though the effectiveness is PKC isoform-dependent (Ku et al., 
1997; Li et al., 1998; Yu et al., 2001). 
 A second kinase with significant involvement in hTERT regulation is Akt protein 
kinase, or protein kinase B.  It has been suggested the hTERT protein contains two distinct 
phosphorylation sites, which, when phosphorylated by Akt kinase, increase telomerase’s in 
vitro enzymatic activity (Kang et al., 1999).  Accordingly, wortmannin downregulates cell-
type specific telomerase activity via Akt kinase inhibition (Kang et al., 1999). 
 The tyrosine kinase c-Abl also possesses hTERT phosphorylation potential, however, 
its effects on telomerase activity oppose those of protein kinase C and Akt kinase.  Via its 
SH3 domain, c-Abl directly interacts with and phosphorylates hTERT resulting in a decrease 
in telomerase activity (Kharbanda et al., 2000).  Therefore, cells over-expressing c-Abl will 
typically have low levels of telomerase activity whereas cells lacking c-Abl will show signs 
of upregulated telomerase expression and increased telomere length. 
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 Importantly, experiments studying T-lymphocyte activation revealed that the up-
regulation of telomerase activity after hTERT phosphorylation may be the result of 
subcellular localization of hTERT from the cytoplasm into the nucleus (Liu et al., 2001).  It 
is believed that phosphorylating hTERT tags it for nuclear import to bring it into close 
contact with the chromosomes and extend the telomeres. 
 
c.  Telomeric accessibility 
 
Telomere accessibility is the salient determinant in telomerase activity regulation.  If 
the 3’ overhang of the chromosome is not exposed and available for telomerase-mediated 
extension, then telomerase activity is not detectable.  The formation of a t-loop at the end of 
the telomere dictates accessibility and controls telomere homeostasis.  The accessibility of 
the 3’ overhang of the telomere to telomerase is therefore the last line of regulation and is 
accomplished by the involvement and collaboration of a number of telomeric binding 
proteins (Evans and Lundblad, 2000; de Lange, 2002).  
 The telomeric repeat binding factors TRF1 and TRF2 are the chief components of 
telomere homeostasis (van Steensel and de Lange, 1997; Smogorzewska et al., 2000).  As 
mentioned above, these two proteins bind duplex telomeric DNA.  The over-expression of 
either factor causes telomere shortening in telomerase-positive cells as a result of preventing 
telomere-telomerase interaction (Smogorzewska et al., 2000).  The role of TRF1 is to 
evaluate and regulate telomere length at each chromosome (van Steensel and de Lange, 1997; 
Smogorzewska et al., 2000; Ancelin et al., 2002).  TRF1 is also implicated in parallel pairing 
of telomeric tracks as it has been shown by electron microscopy to seize and arrest telomeric 
repeat arrays and preclude the unwinding of DNA (Griffith, J. et al., 1998).  Furthermore, not 
only does TRF1 prevent access to the G-strand of the telomere, but it also prevents DNA 
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polymerase-mediated C-strand synthesis, thus inhibiting telomere elongation by multiple 
mechanisms (Smucker and Turchi, 2001).  Over-expression of a dominant negative TRF1 
mutant in telomerase-positive cells therefore initiates telomere elongation as the endogenous 
TRF1 is displaced from the telomere (van Steensel and de Lange, 1997; Karlseder et al., 
2002).  TRF2, like TRF1, when over-expressed, results in telomere shortening 
(Smogorzewska et al., 2000; Karlseder et al., 2002).  Interestingly, some data suggests that 
TRF2 also has the potential to initiate a telomeric DNA degradation pathway (Ancelin et al., 
2002).   
TRF1 and TRF2, however, are not the only proteins involved in telomerase regulation 
as Pot1 also plays a role in dictating telomeric accessibility.  Pot1 regulates telomere length 
by binding to single-stranded TTAGGG repeats at the chromosome ends (Baumann and 
Cech, 2001), binding to TRF1 (Loayza and De Lange, 2003) and perhaps recruiting 
telomerase to the telomere (Evans and Lundblad, 1999; Evans and Lundblad, 2000).  Pot1 
itself is actually recruited to the telomere by TRF1 (Loayza and De Lange, 2003).  
Furthermore, the amount of Pot1 bound to the telomere, which depends on the length of 
single-stranded DNA, is regulated by TRF1 (Loayza and De Lange, 2003).  TRF1, which 
binds to the double stranded region of the telomere, evaluates overall telomere length and, 
through its interaction with Pot1, relays this information to the telomere terminus (Loayza 
and De Lange, 2003).  This collaboration therefore allows Pot1 to control telomerase-
mediated telomere elongation (Loayza and De Lange, 2003).  By over-expressing Pot1 splice 
variants in telomerase-positive human cell lines Colgin et al. first revealed that Pot1 acts as a 
positive regulator of telomere length (Colgin et al., 2003).  Lei et al. further defined the role 
of Pot1 as they showed that Pot1 can actually act as both a positive and negative regulator of 
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telomere extension in vitro (Lei et al., 2005).  Depending on the number of nucleotides that 
are free from Pot1 binding on the 3’ overhang, telomere accessibility, and therefore 
telomerase activity, will either be promoted or hindered (Lei et al., 2005).   Additionally, 
Loayza et al. have shown that Pot1(∆OB), a Pot1 mutant that is deficient in single-stranded 
DNA binding but still able to be recruited to the telomere by TRF1, perturbs TRF1-mediated 
telomere length regulation and induces telomere elongation in human HTC75 cells (Loayza 
and De Lange, 2003).  These results are expected as Pot1(∆OB) is unable to cap the telomere 
or aid in t-loop formation, thus allowing telomerase unlimited access to the telomere.  There 
exist many other telomeric binding proteins which are no doubt associated with telomere 
integrity, however, the roles described here for TRF1, TRF2 and Pot1 are the most well-
defined and the most compelling in terms of telomerase accessibility and regulation.  
 
 
B. Previously documented telomerase inhibitors 
 
 Since the majority of cancer cell types require telomerase-mediated telomere 
extension for survival (Masutomi and Hahn, 2003), the inhibition of telomerase should result 
in cancer cell mortality.  In order for a drug to be considered an optimal telomerase inhibitor 
it must act through a telomere-dependent mechanism and accomplish a number of goals 
leading to the death of cancer cells (White et al., 2001).  The inhibitor must first decrease 
telomerase activity and then, following a lag phase, progressively lead to telomere shortening 
after each cell division.  Second, the addition of telomerase inhibitors should ultimately lead 
to the growth arrest or death of cancer cells.  Finally, if a telomerase inhibitor is in fact acting 
through a telomere-dependent mechanism, then the amount of time it takes a cell to decrease 
proliferation after being given a telomerase inhibitor should vary depending on the cell's 
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initial telomere length (White et al., 2001).   This last requirement, however, is changing and 
being redefined as the new secondary roles of telomerase in tumorigenesis described above 
are being discovered and elucidated. 
Several methods to affect telomerase inhibition have been documented (White et al., 
2001; Saretzki, 2003).  These include, but are not limited to, reverse transcriptase inhibitors, 
antisense oligonucleotides directed at the RNA subunit, particularly the template, G-
quadruplex-stabilizing compounds, natural products and small molecules.  These inhibitors 
generally target either the telomerase-catalyzed primer extension reaction or the telomerase 
primer (for some G-quadruplex-interacting molecules).   
 
1. Reverse transcriptase inhibitors 
 
Reverse transcriptase inhibitors, used widely in the treatment of Human 
Immunodeficiency Virus (HIV), have been studied as anti-telomerase agents, though the 
results of these studies are inconsistent (White et al., 2001).  The most extensively studied 
drug of this class of inhibitor in terms of telomerase inhibition is 3′-azido-3′-deoxythymidine 
(AZT) (Figure 1.4).  Some studies using AZT revealed inhibition of telomerase activity and 
decreased proliferation of cells in culture, but no change in telomere length and no growth 
arrest (Strahl and Blackburn, 1996; Gomez et al., 1998; Melana et al., 1998; Murakami et al., 
1999).  Other studies using the reverse transcriptase inhibitor dideoxyguanosine did reveal 
telomere shortening in specific cell lines but no noticeable changes in cell viability were 
observed (Strahl and Blackburn, 1996).  One possible explanation for these mixed results 
may be that these reverse transcriptase inhibitors are not acting through a selective inhibition 
of telomerase but are eliciting toxic effects on the cells by inhibiting mitochondrial DNA 
replication (White et al., 2001). 
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2. Antisense oligonucleotides directed against hTR 
 
 The use of antisense oligonucleotides targeting hTR became an attractive approach to 
inhibiting telomerase once Feng et al. identified the sequence of the RNA subunit in 1995 
(Feng et al., 1995).  The use of oligonucleotides as "drugs" has been difficult, however, 
because of their high cost and their low intracellular bioavailability caused by problems with 
cellular uptake and degradation.  Recent advances in oligonucleotide modifications, though, 
have begun to address these problems.  Several classes of modified oligonucleotides have 
been tested for their roles in telomerase inhibition including simple phosphodiesters 
(Glukhov et al., 1998), 2-5A linked phosphodiesters (Kondo et al., 1998), phosphorothioate-
substituted molecules (Pitts and Corey, 1998; Elayadi et al., 2001), 2'-O-methyl molecules 
(Pitts and Corey, 1998), 2'-O-(2-methoxyethyl) (2'-MOE) molecules (Elayadi et al., 2001), 
N3'→P5' thio-phosphoramidate (NPS) molecules (Figure 1.4) (Asai et al., 2003), PNA 
molecules (Norton et al., 1996) and hammerhead ribozymes (Wan et al., 1998).  The most 
promising results thus far have come from antisense  oligonucleotides  that  target  the  
template   portion  of  hTR   (Elayadi et al., 2001; Corey, 2002; Asai et al., 2003).    By 
forming a stable duplex between an antisense molecule and the template, the telomeric 
primer is unable to interact with the telomerase complex and thus cannot be extended.  
Elayadi et al. used template-targeting 2'-MOE RNA molecules to inhibit telomerase and 
found that some had IC50 values ranging from 5-10 nM in cell extracts (Elayadi et al., 2001).  
Asai et al. used a NPS oligonucleotide, GRN163, to target the template which yielded an IC50 
of ~1 nM in various tumor cell lines in the presence of carriers (e.g. Lipofectamine) (Figure 
1.4) (Asai et al., 2003).  GRN163, developed by Geron Corporation, not only inhibited 
telomerase activity  in  tumor  cell  culture  but  also  caused  telomere shortening and cellular 
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Figure 1.4 Previously documented telomerase inhibitors.  GRN163 is a N3'→P5' thio-phosphoramidate 
(NPS) oligonucleotide which contains a 3-terminal amino group.  BIBR1502, R=H. 
senescence or apoptosis following a lag phase that correlated with initial telomere length 
(Asai et al., 2003).  As evidence of the clinical usefulness of telomerase inhibition, Geron has 
filed an investigational new drug application and has begun clinical trials on GRN163.  
Furthermore, Djojosubroto et al. have revealed that GRN163L, a lipid-modified derivative of 
the parent compound also presently in human FDA clinical trials, is a more potent and 
efficacious inhibitor of telomerase activity and tumor growth in vitro and in vivo 
(Djojosubroto et al., 2005).  
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3. G-quadruplex stabilizing compounds  
 
G-quadruplex-stabilizing compounds are promising telomerase inhibitors.  G-rich, 
single-stranded DNA, such as that found at the end of the telomere, has been shown to form 
coplanar tetraplex structures. These structures, termed G-quadruplexes, are stabilized by 
pairs of Hoogsteen hydrogen bonds between adjacent guanine bases and are able to form 
both intra- and inter-molecular structures (Neidle and Read, 2000).  Because telomeric DNA 
can fold into a quadruplex structure, quadruplex-stabilizing compounds can prevent 
telomerase from accessing the telomere and therefore inhibit telomere extension.  A variety 
of G-quadruplex-interacting molecules have been tested and found to inhibit telomerase 
activity including anthraquinones (Sun et al., 1997; Read, M. A. et al., 1999; Read, M. et al., 
2001), acridine derivatives (Harrison et al., 1999), porphyrin derivatives (Han et al., 2001; 
Shi et al., 2001), perylenes (Fedoroff et al., 1998; Han et al., 1999; Rangan et al., 2001), 
ethidium derivatives (Koeppel et al., 2001), fluoroquinophenoxazines (Duan et al., 2001) and 
fluorenone-based compounds (Perry et al., 1999).  Though this class of telomerase inhibitor 
has been shown to inhibit telomerase activity and induce growth arrest, telomere shortening 
is often not an observed effect (Neidle and Read, 2000; White et al., 2001; Saretzki, 2003).  
In addition, some of these compounds have been found to exhibit nonspecific cytotoxicity 
and low relative affinities for quadruplex versus duplex DNA (Gowan et al., 2001).  Despite 
these pitfalls, one potentially therapeutically relevant G-quadruplex-stabilizing compound is 
the natural product telomestatin (Figure 1.4), which selectively interacts with the human 
telomeric intramolecular G-quadruplex (Shin-ya et al., 2001; Kim, M. Y. et al., 2002).  This 
fungal derivative interacts with the quadruplex in a 2:1 stacking complex, similar to the 
porphyrin-quadruplex interaction.  Another promisingly potent G-quadruplex-stabilizing 
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compound is 9-[4-(N,N-dimethylamino)phenylamino]-3,6-bis(3-pyrrolodinopropionamido) 
acridine (BRACO-19) (Figure 1.4).  This 3,6,9-trisubstituted acridine derived compound, 
discovered by computer modeling, has been shown to inhibit telomerase in the nanomolar 
range, decrease proliferation and induce senescence in a breast cancer cell line (Gowan et al., 
2002).  In human uterus carcinoma cells, BRACO-19 treatment results in a decrease in both 
hTERT expression and telomere length (Burger et al., 2005).  Furthermore, this small 
molecule possesses low nonspecific acute cytotoxicity, enhances ubiquitin-mediated 
degradation of hTERT and exhibits both in vitro and in vivo antitumor activity (Gowan et al., 
2002; Burger et al., 2005). 
 
4. Natural products 
 
Aside from telomestatin mentioned above, other natural product telomerase inhibitors 
include tea catechins (Naasani et al., 1998), mistletoe extracts (Lyu et al., 2002) and 
curcumin (Ramachandran and You, 1999; Ramachandran et al., 2001; Ramachandran et al., 
2002).  The tea catechin epigallocatechin gallate has been found to inhibit telomerase 
activity, decrease proliferation and cause telomere shortening in leukemia and 
adenocarcinoma cells (Naasani et al., 1998).  However, the precise mechanisms of these 
effects are speculative (Naasani et al., 1998) as tea catechins may also elicit a variety of other 
anticancer effects involving antioxidation (Yen and Chen, 1995) and interactions with a 
number of targets (Agarwal et al., 1992; Liao and Hiipakka, 1995; Suganuma et al., 1996; 
Hasaniya et al., 1997; Jankun et al., 1997; Lin, Y. L. and Lin, 1997).  Korean mistletoe lectin 
downregulates telomerase activity and induces apoptosis (Lyu et al., 2002).  This induction 
of apoptosis, though, is not solely due to telomerase inhibition due to the fact that this same 
extract also downregulates Bcl-2 and upregulates Bax (Lyu et al., 2002).  Curcumin, the 
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yellow pigment found in the rhizomes of turmeric, has been found to inhibit telomerase 
activity in human mammary epithelial and breast carcinoma cell lines by down-regulating 
hTERT expression (Ramachandran et al., 2001; Ramachandran et al., 2002).  Any effects on 
cell viability by curcumin, however, cannot be directly or completely linked with the down-
regulation of hTERT because curcumin also downregulates Ki67, PCNA, and mutated p53 
mRNAs in breast cancer cells (Ramachandran and You, 1999).   
 
5. Small molecules 
A number of telomerase inhibitors have been identified through the screening of large 
compound collections and combinatorial libraries.  The use of large-scale screening models 
such as NCI-COMPARE has aided this approach.  NCI-COMPARE is a bioinformatics 
screening model developed by Paull et al. which structurally categorizes molecules based on 
a given initial compound (Paull et al., 1989).  Naasani et al. applied their disease-oriented 
screening database (Yamori, 1997) to COMPARE analysis and identified a number of 
compounds as potent telomerase inhibitors (Naasani et al., 1999).  The most potent inhibitor 
found was rhodacyanine FJ5002, which yields an IC50 of ~2 µM (Figure 1.4).  U937 human 
leukemia cells treated with FJ5002, which is believed to inhibit telomerase by a direct 
interaction, underwent telomere erosion and cellular senescence (Naasani et al., 1999). 
 Damm et al. describe a high-throughput endeavor to identify novel telomerase 
inhibitors using their non-peptide, non-nucleoside BIBR class of compounds (Damm et al., 
2001).  They found BIBR1532 (2-[(E)-3-naphtalen-2-yl-but-2-enoylamino]-benzoic acid) to 
be the most potent inhibitor with an IC50 of 93 nM (Figure 1.4).  BIBR1532 induced telomere 
erosion, a senescent phenotype and telomere dysfunction in multiple cell types (Damm et al., 
2001).  Furthermore, BIBR1532 is highly selective for telomerase as the compound had no 
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adverse effects on HIV-1 reverse transcriptase or various RNA polymerases or DNA 
polymerases (Damm et al., 2001).  Additional studies revealed that BIBR1532 inhibited both 
recombinant and cellular telomerase activity by perturbing enzymatic processivity (Pascolo 
et al., 2002).  Its mode of action was further defined as BIBR1532 does not exert its 
inhibitory effects by binding to the telomeric primer or the dNTP binding site.  In fact, it is 
believed that this new class of telomerase inhibitor perturbs catalytic processivity by a mode 
similar to that for non-nucleoside HIV-1 reverse transcriptase inhibitors (Pascolo et al., 
2002).  The use of these and other compound collections and combinatorial libraries, 
combined with the development of new compound screening algorithms, will no doubt 
continue to expand the list of identified telomerase inhibitors. 
 The high-throughput screening of small synthetic organic molecules has also led to 
the identification of compounds that activate or derepress telomerase activity.  This finding is 
of therapeutic relevance in the cancer field as it led to the identification of a previously 
unidentified mechanism of hTERT regulation.  Won et al. set out to identify novel small 
molecules that possessed hTERT derepression capabilities.  After screening a 20,000 
member library from the Korea Advanced Institute of Science and Technology they 
discovered CGK1026 as a very promising prospect (Figure 1.4) (Won et al., 2004).  Won et 
al. describe a mechanism of cellular hTERT repression in which E2F and pocket proteins 
interact with the hTERT promoter in a cell cycle-dependent manner while the recruitment of 
HDAC into the E2F-pocket protein complex suppresses promoter activity (Won et al., 2004).  
They therefore found that CGK1026 derepresses or activates hTERT expression via the 
disruption of HDAC-E2F-pocket protein complexes (Won et al., 2004).  Accordingly, 
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adopting the anticancer approach of stabilizing HDAC-E2F-pocket protein interactions could 
prove to be a viable means to inhibit telomerase activity. 
 
6. Pitfalls of previous approaches to inhibit telomerase 
 
 Interestingly, some of these previously described telomerase inhibitors do not satisfy 
all of the criteria for acting through a telomere-dependent mechanism even though they 
inhibit telomerase activity.  There are two possible explanations for these occurrences.  First, 
the inhibition of telomerase could signal a cancer cell to initiate the ALT mechanism.  The 
ALT mechanism could then stabilize telomere lengths and may lead to anti-telomerase 
resistance (Mokbel, 2003).  Though it has been found that ALT cannot fully replace 
telomerase function (Stewart et al., 2002), the initiation of the ALT mechanism could still 
hamper the anti-tumorigenic effects of the telomerase inhibitor by maintaining telomere 
lengths.  Secondly, some of these inhibitors may not be affecting telomerase's secondary role 
in tumorigenesis.  Many of the previously described telomerase inhibitors knock out 
telomerase activity without significantly affecting the holoenzyme complex.  Therefore, the 
physical presence of the intact telomerase complex may still be able to protect the telomere 
and thus delay, if not prevent, telomere shortening and entry into senescence or apoptosis.  
However, the precise mechanism of telomerase’s role in preventing apoptosis has yet to be 
fully elucidated and may be telomere length-independent. 
 
 
C. Targeting human telomerase assemblage 
 
1. Significance 
 
Another aspect of telomerase biochemistry that has just recently been a major focus 
for drug discovery is assemblage of the ribonucleoprotein complex.  Our hypothesis is that 
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targeting telomerase holoenzyme assemblage will create a misassembled complex that not 
only perturbs telomerase activity leading to telomere shortening, growth arrest and cell death, 
but will also interrupt the enzyme's secondary, anti-apoptotic property.  If this is the case, 
then telomerase assemblage inhibitors could induce cancer cell death faster than the typical 
telomerase inhibitors discussed above (i.e. no lag phase).   
 
 
D. Specific aims of this research 
 
1. (Chapter II)  Determine the feasibility of inhibiting human telomerase activity by 
affecting assemblage with hTR-targeting oligonucleotides in a direct assay. 
2. (Chapter III)  Test the hypothesis that known RNA-binding ligands will affect 
human telomerase assemblage and activity. 
3. (Chapter IV)  Evaluate the human telomerase assemblage inhibiting effects of the 
natural product tanshinone II-A and a group of novel derivatives. 
4. (Chapter V)  Characterize the roles of Hsp90 in human telomerase assemblage and 
activity. 
5. (Chapter VI)  Design and develop a high-throughput screen capable of identifying 
novel inhibitors of telomerase assemblage using scintillation proximity assay (SPA) 
technology. 
 
 
 
 
 
 
 
 
 
Chapter II.  Inhibiting telomerase assemblage with specific hTR-targeted    
                     oligonucleotides 
 
 
Adapted from: Keppler, B.R. and M.B. Jarstfer, Inhibition of Telomerase Activity by 
Preventing Proper Assemblage. Biochemistry, 2004. 43(2): p. 334-43. 
 
 
A.  Introduction 
Several methods to affect telomerase inhibition have been documented (White et al., 
2001; Saretzki, 2003).  These include reverse transcriptase inhibitors (Strahl and Blackburn, 
1996; Gomez et al., 1998; Melana et al., 1998; Murakami et al., 1999), G-quadruplex-
stabilizing compounds (Neidle and Read, 2000), natural products (Naasani et al., 1998; Kim 
et al., 2002; Lyu et al., 2002), molecules screened from synthetic libraries (Hayakawa et al., 
1999; Naasani et al., 1999; Damm et al., 2001) and antisense oligonucleotides directed at the 
RNA subunit, particularly the template (Elayadi et al., 2001).  One aspect of telomerase 
biochemistry that has not been a major focus for drug discovery is assemblage of the 
ribonucleoprotein complex.  We have therefore initiated a program to investigate the 
feasibility of inhibiting telomerase assemblage.  In our initial efforts, we have specifically 
addressed the possibility of targeting hTR with oligonucleotides that block assemblage of the 
holoenzyme.  Previous studies documented that non-templating portions of hTR can be 
targets for PNA-based inhibitors though inhibition of assemblage has not specifically been 
examined (Hamilton et al., 1999). 
 The telomerase RNA subunit has been identified from various organisms, including 
ciliates, mammals and yeast (Romero and Blackburn, 1991; Lingner et al., 1994; Singer and 
Gottschling, 1994; Blasco et al., 1995; Feng et al., 1995; Tsao et al., 1998; Chen et al., 2000; 
Chen et al., 2002).  A proposed secondary structure of hTR has been developed based on the 
sequencing work by Feng et al. (Feng et al., 1995) and the comparative phylogenic analysis 
of various vertebrate telomerase RNAs by Chen et al. (Chen et al., 2000).  hTR contains a 
number of distinct domains which are conserved among all vertebrates (see Figure 1.3).  The 
conserved pseudoknot and CR4-CR5 domains of hTR, for example, have been shown to 
interact independently with hTERT and are required for telomerase activity (Tesmer et al., 
1999; Beattie et al., 2000; Mitchell and Collins, 2000; Bachand and Autexier, 2001; Martin-
Rivera and Blasco, 2001; Chen et al., 2002; Chen and Greider, 2003).  Further evaluation of 
the CR4-CR5 domain soon revealed that the specific nucleotides responsible for binding to 
hTERT are those that constitute the P6.1 stem-loop (nucleotides 302-314) (Chen et al., 
2002).  hTR has also been implicated in telomerase dimerization via the P3 pairing region of 
the pseudoknot (Ly et al., 2003b) and the J7b/8a internal loop of the CR7 domain (Ren et al., 
2003).  Here, we confirm that the CR4-CR5 domain and the P3/P1 pairing region both 
interact autonomously with hTERT and report that targeted disruption of these interactions 
prior to holoenzyme assembly disrupts telomerase activity. 
  
B. Results 
 1. Identification of susceptible regions of hTR 
To define regions of hTR that can be targeted for the disruption of telomerase 
assemblage, we tested a series of DNA oligonucleotides that were complementary to various 
regions of hTR for their ability to inhibit reconstituted telomerase activity in vitro (Table 
2.1).  Previously, the use of PNAs that were complimentary to non-templating regions of 
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telomerase were shown to inhibit telomerase when added prior to assemblage (Hamilton et 
al., 1999).  Because the PNA-RNA duplex is very stable, we thought that the PNAs could 
change the structure of the RNA subunit to inhibit telomerase as opposed to blocking 
hTR/hTERT interactions, which we were interested in.  For example, a PNA that targeted 
nucleotides 1-12 was a strong inhibitor of telomerase prior to assemblage  (Hamilton et al., 
1999),  even  though these  nucleotides are not required for telomerase activity (Ly et al., 
2003a).  This suggests that while the folded structure of hTR was perturbed, specific 
hTR/hTERT  interactions were not inhibited.  We chose to examine DNA oligonucleotides to 
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 Table 2.1 Summary of inhibition data with hTR-targeted oligonucleotidesaNucleotidesb  % Activityc Name  Sequence  hTR region targeted  targeted  
 
hTRas001  
hTRas002  
hTRas003  
hTRas004  
hTRas005  
hTRas006  
hTRas007  
hTRas008  
hTRas009  
hTRas010  
5'-ATGGCAAGTCCGAATCGATCGT-3'  
5'-TAGGGTTAGACAA-3'  
5'-AAAGTCAGCGAGAAAAACAGCG-3'  
5'-AACGGGCCAGCAGCTGACATTT-3'  
5'-TGGGTGCCTCCGGAGAAGCCCC-3'  
5'-CGGCTGACAGAGCCCAACTCTT-3'  
5'-GCCTGAAAGGCCTGAACCTCGC-3'  
5'-ACAGCTCAGGGAATCGCGCCGC-3'  
5'-AACGGGCCAGCAGCUGACAUUU-3'd
804 
97 
97 
37 
100 
54 
115 
74 
12
18 
N/A  
42-54  
94-115  
174-195  
268-289  
301-322  
343-364  
397-418  
174-195 
301-322  
None 
Template (CR1) 
Pseudoknot Domain (CR2/CR3)  
P3/P1 Pairing Region  
L6 Loop 
CR4-CR5 Domain 
Hypervariable Paired Region  
CR7 Domain 
P3/P1 Pairing Region
CR4-CR5 Domain 5'-CGGCUGACAGAGCCCAACUCUU-3'd  a DNA oligonucleotides were added to hTERT and hTR prior to assemblage. Telomerase activity was 
determined as described in the Materials and methods.  bNucleotides within hTR that were targeted by 
the oligonucleotides.  c"% Activity" indicates the amount of residual telomerase activity at a 1 µM 
concentration compared to the  primer-only control.  dhTRas009 and hTRas010 are 2'-O-methyl 
oligonucleotides and underlined nucleotides indicate phosphorothioate linkages. iminish this effect in an attempt to define regions of hTR/hTERT interactions that can be 
locked.  Eight DNA oligonucleotides (hTRas001-hTRas008) were screened for their ability 
o affect telomerase using an assemblage assay.  All oligonucleotide inhibitors were 
aintained at a concentration of 1 µM throughout the experiment. A positive control with no 
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oligonucleotide inhibitor was used to determine 100% activity and hTERT-only and hTR-
only negative controls were used as controls for background activity (Figure 2.1).  We found 
that only oligonucleotides hTRas004 and hTRas006, which target the P3/P1 pairing region 
and CR4-CR5 domain, respectively, significantly decreased telomerase activity, defined as 
<55% residual activity when compared to the positive control (Table 2.1 and Figure 2.1).  
Interestingly, hTRas008, which targets the CR7 domain, was slightly refractory towards 
telomerase  activity  (~70%  residual activity).   We also noted that the addition of  a  random 
Lane:     1        2        3         4        5        6       7         8        9        10       11      12
Oligo (hTRas00):    - - - 1        2        3         4        5         6       7        8
32P-primer
L.C.
 
Figure 2.1  Assemblage assay using hTR-targeted oligonucleotides.  DNA oligonucleotides 
were added to hTERT and hTR before assemblage and assayed for activity.  Lane 1 is a protein-
only control and lane 2 is a RNA-only control.  Lane 12 is a 32P-labeled primer to mark the 
beginning of primer extension.  L.C. indicates loading control.  Only telomerase-dependent bands 
were used for quantification (i.e. not bands seen in negative controls). 
 
 
 
DNA molecule, hTRas001, resulted in increased telomerase activity (~800%). By contrast, a 
nonspecific PNA inhibited telomerase when added pre-assemblage with an IC50 = 30 µM 
(Hamilton et al., 1999), highlighting potential nonspecific effects of PNAs. 
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2. Pre- and post-assemblage assays 
  a. Concentration dependence of hTRas009 and hTRas010 inhibition 
 To improve hybridization of the inhibitory oligonucleotides to hTR, 2'-O-methyl 
modifications were made at each nucleotide (Monia et al., 1993), and to afford increased 
nuclease resistance, phosphorothioate linkages were incorporated at the ends of each 
oligonucleotide (Eckstein, 2000) (Table 2.1).  The modified oligonucleotides were tested for 
their ability to inhibit telomerase activity in an assemblage assay at a range of  concentrations   
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Figure 2.2  Concentration dependence of telomerase inhibition by hTRas009 and hTRas010 
when added before assemblage. hTRas009 (A) or hTRas010 (B) were added to an assemblage 
assay at concentrations of 1 nM, 10 nM, 100 nM, 1 µM and 10 µM (lanes 2-6 respectively). Lane 1 
is a primer-only control.  Lane 7 is a no-primer control.  Lane 8 is a 32P-labeled primer to mark the 
beginning of primer extension.  The 32P-labeled loading control (L.C.) and the human telomere 
primer-extension products (+4, +10, +16, +22, etc. nucleotides added) are indicated.  IC50 values 
were calculated and inhibition curves were plotted for hTRas009 (C) and hTRas010 (D) as 
described in the Materials and methods.  IC50 curves are based on results from duplicate 
experiments.  Error bars in C and D indicate standard deviation and IC50 error indicates standard 
error. 
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(Figures 2.2A and B).  At high concentration (10 µM) of hTRas009 or hTRas010 we 
observed a new product band in the analysis (lane 6, Figures 2.2A and 2.2B).  We therefore 
carried out an assay with 10 µM of oligonucleotide in the absence of a telomeric primer (lane 
7, Figures 2.2A and 2.2B).  These no-primer controls resulted in the production of the same 
products (compare lanes 6 and 7, Figures 2.2A and 2.2B).  Furthermore, these artifacts were 
also produced in reactions catalyzed by reticulocyte lysate expressing an empty vector 
demonstrating that  they  are  telomerase  independent  (Figure 2.3).   Therefore, the bands in  
Lane:             1               2               3             4               5   
hTRas009 (µM):         0               10              10 10 0  
L.C.
empty vector:          - - - +               +
hTERT:         +                +                +              - -
primer:        +                +                 - - +
 
Figure 2.3  High concentrations of hTRas009 in an assemblage assay produce telomerase-
independent artifacts.  Lanes 4 and 5 contain no hTERT.  L.C. indicates loading control.  
 
 
lane 6 and lane 7 of Figure 2.2 not attributable to telomerase-catalyzed primer extension were 
excluded from the IC50 calculations.  Both hTRas009 (IC50 = 72.5 ± 15.3 nM) and hTRas010 
(163 ± 29.9 nM) were nanomolar inhibitors of telomerase (Figures 2.2C and 2.2D).  By 
comparison, oligonucleotide inhibitors that target the template portion inhibit telomerase in 
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the low nanomolar range (Corey, 2002), though the concentration of hTR in these assays is 
much lower than in our assays, making a direct comparison impossible.  Importantly, 
telomerase activity was almost completely eradicated (~5% residual activity) by either 
oligonucleotide at high concentration (10 µM).   
 
b. Direct telomerase assay in the presence of hTRas009 and hTRas010   
Telomerase was pre-assembled in vitro and assayed in the presence of either 
hTRas009 or hTRas010.   The direct telomerase assays were conducted in the presence of the  
    1            2            3            4           5 
hTRas010. hTRas009
100          77           88            64          59% Activity:
L.C.
 1             2             3              4            5            6Lane:
 
Figure 2.4  Concentration dependence of telomerase inhibition by hTRas009 and hTRas010 
when added after assemblage. hTRas010 (lanes 2 and 3) or hTRas009 (lanes 4 and 5) were 
added to the direct telomerase assay at concentrations of 1µM (lanes 2 and 4) and 10µM (lanes 3 
and 5).  Lane 1 is a primer-only control.  Lane 6 is a 32P-labeled primer to mark the beginning of 
primer extension.  The 32P-labled loading control (L.C.) is indicated.  "% Activity" values 
indicate the amount of residual telomerase activity as compared to the primer-only control. 
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two highest oligonucleotide concentrations tested in the assemblage assay (Figure 2.4).  
Under these conditions, neither oligonucleotide significantly inhibited telomerase activity 
when compared to their inhibition in the assemblage assay (59% and 88% residual activity 
for hTRas009 and hTRas010, respectively, in the direct telomerase assay as compared to 
~5% residual activity for either oligonucleotide in the assemblage assay).  
 
3.  hTRas009 and hTRas010 affect the association of hTR with hTERT 
 
Since hTRas009 and hTRas010 only inhibit telomerase when added prior to 
assemblage, we hypothesized that they interfere with proper assemblage but do not directly 
inhibit enzymatic activity.  We therefore studied the ability of these antisense molecules to 
affect binding of hTR to hTERT using a co-immunoprecipitation assay.  Because the 
pseudoknot and CR4-CR5 domains have previously been shown to interact independently 
with hTERT (Tesmer et al., 1999; Mitchell and Collins, 2000; Chen et al., 2002; Chen and 
Greider, 2003), we tested each oligonucleotide for their ability to block binding of their 
respective targeted domains to hTERT (Figure 2.5).  T7-tagged hTERT was translated in the 
presence of [35S]-methionine, which allowed normalization of the co-immunoprecipitation 
data, and was incubated with 32P-labeled RNA fragments to allow for RNA/hTERT binding.  
The resulting complexes were then immunoprecipitated.  Controls with no oligonucleotide 
were performed along with two different concentrations of oligonucleotide (200 nM and 1 
µM).  We found that, in the absence of inhibitory oligonucleotides, the pseudoknot domain 
(nucleotides 46-209) and the CR4-CR5 domain (nucleotides 243-328) of hTR both 
independently interact with hTERT, consistent with previous reports (Tesmer et al., 1999; 
Mitchell and Collins, 2000; Chen et al., 2002; Chen and Greider, 2003) (lanes 1 and 4, Figure  
2.5).  When the pseudoknot RNA fragment was incubated with hTERT in the presence of 
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hTRas009, co-immunoprecipitation of the RNA with hTERT was inhibited by ~50% (lanes 2 
and 3, Figure 2.5).  Conversely, hTRas010  was  able  to  inhibit  binding  of  the  CR4-CR5  
RNA  fragment  by  92%  of  the maximum binding (lanes 5 and 6, Figure 2.5). 
 
hTERT
RNA
hTRas009:            0          200nM         1µM                  0                 0              0           0                0             1µM        1µM
hTRas010:            0                0                0       0            200nM       1µM                 0             1µM              0          1µM
hTR(46-209) hTR(243-328) full-length hTR
% Bound:     100         53           53                100     26           8         100          86           92         53
Lane:        1            2             3                   4   5            6                  7             8        9          10  
 
 
 
 
 
 
 
 
Figure 2.5  Inhibition of hTR/hTERT interactions by hTRas009 and hTRas010.  32P-labeled 
pseudoknot RNA fragment (lanes 1-3), 32P-labeled CR4-CR5 RNA fragment (lanes 4-6) or 32P-labeled 
full-length hTR (lanes 7-10) were incubated with 35S-hTERT either in the presence or absence of 
oligonucleotide inhibitor(s).  The resulting complexes were co-immunoprecipitated and resolved on a 
denaturing Bis-Tris SDS gel.  The [35S]-labeled hTERT bands were used as a loading control.  hTRas009 
was added to an assembly reaction at a concentration of 200 nM (lane 2) or 1 µM (lane 3) to inhibit 
binding of the pseudoknot RNA fragment. Lane 1 is a control reaction with no oligonucleotide. 
hTRas010 was added to an assembly reaction at a concentration of 200 nM (lane 5) or 1 µM (lane 6) to 
inhibit binding of the CR4-CR5 RNA fragment.  A control with no oligonucleotide was also performed 
(lane 4).  1 µM hTRas010 (lane 8), 1 µM hTRas009 (lane 9) or 1µM each of hTRas009 and hTRas010 
(lane 10) was added to an assembly reaction to inhibit binding of full-length RNA. Lane 7 is a control 
reaction with no oligonucleotide.  "% Bound" values indicate the amount of RNA bound to the protein 
when compared to control reactions with no oligonucleotide.  The "% Bound" values in lanes 1-3 are 
average values from duplicate experiments.  Note: The pseudoknot RNA fragment (nucleotides 46-209), 
CR4-CR5 RNA fragment (nucleotides 243-328), and full-length RNA (451 nucleotides) are different 
lengths despite the depiction in the figure. 
 
We also tested the effect of hTRas009 and hTRas010 on the association between 
hTERT and full-length hTR (lanes 7-10, Figure 2.5).  32P-labeled hTR (451 nt) was incubated 
with 35S-labeled hTERT either alone, with 1 µM hTRas009, with 1 µM hTRas010, or with 
both 1 µM hTRas009 and 1 µM hTRas010.  Compared to the control with no 
oligonucleotide, hTRas009 and hTRas010 had little effect on the association of hTR and 
hTERT (compare lanes 8 and 9 to lane 7, Figure 2.5).  However, when both hTRas009 and 
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hTRas010 were present, hTR binding was decreased by ~50% compared to the control with 
no oligonucleotide (compare lane 10 to lane 7, Figure 2.5). 
To demonstrate the specificity of the oligonucleotides for their respective 32P-labeled 
RNA fragments, hTRas009 was incubated with 35S-labeled hTERT and the CR4-CR5 RNA 
fragment, and hTRas010 was incubated with 35S-labeled hTERT and the pseudoknot RNA 
fragment. We found that neither oligonucleotide was able to block the binding between the 
RNA and protein compared to the controls with no oligonucleotide (Figure 2.6A).  Instead, 
we saw an increase in the association of the RNA fragments with hTERT when the non-
targeting oligonucleotides were present.  Nonspecific binding was analyzed using an empty 
vector control.  In these samples, less than 5% of the RNAs bound to beads compared to 
samples containing hTERT (Figure 2.6B). 
 
32P-CR4
32P-PD
32P-hTR
32P-RNA
35S-hTERT
hTR(46-209) hTR(243-328)
hTRas009 (µM):             0                            0                  0                            1
hTRas010 (µM):             0                            1                  0                            0 
hTERT:              - +
A.
B. empty vector:              +                      -
 
 
 
 
 
 Figure 2.6  Oligonucleotide and RNA specificity (A) Non-targeting 
oligonucleotides cause no decrease in pull-down of RNA.  35S-hTERT bands were 
used to normalize 32P-RNA bands.  (B) Nonspecific binding of RNA to beads in the 
absence of hTERT is minimal.  hTR designates full-length telomerase RNA, PD 
designates hTR(46-209) and CR4 designates hTR(243-328). 44
4.  hTRas009 affects hTR homo-dimerization 
 
 Recently, hTR was shown to dimerize through an intermolecular interaction between 
stems of the hTR pseudoknot (Ly et al., 2003b). To determine if hTRas009 or hTRas010 
affect hTR homo-dimerization, 32P-labeled hTR was incubated either in the presence or 
absence of hTRas009 or hTRas010 at a final concentration of 10 µM and resolved on a 
nondenaturing gel (Figure 2.7).  As expected, we found that the addition of hTRas010 (lane 
4) had no effect on hTR homo-dimerization as compared to the control (lane 2), however, the 
addition of hTRas009 (lane 6) decreased dimerization by about 50% as compared to the 
control (Figure 2.7).  A similar trend in dimerization values is seen for the non-incubated 
controls (lanes 1, 3, and 5).   
 
Dimer
Monomer
Lane:     1          2      3         4           5       6
% Dimerized:     7         40   7         41        0.7        19
10µM hTRas009:      - - - - +      +
10µM hTRas010:      - - +       +          - -
37°C:      - +           - +           - +
 
 
Figure 2.7  hTRas009 inhibits hTR homo-dimerization.  32P-labeled full-length hTR was 
allowed to dimerize either alone (lanes 1-2) or in the presence of 10µM hTRas010 (lanes 3-4) 
or 10µM hTRas009 (lanes 5-6).  Samples were either incubated at 37 °C to allow for 
dimerization (+) or were kept on ice to prevent dimerization (-). "% Dimerized" values 
indicate the amount of hTR found in the dimer form compared to the total amount of hTR in 
the sample.   
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C. Discussion 
 
The involvement of telomerase in a wide range of cancers has made it an attractive 
target for anticancer drug discovery.  Though a complete description of human telomerase 
and all of its subunits awaits further elucidation, the minimally active complex, a dimer of 
hTR and hTERT, provides several conceivable approaches for inhibition.  In particular, the 
identification and proposed secondary structure of hTR (Chen et al., 2000) has opened a 
number of doors for specific antisense inhibition.  Oligonucleotides that are complementary 
to the template of hTR have been extensively studied (Elayadi et al., 2001), and 
oligonucleotides that target non-templating portions have received some attention (Hamilton 
et al., 1999; Pruzan et al., 2002).  Here, we investigated the ability to inhibit telomerase 
activity by abrogating assemblage of the holoenzyme complex.  We identified two 2'-O-
methyl RNA oligonucleotides that bind to specific regions of hTR and inhibit telomerase 
activity with IC50 values in the nanomolar range. 
We used eight DNA oligonucleotides that are complimentary to separate regions of 
hTR (Table 2.1) and discovered that targeting the pseudoknot domain at the P3/P1 
intersection and the CR4-CR5 domain at the P6.1 stem-loop resulted in the greatest 
inhibitory effects.  A third oligonucleotide, hTRas008, which targets the CR7 domain, also 
decreased telomerase activity, however, we chose not to follow-up on this result at this time.  
Interestingly, hTRas001, an oligonucleotide that is not specific for any region of hTR, 
increased telomerase activity.  This unexpected result suggests that a nucleic acid-binding 
protein or proteins in the reticulocyte lysate are refractory towards telomerase activity and/or 
assemblage.  Because this oligonucleotide does not target any region of the hTR, it was free 
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to interact with other entities in the reticulocyte lysate.  This suggests that the addition of 
random DNA to telomerase reconstitution assays performed in reticulocyte lysates can 
increase the yield of active complexes.  PNAs that are complimentary to a wide variety of 
hTR regions inhibit telomerase when added prior to assemblage (Hamilton et al., 1999).  By 
contrast, DNA oligonucleotides were only inhibitory when targeting three specific regions of 
hTR.  This is presumably because DNA oligonucleotides form less stable duplexes that can 
be out competed by native structures.  For example, hTRas002, which is complementary to 
the template, did not inhibit telomerase even though corresponding PNAs are excellent 
inhibitors (Hamilton et al., 1999).  In the case of the DNA oligonucleotide, hTRas002, the 
inhibitor was unable to compete with the telomeric primer for the template.  We therefore 
concluded that the DNA oligonucleotides we identified in our screen block interactions 
between hTR and hTERT as opposed to disrupting more stable native hTR structures, though 
we cannot rule this out. 
Ultimately, we decided to conduct further studies on the oligonucleotides targeting 
the P3/P1 pairing region (hTRas004) and the CR4-CR5 domain (hTRas006), two regions of 
hTR that were previously shown to be required for both telomerase activity and the 
association of hTR with hTERT (Tesmer et al., 1999; Beattie et al., 2000; Mitchell and 
Collins, 2000; Bachand and Autexier, 2001; Martin-Rivera and Blasco, 2001; Chen et al., 
2002; Chen and Greider, 2003).  For these experiments we re-synthesized the DNA 
oligonucleotides with 2'-O-methyl-modified RNA and phosphorothioate linkages on their 5'- 
and 3'-ends (hTRas009 and hTRas010, Table 2.1).  These alterations increased the inhibitory 
effects of the oligonucleotides. The increased inhibition can be attributed to the fact that 2'-
O-methyl RNA oligonucleotides hybridize to RNA better than DNA oligonucleotides (Monia 
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et al., 1993).  The phosphorothioate modifications were designed for future cell culture 
experiments in order to decrease oligonucleotide degradation. 
In assemblage assays, hTRas009 (IC50 = 72.5 ± 15.3 nM) was found to be a more 
potent inhibitor of telomerase activity than hTRas010 (IC50 = 163 ± 29.9 nM) (Figure 2.2).  
The banding pattern observed is characteristic of human telomerase activity with the first 
major extension product being four nucleotides longer than the primer and each successive 
major product having six additional nucleotides.  We also noted the presence of unexpected 
bands in the no-primer controls revealing that hTRas009 and hTR010, at concentrations of 10 
µM, act as substrates for 32P-dGTP addition by some component of the reticulocyte lysate 
(lane 7, Figures 2.2A and 2.2B).  This observation, however, should not influence the 
inhibitory effects of the oligonucleotides as the unexpected bands were not seen at lower 
concentrations.  Furthermore, although hTRas009 has a lower IC50 value than hTRas010, 
both oligonucleotides were able to completely inhibit (~5% residual activity) telomerase 
activity at the highest concentration tested (10 µM).  Notably, the IC50 values for both 
hTRas009 and hTRas010 are in the same range as the hTR concentration (95 nM) used in the 
assemblage reactions.   
Neither hTRas009 nor hTRas010 significantly inhibited telomerase activity when 
added after telomerase was allowed to assemble (Figure 2.4), though hTRas009 inhibited 
slightly, with 59% residual activity. Perhaps a high concentration of hTRas009 can disrupt 
interactions within the intact telomerase complex.  Similar results were found for several 
PNAs that target non-templating regions of hTR (Hamilton et al., 1999).  These results 
suggest that enzyme activity was inhibited by impeding essential interactions between hTR 
and hTERT or by disrupting the folding of hTR.  Further, our results indicate that the P3/P1 
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pairing region and the CR4-CR5 domain are not exposed once proper holoenzyme formation 
is complete.  Alternatively, if these domains remain exposed in the holoenzyme, then 
oligonucleotide interactions after holoenzyme formation do not interfere with activity.  
Chemical and enzymatic foot-printing of hTR revealed that the P6.1 stem-loop, within the 
CR4-CR5 domain, and the P3/P1 pairing region are protected from cleavage reagents when 
complexed with hTERT (Antal et al., 2002).  This is consistent with the idea that hTRas009 
and hTRas010 cannot hybridize to hTR once the telomerase complex has completely and 
properly formed.  
We tested the hypothesis that hTRas009 and hTRas010 inhibit telomerase by 
specifically inhibiting interactions between hTERT and the targeted hTR domains.  
Independent fragments of hTR that are specifically targeted by their respective 
oligonucleotides were co-immunoprecipitated with hTERT.  As expected, we observed that 
the pseudoknot and CR4-CR5 domains of hTR independently bind hTERT in the absence of 
oligonucleotide (lanes 1 and 4, Figure 2.5).  hTRas010, which targets hTR at nucleotides 
301-322, hybridizes with the entire P6.1 stem-loop (nucleotides 302-314) and blocks 92% of 
the binding between hTERT and the CR4-CR5 domain at 1 µM (lane 6, Figure 2.5).  This is 
the expected result if the interaction between the CR4-CR5 domain and hTERT is dependent 
on interactions with the P6.1 stem-loop, as previously observed by the Greider lab (Chen et 
al., 2002).  Interestingly, 1 µM hTRas009 did not exhibit the same degree of inhibition for 
the interaction between the pseudoknot fragment and hTERT (lane 3, Figure 2.5).  The fact 
that hTRas009 was able to decrease the ability of hTERT to bind the pseudoknot fragment by 
~50% of the maximum suggests that the region it targets (nucleotides 174-195) is important 
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for protein binding.  However, it appears that other regions in the pseudoknot domain 
(nucleotides 46-209) also contribute to interactions with hTERT.   
If hTRas009 does not completely prevent biding of hTERT to the pseudoknot 
domain, what is its mechanism of inhibition?  One intriguing possibility is that hTRas009, 
which hybridizes to the P3/P1 pairing region, perturbs telomerase activity by interrupting 
hTR homo-dimerization.  Ly et al. proposed that hTR homo-dimerization involving contacts 
in the P3 pairing region results in an essential trans-pseudoknot structure (Ly et al., 2003b).  
They demonstrated that mutants incapable of forming the P3-trans interaction were unable to 
reconstitute telomerase activity but were able to bind to hTERT and suggested that hTR 
dimerization may provide a foundation for holoenzyme assembly.  We tested the ability of 
hTRas009 to inhibit hTR homo-dimerization by nondenaturing PAGE (Figure 2.7).  The 
addition of hTRas009 (lane 6) blocked ~50% of hTR homo-dimerization as compared to the 
control (lane 2), whereas the addition of hTRas010 (lane 4) had no effect, as expected 
(Figure 2.7).  We therefore propose that the mechanism of inhibition of telomerase activity 
by hTRas009 includes disrupting both RNA-protein interactions and hTR homo-
dimerization.  Based on this, it is surprising that hTRas003, which targets nucleotides 94-115 
in the P3 pairing region of the pseudoknot domain, was not an inhibitor of assemblage (see 
Table 2.1).  Interestingly, a PNA that targeted nucleotides 93-105 was an inhibitor (IC50 = 0.1 
µM) of telomerase when added post-assemblage, and a PNA that targeted the other portion of 
the dimerization domain, nucleotides 180-194, was a more potent inhibitor (IC50 = 0.01 µM) 
(Hamilton et al., 1999).  One explanation is that the PNA targeting nucleotides 180-194 and 
hTRas009, which targets nucleotides 174-195, either form more stable duplex structures 
compared to the native RNA structure or disrupt important interactions between hTR and 
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hTERT.  It is notable that hTR homo-dimerization was not entirely disrupted.  This may be 
explained by the recent observation that a second RNA/RNA interaction site within the CR7 
domain can contribute to homo-dimerization (Ren et al., 2003), and may be related to  the 
observed inhibition by hTRas008.  In support of this, Ren et al. showed that an 
oligonucleotide that targets a similar sequence in hTR inhibited hTR multimerization (Ren et 
al., 2003).   
In order to further characterize the effects of hTRas009 and hTRas010 on hTR 
binding to hTERT, each oligonucleotide alone or both oligonucleotides together were 
incubated with full-length hTR (451 nt) and hTERT. We found that hTRas009 or hTRas010 
alone had little affect on hTR/hTERT binding (lanes 8 and 9, Figure 2.5). When both 
oligonucleotides were used in combination, however, 53% of the RNA remained bound as 
compared to the control suggesting that other parts of the full-length RNA continued to 
interact with hTERT (lane 10, Figure 2.5).  Interestingly, the percentage of RNA still bound 
to hTERT is the same as that in the experiment using hTRas009 alone to inhibit binding of 
the pseudoknot RNA fragment to hTERT (compare % Bound values in lanes 3 and 10, 
Figure 2.5).  This suggests that the elements of hTR that continue to bind hTERT in the 
presence of both oligonucleotides reside in the pseudoknot domain (nucleotides 46-209).  
One explanation for this result is that hTERT interacts with hTR at a minimum of three 
specific positions and hTRas009 blocks one, hTRas010 blocks another, and the third resides 
between nucleotides 46-159 as suggested by our work and the work of Bachand et al. 
(Bachand and Autexier, 2001) (Figure 2.8). 
Our results demonstrate that targeting telomerase holoenzyme assemblage is an 
effective approach towards inhibiting telomerase activity.  Both hTRas009 and hTRas010 
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had a significant inhibitory effect on telomerase activity in the assemblage assay (Figures 
2.2A and 2.2B).  However, neither appreciably decreased full-length hTR binding alone 
(lanes 8-9, Figure 2.5) suggesting that this inhibitory approach not only prevents proper 
telomerase  assembly  but  also  sequesters  the  telomerase  subunits  in  an  inactive state.  A 
A.                                        B.      C.          D.
E.                                      F.                               G.                   H.
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Figure 2.8  hTRas009 and hTR010 prevent proper telomerase assemblage by blocking 
essential interactions between hTR and hTERT. (A) In the absence of oligonucleotide 
inhibitor, hTERT (dark blue circle) interacts directly with hTR via the CR4-CR5 domain 
(yellow), the P3/P1 pairing region (green) and other portions of the pseudoknot domain (light 
blue).  (B) hTRas009, targeting the P3/P1 pairing region, partially blocks hTR/hTERT binding. 
(C) hTRas010, targeting the CR4-CR5 domain,  partially blocks hTR/hTERT binding.  (D) 
hTRas009 and hTRas010 partially block hTR/hTERT binding.  (E) Proposed model for 
telomerase complex dimerization via the P3 pairing regions in the absence of oligonucleotide 
inhibitor.  (F) hTRas009 partially blocks hTR/hTERT binding and blocks dimerization.  (G) 
hTRas010 partially blocks hTR/hTERT binding while dimerization remains intact.  (H) 
hTRas009 and hTRas010 partially block hTR/hTERT binding and block dimerization. 
Oligonucleotides are depicted by the red lines.  consistent with this data is that hTRas009 and hTR010 prevent proper telomerase 
blage by blocking essential interactions between hTR and hTERT (Figure 2.8). 
Although hTRas009 and hTRas010 were unable to reverse the interaction between 
sembled hTR and hTERT in order to inhibit telomerase activity (Figure 2.4), this mode 
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of inhibition should be relevant to cancer therapy.  In cancer cells, hTR has an extended half-
life concomitant with a high transcription rate (Yi et al., 1999).  This suggests that the 
telomerase complex itself has a high turnover rate.  In addition, as cancer cells divide, more 
telomerase must be generated.  Molecules that sequester hTR and induce misassemblage 
could then have an opportunity to elicit their effects on rapidly reproducing cells.  In fact, it 
has been demonstrated that PNAs targeting non-templating regions of hTR can inhibit 
intracellular telomerase (Hamilton et al., 1999). The approach described here to block 
telomerase assemblage could also provide a chemogenetic method to study telomerase 
assemblage in cultured cells. 
 
 
D. Materials and methods 
 
1. Oligonucleotides.  
All oligonucleotides were purchased from and purified by Integrated DNA 
Technologies (Coralville, Iowa).  Oligonucleotide concentrations were determined by UV 
absorbance at 260 nm using the molar extinction coefficient provided by Integrated DNA 
Technologies.  
 
2. pET-28c-hTERT and phTR+HH expression plasmids.   
 
An hTERT plasmid (pCl-neo-hTERT) was a gift from Dr. Lorel Colgin (Children's 
Medical Research Institute, Westmead Australia) and CAMBIA (Canberra Australia) (Colgin 
et al., 2000). The hTERT-containing insert from this plasmid was subcloned into the EcoRI 
and SalI sites of the T7-tag-containing plasmid pET-28c (Novagen) to give the construct 
pET-28c-hTERT.  phTR+HH, a plasmid designed for in vitro transcription of human 
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telomerase RNA with a self-cleaving hammerhead ribozyme that generates the natural 5’ 
end, was a gift from Dr. Jamie Sperger (University of Colorado, Boulder). 
 
3. In vitro transcription and purification of hTR.  
15 µg of phTR+HH was linearized by digestion with Fok-1 followed by extraction 
with phenol/chloroform/isoamyl alcohol, precipitation with ethanol and resuspension in a 
suitable volume of TE (10 mM Tris-HCl, pH 7.5 and 1 mM EDTA).  In vitro transcription 
was carried out at 37 ºC for 18 h using the linearized DNA, 0.32 units/µL T7 RNA 
polymerase (Promega), 1× transcription-optimized buffer (Promega), 10 mM DTT, 0.8 
units/µL RNasin (Fisher Scientific), 5 mM MgCl2 and 1 mM each NTP.  After transcription, 
the magnesium-inorganic diphosphate complexes were removed by centrifugation for 2 min 
at 22 000g.  Cleavage by the hammerhead ribozyme was initiated by the addition of MgCl2 to 
a final concentration of 12 mM followed by incubation at 45 ºC for 1 h.  The entire reaction 
was then treated with 15 units of RQ1-DNase (Promega) for 20 min at 37 ºC followed by 
extraction with phenol/chloroform/ isoamyl alcohol and ethanol precipitation.  The RNA was 
resuspended in a suitable volume of denaturing loading buffer (7 M urea/10% glycerol/1× 
TBE) and purified on a 4% denaturing polyacrylamide gel.  The RNA was recovered using a 
modified version of the "crush and soak" method (Maxam and Gilbert, 1977).  Briefly, the 
RNA was located in the gel by UV shadowing, cut out, crushed by passing through a sterile 
plastic syringe and extracted into 2 volumes of 1× TEN (10 mM Tris-HCl, pH 7.5, 1 mM 
EDTA and 200 mM NaCl) at 4 ºC for 16 h.  After centrifugation, the supernatant was 
collected and a second extraction was performed with 2 volumes of 1× TEN at room 
temperature for 1 h.  The combined supernatants were filtered through a Whatman GF/C 
filter, precipitated with ethanol and resuspended in a suitable volume of TE. 
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4. Synthesis of hTERT.   
hTERT was transcribed and translated using the TNT Coupled Reticulocyte Lysate 
Systems kit (Promega).  A 400 µL reaction contained 8 µg of pET-28c-hTERT, 16 µL of 
[35S]-methionine (1175 Ci/mmol, 10 µCi/µL; Perkin Elmer) and other components provided 
in the kit as described by the manufacturer.  The reaction was incubated at 30 ºC for 90 min, 
flash-frozen in a dry ice/ethanol bath and stored at –80 oC.  hTERT used in the direct 
telomerase assay and the assemblage assay was made without [35S]-methionine as described 
by the manufacturer.  A reticulocyte lysate reaction with pET-28c (empty vector control) in 
place of pET-28c-hTERT served as a negative control in several experiments.   
 
5. Reconstitution of telomerase.   
Pre-assembled telomerase was prepared by adding 4 µg of in vitro transcribed hTR to 
the 400 µL reticulocyte lysate reaction prior to incubation for 90 min at 30 oC. Direct 
telomerase assays contained 10 µL of pre-assembled telomerase.  Reconstitution of 
telomerase in the assemblage assay was initiated by combining 10 µL (~50 fmol) of hTERT 
from a reticulocyte lysate reaction, 212.5 ng of in vitro transcribed hTR and the appropriate 
amount of water or oligonucleotide inhibitor to a final volume of 15 µl followed by 
incubation at 30 ºC for 90 min.  The pre-assembled telomerase complex and the hTERT 
protein were used in assays without further purification from the reticulocyte lysate. 
 
6. Direct telomerase assay.  
Telomerase activity was measured using a modification of a previously described 
direct assay (Chen and Greider, 2003).  Each 25 µL reaction contained 50 mM Tris-HCl, pH 
8.0, 50 mM KCl, 1 mM MgCl2, 5 mM β-mercaptoethanol, 1 mM spermidine, 1 µM human 
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telomere primer (5'-TTAGGGTTAGGGTTAGGG), 0.5 mM dATP, 0.5 mM dTTP, 2.9 µM 
dGTP, 0.33 µM [α-32P]-dGTP (3000 Ci/mmol, 10 µCi/µL; Perkin Elmer) and 10 µL of pre-
assembled telomerase.  Inhibition studies also included varying amounts of oligonucleotide 
inhibitor.  Primer extension was carried out at 30 ºC for 90 min.  After the addition of a 32P-
labeled loading control (114 nucleotide, 5’-end labeled DNA oligonucleotide, 1000 cpm per 
reaction), the primer extension products were extracted with phenol/chloroform/isoamyl 
alcohol and ethanol precipitated in the presence of 0.6 M NH4OAc and 35 ng/µL glycogen.  
Products were precipitated at –80 ºC in 2.5 volumes of absolute ethanol for 30 min followed 
by centrifugation at 22 000g at 4 ºC for 25 min and washing with 2 volumes of 70% ethanol.  
Pellets were resuspended in a suitable volume of TE and ethanol precipitation was repeated 
to ensure the removal of all unincorporated [α-32P]-dGTP.  The final pellets were dissolved 
in a formamide loading buffer containing 40% formamide, 10 mM Tris-HCl, pH 8.0, 10 mM 
EDTA, 0.05% xylene cyanol and 0.05% bromophenol blue.  The products were heated at 95 
ºC for 5 min and resolved on a pre-warmed, 0.4 mm thick, 20 x 20 cm, 10% 
polyacrylamide/7 M urea/1× TBE gel.  A small amount of the human telomere primer was 
labeled with [γ-32P]-ATP and T4 Polynucleotide Kinase (Fisher) and loaded in a separate 
lane to be used as a marker for the start of primer elongation.  The gel was run at 800 V for 1 
h in 1× TBE. After drying the gel and exposing it to a phosphorimager screen (Molecular 
Dynamics) overnight, telomerase activity was imaged using a phosphorimager (Molecular 
Dynamics Storm 860) and quantified with ImageQuant (version 5.2).  The intensities of each 
band in each sample were summed and normalized to the loading control. 
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7. Assemblage assay.  
Each 25 µL reaction contained 50 mM Tris-HCl, pH 8.0, 50 mM KCl, 1 mM MgCl2, 
5 mM β-mercaptoethanol, 1 mM spermidine, 1 µM human telomere primer (5'-
TTAGGGTTAGGGTTAGGG), 0.5 mM dATP, 0.5 mM dTTP, 2.9 µM dGTP, 0.33 µM [α-
32P]-dGTP (3000 Ci/mmol, 10 µCi/µL; Perkin Elmer) and 15 µL of reconstituted telomerase 
(see Reconstitution of Telomerase above).  Inhibition studies also included varying amounts 
of oligonucleotide inhibitor.  Primer extension was carried out at 30 ºC for 90 min and the 
samples were processed as described for the direct telomerase assay.  Notably, the inhibitor 
concentration was maintained during both the assembly reaction and extension reaction. 
 
8. Synthesis of 32P-labeled CR4-CR5 and pseudoknot RNA fragments and full-   
    length hTR.   
 
RNA fragments were generated using a modification of the protocol described by 
Chen et al. (Chen and Greider, 2003).  The desired DNA templates were amplified by PCR 
using the phTR+HH plasmid described above.  The pseudoknot PCR fragment (nucleotides 
46-209) was synthesized using the T7 promoter-containing forward primer 5'-
GGGTACCTAATACGACTCACTATAGGCTAACCCTAACTGAGAAGGGCGTAGGCG
CCGTG-3' and the reverse primer 5'-CCCCGGGAGGGGCGAACGGGCCA-3'.  The CR4-
CR5 PCR fragment (nucleotides 243-328) was synthesized using the T7 promoter-containing 
forward primer 5'-GCGGGAATTCTAATACGACTCACTATAGGCCCGCCTGGAGGCC-
GC-3' and the reverse primer 5'-GACCCGCGGCTGACAGAGC-3'.  Both RNA fragments 
start with two guanosine residues on their 5' end in order to aid in T7 transcription efficiency.  
The PCR products were resolved on a 0.8% agarose gel and purified using a Wizard PCR 
Preps DNA Purification System (Promega).  In vitro transcription was carried out at 37 ºC 
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for 18 h using the purified PCR products or linearized phTR+HH, 1 unit/µL T7 RNA 
polymerase (Promega), 1× transcription optimized buffer (Promega), 10 mM DTT, 1 unit/µL 
RNasin (Fisher Scientific), 5 mM MgCl2, 1 mM ATP, 1 mM GTP, 1 mM UTP, 20 µM CTP 
and 0.75 µM [α-32P]-CTP (800 Ci/mmol, 10 µCi/µL; Perkin Elmer).  After transcription, the 
magnesium-inorganic diphosphate complexes were removed by centrifugation for 2 min at 
22 000g.  The addition of MgCl2 to the hTR+HH transcription reaction was not required in 
this protocol as gel analysis revealed that the hammerhead had cleaved during the 18 h 
incubation at 37 ºC.  The reaction was then treated with 7 units of RQ1-DNase (Promega) for 
20 min at 37 ºC followed by extraction with phenol/chloroform/isoamyl alcohol.  The RNA 
was precipitated with ethanol in the presence of 2 M NH4OAc and resuspended in a suitable 
volume of TE.  A second ethanol precipitation was performed to decrease the amount of 
unincorporated NTPs.  The samples were then passed through Microspin G-25 columns 
(Amersham) to ensure the removal of all unincorporated [α-32P]-CTP. 
 
9. Immunoprecipitation/RNA pull-down.   
A 75 µL reaction contained 50 µL (~250 fmol) of 35S-labeled hTERT from a 
reticulocyte lysate reaction and 400-900 fmol of 32P-labeled pseudoknot or CR4-CR5 RNA 
fragment or full-length hTR (1.3-1.9 x 106 cpm per reaction).  Inhibition studies also 
included varying amounts of oligonucleotide inhibitor(s).  Reactions were incubated at 30 ºC 
for 90 min to allow binding between the RNA and the protein.  Each reaction was 
immunoprecipitated using 25 µL of anti-T7 antibody agarose beads (Novagen).  Before use, 
the anti-T7 beads were washed four times with 375 µL of wash buffer #1 (20 mM Tris-
acetate, pH 7.5, 10% glycerol, 1 mM EDTA, 5 mM MgCl2, 100 mM potassium glutamate, 
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0.1% IGEPAL and 1 mM DTT) and blocked twice with 250 µL of blocking buffer (20 mM 
Tris-acetate, pH 7.5, 10% glycerol, 1 mM EDTA, 5 mM MgCl2, 100 mM potassium 
glutamate, 0.1% IGEPAL, 1 mM DTT, 0.5 mg/mL lysozyme, 0.5 mg/mL BSA, 0.05 mg/mL 
glycogen and 0.1 mg/mL yeast RNA) for 15 min at 4 ºC.  In between each washing and 
blocking step the beads were precipitated by centrifugation at 1500g and the supernatant was 
removed.  75 µL of blocking buffer was then mixed with the 75 µL RNA/protein sample and 
centrifuged at 17 000g for 10 min at 4 ºC to remove any precipitates.  This supernatant was 
then added to the blocked beads and the samples were mixed on a rotary platform for 2 h at 4 
ºC.  Following mixing, the beads were washed three times with 325 µL of Wash Buffer #2 
(20 mM Tris-acetate, pH 7.5, 10% glycerol, 1 mM EDTA, 5 mM MgCl2, 300 mM potassium 
glutamate, 0.1% IGEPAL and 1 mM DTT) and twice with 325 µL of TMG (10 mM Tris-
acetate, pH 7.5, 1 mM MgCl2 and 10% glycerol).  The beads were precipitated by 
centrifugation at 1500g in between each wash and the supernatant was removed.  The beads 
were then resuspended in 1× SDS gel loading buffer containing 10 mM DTT.  Samples were 
heated for 5 min at 95 ºC and the supernatant was loaded onto a 4-12% Bis-Tris SDS gel 
(Invitrogen).  The gel was run at 130 V for 1 h, dried and exposed to a phosphorimager 
screen overnight.  RNA band intensities were quantified, normalized to the 35S-hTERT 
protein bands and compared to the positive control. 
 
10. Inhibition studies.   
Direct telomerase or assemblage assays were conducted as described above with 
varying concentrations of inhibitors.  IC50 values were calculated using the Regression 
Wizard program of SigmaPlot (version 7.0).  Six data points were used with oligonucleotide 
 59
 60
concentrations ranging from 0 to 10 µM.  The following four-parameter logistic curve 
equation was used: 
 
y = D + [(A-D)/(1 + (x/C)^B)] 
 
where x is the concentration of inhibitor, y is the % Activity relative to the primer-only 
control, A is the maximal activity, B is the slope factor, C is the IC50 (i.e. the concentration 
required for 50% inhibition) and D is the minimal activity.  Inhibition data were plotted as % 
Activity vs. log oligonucleotide concentration and fit using the same equation. 
 
11. Nondenaturing polyacrylamide gel electrophoresis of 32P-hTR. 
Nondenaturing PAGE was performed using a modification of the protocol described 
by Ly et al. (Ly et al., 2003b).  Briefly, each 10 µL reaction contained 0.6 µg of unlabeled 
hTR and about 11000 cpm of tracer 32P-hTR.  The samples were heated at 95 ºC for 5 min, 
immediately placed on ice and adjusted to 50 mM NaCl, 25 mM Tris-Cl, pH 7.0, 10 mM 
MgCl2.  hTRas009 or hTR010 was then added to a final concentration of 10 µM.  Samples 
were then either kept on ice or incubated at 37 ºC for 2 hrs to allow for dimerization.  Sample 
products were analyzed on a 4% nondenaturing gel in 90 mM Tris-borate, 0.1 mM MgCl2.  
The gel was run at 100 V for 6 hrs in a cold room (4 ºC).  After drying the gel and exposing it 
to a phosphorimager screen overnight, the extent of dimerization was quantified. 
 
 
 
 
 
 
 
 
Chapter III.  RNA-binding ligands affect telomerase assemblage 
 
 
Adapted from: Dominick, P. K., Keppler, B. R., Legassie, J. D., Moon, I. K. and M.B. 
Jarstfer, Nucleic-Acid Binding Ligands Identify New Mechanisms to Inhibit Telomerase. 
Bioorganic and Medicinal Chemistry Letters, 2004. 14, 3467-3471 
 
 
A.  Introduction 
In devising a new approach towards telomerase inhibition, we considered the 
available targets and the past approaches taken to mediate telomerase activity.  Telomerase is 
a multi-subunit ribonucleoprotein complex, but the minimal requirements to establish 
telomerase activity in vitro include only the catalytic protein subunit, hTERT (human 
telomere reverse transcriptase) and the RNA subunit, hTR (human telomerase RNA), which 
contains the template for reverse transcription (Beattie et al., 1997; Weinrich et al., 1997).  
Several approaches to inhibit telomerase have been investigated and can be broken down into 
four major categories: G-quadruplex stabilizers (Cuesta et al., 2003), antisense 
oligonucleotides (Corey, 2002), reverse transcriptase inhibitors (Strahl and Blackburn, 1996) 
and non-reverse transcriptase inhibitors (Damm et al., 2001; Beltz, 2002).  The most 
effective of these to date are phosphoramidate, locked nucleic acid (LNA) and 2'-
methoxyethyl oligonucleotides that are complementary to the template portion of hTR 
(Corey, 2002).  In fact, the only FDA-approved telomerase inhibitors presently in clinical 
trials are GRN163, a template-targeting thio-phosphoramidate oligonucleotide, and 
GRN163L, a lipid-modified version of GRN163.  Given the current drawbacks of 
oligonucleotide-based therapeutics, however, small molecule telomerase inhibitors continue 
to be an area of great interest.  In order to explore novel mechanisms for the inhibition of 
telomerase, we have developed a parallel screen to identify molecules that inhibit telomerase 
by affecting proper assemblage of the holoenzyme complex (see Chapter II) (Keppler and 
Jarstfer, 2004).  Here, we describe the use of this screen to sieve through a small library of 
nucleic acid-binding ligands.  Potential inhibitors include several aminoglycosides, DNA  
intercalators  including the  known  telomerase  inhibitor  proflavine  as  a control  and  DNA 
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 Figure 3.1  Compounds tested as telomerase inhibitors.   
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minor groove binders (Figure 3.1).  Our main objective in this study was to identify small 
molecules that inhibit telomerase by interacting with hTR, leading to a dysfunctional 
telomerase complex. 
  
 
B. Results 
 
1. Pre- and post-assemblage assays 
To determine if the selected small molecules were inhibitors of human telomerase 
activity each compound was first tested in an assemblage assay.  Compounds were added at a 
final concentration of 50 µM prior to hTERT/hTR association.  After allowing assemblage, 
telomerase activity was assayed using a direct assay (Figure 3.2A).  In the direct assay, the 
concentration of inhibitor present in the assemblage portion was maintained.  The most 
potent inhibitors (defined as ≥ 50% inhibited) were quinacrine, Hoechst 33258, lividomycin, 
4’,6-diamidino-2-phenylindole (DAPI), gentamycin, neomycin, proflavine and 
paromomycin.  These inhibitory compounds were then tested at the same concentration in 
direct assays using pre-assembled telomerase (Figure 3.2B).  Compounds that were 
inhibitory were divided into two groups: compounds in Group I inhibited telomerase to a 
greater extent (> 2 fold difference) when added prior to assemblage whereas those in Group 
II inhibited to a similar extent (< 2 fold difference) irrespective of the order of addition 
(Table 3.1).  This group of compounds was also assayed for their ability to inhibit telomerase 
from other organisms.  All fourteen small molecules were tested in turn using recombinant 
telomerase from the ciliated protozoan Tetrahymena thermophila both before and after 
assembly of its protein (tTERT) and RNA (tTR) counterparts.  We found that only 
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proflavine, quinacrine, Hoechst 33258 and DAPI had an inhibitory effect (Table 3.1).  We 
also determined  the inhibitory  potential of our small  library against endogenous  telomerase  
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 Figure 3.2  RNA binding ligand-induced inhibition of telomerase pre- and post-
assemblage  (A) Inhibition of telomerase by nucleic-acid ligands added before telomerase 
assemblage.  Lane 1, no inhibitor; 2, quinacrine; 3, Hoechst 33258; 4, spectinomycin; 5, 
amikacin; 6, lividomycin; 7, DAPI; 8, gentamycin; 9, neomycin; 10, hygromycin; 11, 
tetracycline; 12, distamycin A; 13, apramycin; 14, proflavine; 15, paromomycin.  Ligand 
concentration was maintained at 50 µM throughout the assay.  (B) Inhibition of assembled 
telomerase by nucleic acid-binding ligands.  Lane 1, no inhibitor; 2, quinacrine; 3, Hoechst 
33258; 4, lividomycin; 5, DAPI; 6, gentamycin; 7, neomycin; 8, proflavine; 9, paromomycin. 
Ligand concentration was maintained at 50 µM throughout the assay.  L.C. is a loading control 
and 32P-labeled primer indicates the start of primer elongation. 
 
fied from the ciliated protozoan Euplotes aediculatus.  In this organism, proflavine, 
acrine, Hoechst 33258 and distamycin A were the only compounds found to significantly 
rb telomerase activity (Table 3.1).   
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 Table 3.1 Percent inhibition of telomerase by selected nucleic acid-binding ligandsIntercalators
Proflavine
Quinacrine
DNA minor groove binders
Hoechst 33258
Diamidino-2-phenylindole
Distamycin A
Aminoglycosides
Neomycin
Gentamycin
Paromomycin
Lividomycin
Apramycin
Amikacin
Spectinomycin
Hygromycin
Other classes
Tetracycline
II
II
I
II
n/a
I
I
I
I
n/a
n/a
n/a
n/a
n/a
95%
82%
81%
90%
10%
70%
64%
60%
50%
30%
25%
0%
0%
10%
90%
50%
34%
72%
n.d.f
23%
19%
29%
12%
n.d.
n.d.
n.d.
n.d.
n.d.
90%
93%
50%
70%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
90%
80%
15%
70%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
52%
75%
86%
0%
75%
0%
0%
0%
10%
0%
0%
0%
0%
0%
Inhibitor
Groupb
Human
Prec
Human
Postc
Tetrahymena
Pred
Tetrahymena
Postd
Euplotese
 aTelomerase from several sources was assayed in the presence of 50 µM of the indicated nucleic-acid 
binding ligand.  100% inhibition indicates no activity observed, and 0% inhibition indicates wild type 
activity.  
bInhibitors were designated as Group I or Group II as defined in the text and n/a indicates that the 
designation is not applicable.   
cDetermined using recombinant hTR and hTERT in a direct assay as described in Chapter II.  
dDetermined using recombinant T. thermophila TERT and TR in a direct assay (Bryan et al., 2000b). 
eDetermined using purified endogenous telomerase from E. aediculatus in a direct assay (Jarstfer and 
Cech, 2002). 
fNot determined.  
2.  Binding studies of Hoechst 33258 to hTR 
Turning our attention toward elucidating the modes of inhibition of the compounds, 
 next determined if they hampered telomerase activity by binding to hTR.  Because 
echst 33258 was previously identified as an RNA-binding ligand that exhibits an easily 
nitored change in fluorescence upon binding to nucleic acids, we used fluorescence 
ectroscopy to directly test our hypothesis (Dassonneville et al., 1997; Cho and Rando, 
00).  We observed the change in fluorescence of 0.2 µM Hoechst 33258 in the presence of 
ll-length hTR, a G-quadruplex formed from the human telomeric DNA sequence 5’-
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(GGGATT)3GGG and the RNA-DNA duplex representing the E. aediculatus telomerase-
primer duplex 5'-dGGTTTTGGGGTTTTG/r3'-CCUUUUCCCCUUUUC (Figure 3.3), which 
was  chosen  because  it forms the most  stable duplex of  the  three telomerase  complexes in   
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Figure 3.3  Hoechst 33258 binds to hTR but not to other nucleic acid components present 
in the telomerase reaction.  The fluorescence intensity of Hoechst 33258 (0.2 µM) was 
monitored as a function of the concentration of three different nucleic acid components as 
indicated.  The hTR curve was fit to the quadratic equation for a binding isotherm (see 
Materials and methods). 
 
 
 
these studies.  Of these, only hTR binding to Hoechst 33258 led to a saturated increase in 
fluorescence (Figure 3.3).  Plotting Hoechst 33258 fluorescence versus hTR concentration, 
we obtained a dissociation constant (KD) of 0.36 µM.   
 
 
C. Discussion 
 
 Our initial effort to determine if hTR can be a small molecule drug target was based 
on the premise that nucleic acid-binding ligands can interact with hTR either before or after 
telomerase assemblage, resulting in a non-functional telomerase complex.  To test this 
proposal, we screened a small library of known nucleic acid-binding ligands as inhibitors of 
recombinant telomerase.  Potential inhibitors (Figure 3.1) were added either before 
assemblage of the telomerase complex or after assemblage (Figure 3.2).  To determine if 
these compounds were specific inhibitors of human telomerase, we examined their ability to 
affect telomerase from two other organisms.  An inhibition study with recombinant 
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telomerase from Tetrahymena thermophila (Bryan et al., 2000) conducted by adding 
inhibitors either before or after assemblage revealed a similar distribution of inhibition as 
observed for human telomerase (Table 3.1).  One notable exception was that none of the 
aminoglycosides tested were inhibitors of the T. thermophila enzyme suggesting a specific 
interaction between the inhibitory aminoglycosides and hTR.  The small library was also 
tested against endogenous Euplotes aediculatus telomerase (Jarstfer and Cech, 2002).  With 
purified E. aediculatus telomerase we found that the DNA minor groove-binding drugs 
distamycin A and Hoechst 33258 were excellent inhibitors as were the intercalators 
quinacrine and proflavine.  Other drugs tested had no significant affect on E. aediculatus 
telomerase activity. 
 After identifying several new telomerase inhibitors, we desired to elucidate the modes 
of inhibition of the compounds that significantly inhibited telomerase from all three 
organisms.  The only compounds that meet this criterion are proflavine, quinacrine and 
Hoechst 33258.  We chose to focus on Hoechst 33258 over the intercalators due to the fact 
that minor groove binders are typically less promiscuous in terms of specificity for nucleic 
acids.  We examined the change in fluorescence of Hoechst 33258 in the presence of several 
nucleic acid components involved in the telomerase reaction cycle and found that only hTR 
produced a large and saturable increase in the fluorescence intensity of Hoechst 33258, 
indicating specificity for hTR (Figure 3.3).  A plot of fluorescence versus concentration of 
hTR gave an approximate dissociation constant of 0.36 µM assuming a single binding site or 
multiple non-cooperative binding sites.  We conclude from this study that hTR is the target 
for inhibition by this ligand.  Because the other Group I inhibitors are known to bind RNA in 
general and we directly observed a specific interaction between Hoechst 33258 and hTR, we 
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suggest that all Group I inhibitors act by interacting with hTR leading to formation of a 
dysfunctional telomerase complex after assemblage.  Additionally, the fact that the 
reticulocyte lysate used to reconstitute telomerase contains large amounts of tRNA, rRNA 
and mRNA further suggests a high specificity of Group I inhibitors for hTR versus other 
RNA molecules. 
The mechanisms of inhibition of the remaining molecules await further investigation.  
However, several points can be highlighted.  The intercalators quinacrine and proflavine 
appear to be telomerase inhibitors that lack species specificity.  Because the telomeric repeats 
produced by telomerase from each of these species can fold into G-quadruplexes, one 
possible mode of action for these molecules is quadruplex stabilization.  Proflavine has been 
reported as an inhibitor of human telomerase (IC50 = 3.9 µM), and a variety of proflavine 
derivatives have been shown to stabilize G-quadruplex structures (Perry and Jenkins, 2001).  
In our direct assays, the banding patterns of the telomerase products generated in the 
presence of quinacrine and proflavine were not consistent with typical quadruplex stabilizing 
compounds, which tend to cause enrichment of products associated with four repeats of the 
telomeric sequence (Sun et al., 1997).  However, we cannot rule out this mode of inhibition 
at this time.  Interestingly, the minor groove binder distamycin A was a strong inhibitor of E. 
aediculatus telomerase, but did not inhibit either recombinant human or T. thermophila 
telomerase.  This was a surprise since a distamycin derivative was previously shown to 
inhibit human telomerase (Zaffaroni et al., 2002).  By contrast, the minor groove binder 
DAPI, which does not inhibit viral reverse transcriptases (Filipowsky et al., 1996), did inhibit 
both recombinant human and T. thermophila telomerase, but did not inhibit E. aediculatus 
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telomerase.  This suggests that the DAPI skeleton would be a useful starting point for the 
synthesis of selective telomerase inhibitors. 
In conclusion, we have utilized a two-part parallel screen to identify inhibitors from a 
small library of known nucleic acid-binding ligands.  Two general types of inhibitors were 
identified.  Several of the compounds, the Group I inhibitors, appear to inhibit telomerase by 
specifically interacting with unbound hTR.  Spectroscopic studies of the interaction between 
Hoechst 33258 and hTR, increased inhibition of human telomerase compared to inhibition of 
telomerase from other species and the increased inhibition of Group I inhibitors when added 
before assemblage of the telomerase complex support this conclusion.  Group II inhibitors 
were similarly effective when added before or after telomerase assemblage. The most likely 
explanation for the differences in Group I and Group II inhibitors is that the Group I binding 
sites are present in hTR and are only available in unbound hTR.  By contrast, Group II 
binding sites, which may be protein, RNA, quadruplex DNA or the RNA–DNA duplex, are 
available in the holoenzyme.  These results provide an impetus to further examine hTR as a 
target for small-molecule drugs.  Furthermore, these studies confirm that telomerase 
assemblage can be targeted with small molecules and plants the seed for future studies, 
which will include the screening of large compound libraries. 
 
 
D.  Materials and methods 
 See Chapter II, section D for information on the pET-28c-hTERT and phTR+HH 
expression plasmids and methods for in vitro transcription and purification of hTR, synthesis 
of hTERT, reconstitution of human telomerase, direct human telomerase assays and human 
assemblage assays. 
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1.  Chemical reagents 
 
4’,6-diamidino-2-phenylindole (DAPI), apramycin sulfate, distamycin A 
hydrochloride, gentamycin sulfate, Hoechst 332558 (bisbenzimide H 33258), hygromycin B, 
lividomycin A sulfate salt, neomycin, proflavine hemisulfate salt, spectinomycin di-
hydrochloride and tetracycline hydrochloride were purchased from Sigma.  Amikacin sulfate 
and quinacrine di-hydrochloride were purchased from Fluka.  Paromomycin sulfate 
monohydrate was purchased from INC Biomedicals Inc.  Each compound was solubilized 
and diluted in ddH2O and stored at -20 ºC. 
 
2.  T. thermophila telomerase assays   
 
These experiments were performed by Jason D. Legassie using a previously described 
protocol (Bryan et al., 2000). 
 
3.  E. aediculatus telomerase assays 
 
These experiments were performed by Ian K. Moon using a previously described 
protocol (Jarstfer and Cech, 2002). 
 
4.  Fluorescence spectroscopy  
 
The fluorescence intensity of 0.2 µM Hoechst 33258 was monitored as a function of 
the concentration of either hTR, (GGGTTA)3GGG or 5'-dGGTTTTGGGGTTTTG/r3'-
CCUUUUCCCCUUUUC as indicated.  Hoechst was excited at 350 nm and monitored at 460 
nm.  Graphs were plotted using SigmaPlot 2000.  The hTR curve was fit to the quadratic 
equation for a binding isotherm: F= F0 + ∆F(([Hoechst]0 + [L]0 + KD) – (([hTR]0 + 
[Hoechst]0 + KD)2 –  4[hTR]0[Hoechst]0)1/2)/2 where F0 is the fluorescence intensity in the 
absence of hTR, F is the fluorescence intensity in the presence of hTR and ∆F is the 
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difference between the fluorescence of 0.2 µM Hoechst in the presence of saturating hTR and 
the absence of hTR.  [hTR]0 and [Hoechst]0 are initial concentrations.  These experiments 
were performed by Dr. Pamela K. Dominick. 
 
5.  Calculation of dissociation constant 
 
 This experiment was performed by Dr. Pamela K. Dominick. 
 
 
 
 
 
 
 
Chapter IV.  The natural product tanshinone II-A and novel derivatives inhibit  
                       telomerase assemblage 
 
 
A.  Introduction 
We have initiated a new platform to identify chemical entities that disrupt the 
assemblage of the telomerase holoenzyme structure (Chapters II and III) (Dominick et al., 
2004; Keppler and Jarstfer, 2004).  This approach is diverse in that it can identify molecules 
that inhibit hsp90, bind the catalytic subunit hTERT or bind the RNA subunit hTR (Figure 
4.1).  Thus, drugs that affect the assemblage of telomerase can do so through several 
mechanisms  including  inhibiting  essential chaperones  (Holt et al., 1999; Villa et al., 2003),   
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 Figure 4.1  Effectors of telomerase assemblage.  (A) Telomerase holoenzyme components 
required in order to attain enzymatic activity.  (B) A screen for molecules that perturb the 
assemblage of telomerase will identify compounds that bind hTR, hTERT or inhibit hsp90. 
The end result of telomerase assemblage modulators is a dysfunctional telomerase complex. 
disrupting critical protein-protein interactions or preventing pertinent protein-RNA 
interactions required for telomerase function (Dominick et al., 2004; Keppler and Jarstfer, 
2004).  The end result of perturbing telomerase holoenzyme assemblage is the in situ 
generation of a dominant negative complex that may be deficient in all telomerase-dependent 
functions.  Previously, we established that blocking specific hTR-hTERT interactions 
prevents proper telomerase assemblage (Chapter II) (Keppler and Jarstfer, 2004), and we 
have shown that small molecules that bind hTR can initiate the formation of a dysfunctional 
telomerase complex (Chapter III) (Dominick et al., 2004).  Here, we examine a class of 
natural products for their ability to produce a dominant negative telomerase complex in an in 
vitro assemblage assay.  
Tanshinones are diterpene pigments isolated from the root of Salvia miltiorrhiza 
BUNGE, which has been used in numerous traditional Chinese folk remedies (Baillie and 
Thomson, 1968; Lee et al., 1987).  Several tanshinones have demonstrated cytotoxic effects 
and are considered prospective leads for developing new anticancer drugs (Wu et al., 1991; 
Ryu et al., 1997).  The best studied and most abundant tanshinone, tanshinone II-A (Tan II-
A), induces apoptosis in a wide variety of cancer cell lines (Sung et al., 1999; Yuan et al., 
2004).  The mechanism of Tan II-A-induced apoptosis, however, is not understood. Given 
the recent evidence that telomerase directly affects apoptosis and the general interest in new 
telomerase inhibitors, we hypothesized that telomerase may be one of the molecular targets 
of Tan II-A.  We examined the effect of several natural tanshinones on telomerase activity to 
test this hypothesis.  Here, we show that the diketone tanshinones Tan II-A, tanshinone I and 
cryptotanshinone inhibit telomerase activity in an in vitro assemblage assay, suggesting that 
they perturb the assemblage of telomerase or are time dependent inhibitors of telomerase.  
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Furthermore, we demonstrate that their cytotoxicity coincides with telomerase activity.  
Thus, tanshinones provide a new structural class of small molecules to explore as telomerase 
inhibitors.   
 
 
B. Results 
 
 1.  Tanshinone II-A is a potent and specific inhibitor of telomerase assemblage 
 
We recently developed a telomerase assemblage assay that allows one to identify 
small molecules that affect telomerase activity through several mechanisms including direct 
inhibition of its enzymatic activity, blocking specific protein-RNA interactions required for 
assemblage of active telomerase and inhibiting the chaperone hsp90, which is required for 
telomerase activity (Holt et al., 1999).  The assay takes advantage of the ability to assemble 
recombinant telomerase in rabbit reticulocyte lysates (RRL) (Beattie et al., 1997; Weinrich et 
al., 1997) followed by a direct assay for telomerase activity using a telomeric primer and [α-
32P]-dGTP  as  one of  the  substrates.   In  this  study,  we  focused on the tanshinone class of  
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 Figure 4.2  Tanshinones tested in this study74
natural products because they have broad anti-proliferative effects that we reasoned could be 
related to inhibition of telomerase-mediated activities (Figure 4.2).    
We evaluated the affect of Tan II-A on telomerase activity by adding varying 
concentrations of Tan II-A to a reaction mixture containing in vitro translated hTERT in RRL 
and in vitro transcribed hTR followed sequentially by an assemblage reaction and a primer 
extension assay to evaluate telomerase activity.  Tan II-A was a potent inhibitor of 
telomerase in this assemblage assay with an IC50 = 4.8 µM (Figure 4.3, curve with 
?symbols).  In a separate experiment, varying concentrations of Tan II-A were added to 
telomerase after it was allowed to assemble (a post-assemblage assay).  Again, Tan II-A was 
an inhibitor of telomerase with an IC50 = 0.5 µM (Figure 4.3, curve with ?symbols), 
however, the maximum amount of inhibition was only 30% when Tan II-A was added to 
assembled telomerase, compared to >95% when Tan II-A was added before assemblage. 
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Figure 4.3  Inhibition of telomerase by tanshinone II-A.  (A) Assemblage assay using varying 
concentrations of Tan II-A (from 0.5 to 100 µM).  (B) Direct assay using varying concentrations 
of Tan II-A (from 0.1 to 100 µM).  The wedge indicates increasing concentrations of Tan II-A. 
LC is a loading control used to normalize the telomerase products present in each lane.  (C) 
Quantification of telomerase assays.  % Activity of experimental samples was determined by 
comparison with a positive control containing DMSO as a carrier. 
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2.  Tanshinone II-A inhibition of various nucleic acid polymerases 
The selectivity of Tan II-A for telomerase was assessed using the Klenow fragment of 
DNA polymerase I, T7 RNA polymerase and MMLV reverse transcriptase as examples of 
other nucleic acid processing enzymes.  At 50 µM, over ten times the IC50 for telomerase, 
Tan II-A did not inhibit the other nucleic acid polymerases, though we did observe a 
noteworthy increase in the activity of M-MLV RT (Figure 4.4).  
T7 RNA Poly M-MLV RT Klenow DNA Poly
DMSO:          +                       - +                      - +                       -
Tan II-A:           - +                        - +                          - +
Relative activity:           1                    0.9           1                     1.8                        1  1.2
 
 
   
Figure 4.4  Effects of Tanshinone II-A on different nucleic acid processing enzymes. 
Positive controls contained an equal volume of DMSO in place of the tanshinone.  “Relative 
activity” refers to the amount of enzymatic activity as compared to the DMSO-only control. 
The concentration of Tan II-A was 50 µM in each experiment. 
    
3.  The tanshinone quinone moiety is essential for inhibition 
To determine the salient features of the tanshinone structure required for inhibition, 
we examined several natural tanshinones (Figure 4.2) for their ability to affect telomerase 
activity when added prior to assemblage.  Tan II-A, Tan I and cryptotanshinone, which all 
have a 1,2-diketone C ring, inhibited telomerase, while neo-tanshinlactone, which has a 
lactone C ring, was a less potent inhibitor (Table 4.1).  Thus, the 1,2-diketone moiety present 
in the tanshinone structure is essential for maximum activity.  Our results also showed that an 
aromatic A ring (compare tanshinone I to Tan II-A) and a heteroaromatic D ring (compare 
Tan II-A to cryptotanshinone) are not required for telomerase inhibition.   
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 Table 4.1  Natural tanshinones affect telomerase activitCompound
Tan II-A
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Percent Telomerase Activity at 50 µM
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 Compounds were added to telomerase assemblage assays at a final concentration of 
50 µM.  Telomerase activity was quantified by comparison with a DMSO-only 
control.  Values are the average of at least two separate experiments and have 
standard errors < 2%. anshinone II-A inhibits telomerase in cultured cells and is selectively 
ytotoxic towards telomerase positive cells 
next tested the cytotoxicity of Tan II-A in telomerase-positive and telomerase-
ells lines to determine if telomerase inhibition coincided with observed 
.  Tan II-A was a potent cytotoxin of the telomerase-positive breast cancer cell 
 (EC50 0.90 µM) and prostate cancer cell line PC-3 (EC50 1.2 µM), consistent 
us reports using a variety of cancer cell lines (Figure 4.5A) (Wu et al., 1991; Ryu 
 Wang, X. et al., 2004b; Yuan et al., 2004).  Furthermore, telomerase activity was 
50% in MCF-7 cells after 24 hr exposure to cytotoxic concentrations of Tan II-A 
B and C).  By contrast, in telomerase-negative GM847 and Saos-2 cells, we 
Tan II-A was much less toxic with an EC50 of >20 µM against both cell lines 
). 
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 Figure 4.5  Consequences of treating immortalized cells with tanshinone II-A.  (A)Cytotoxicity assays of Tan II-A.  (B) Residual telomerase activity of MCF-7 cells 24 hr after 
Tan II-A exposure.  Lane 1, heat inactivated MCF-7 extracts; lane 2, extract from untreated 
MCF-7 cells; lane 3 extract from MCF-7 cells treated with 0.2 µM Tan II-A; lane 4 extract 
from MCF-7 cells treated with 0.8 µM Tan II-A; lane 5 extract from MCF-7 cells treated 
with 3.2 µM Tan II-A.  ITAS, internal amplification standard.  (C) Graphical representation 
of telomerase assays.  Telomerase activity is the percent of residual telomerase activity in 
treated cells relative to untreated control cells and is the average of two independent 
calculations.  Error bars indicate standard deviation. 
 
 
 
 
 
 
 
 
 
C. Discussion 
 
Telomerase has the potential to be a universal anticancer drug target, and many 
approaches to target telomerase have been explored (Saretzki, 2003).  Currently the most 
promising telomerase inhibitors are oligonucleotide-based template antagonists that inhibit 
the enzymatic activity of telomerase (Corey, 2002). Because telomerase is involved in 
several pathways that promote cancer cell proliferation, targeting only the enzymatic activity 
of telomerase might not achieve the maximum potential of telomerase-based therapeutics.  
We have therefore initiated a concerted effort to discover telomerase inhibitors that affect 
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assemblage of the telomerase holoenzyme structure, as opposed to simply inhibiting its 
enzymatic activity.  The hypothesis behind our approach is that disrupting telomerase 
assemblage has the potential of creating, in situ, a dominant negative telomerase complex 
that is dysfunctional in all telomerase-related activities.  In the current study, we investigated 
the ability of the tanshinone natural products to affect telomerase activity.  This compound 
class was examined because the underlying mechanism of tanshinone-induced cytotoxicity 
has not been identified, and because the broad cytotoxicity of tanshinones against cancer 
cells suggests they target a pathway shared by many cell types (Wu et al., 1991).   
 We found that tanshinones containing a 1,2 di-ketone were inhibitors of telomerase 
(Table 4.1) and were demonstrably more active when present during telomerase assemblage.  
This latter result suggests that they perturb telomerase assemblage resulting in a 
dysfunctional complex.  Previous reports suggest that hsp90 inhibitors also inhibit telomerase 
(Holt et al., 1999; Villa et al., 2003) by perturbing telomerase assemblage leading to the 
hypothesis that Tan II-A is an hsp90 inhibitor.  Recent studies in our lab, however, have 
shown that hsp90 inhibitors geldanamycin and novobiocin completely inhibit telomerase 
even after it is assembled, suggesting that the role of hsp90 is more complex than simply 
mediating assemblage.  In contrast to geldanamycin and novobiocin, Tan II-A only partially 
inhibited pre-assembled telomerase resulting in a 30% decrease in activity and an IC50 that 
was comparable to the IC50 obtained when Tan II-A was added during the assemblage 
process (Figure 4.3).  This result suggests that Tan II-A is only a partial antagonist of the 
telomerase holoenzyme, or is a time dependent inhibitor.  If hsp90 were the molecular target 
for Tan II-A, we would expect complete inhibition of pre-assembled telomerase, by 
comparison to geldanamycin and novobiocin.  Inhibition of telomerase by Tan II-A 
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resembles the inhibition of telomerase by nucleic acid-binding ligands Hoechst 33258 and 
neomycin, which have been proposed to inhibit telomerase by targeting its RNA subunit 
(Chapter III) (Dominick et al., 2004).  Based on the similarities of its pattern of inhibition, we 
speculate that Tan II-A also targets hTR.  Alternatively, Tan-IIA could utilize its ortho-
quinone moiety to engage in a REDOX cycling reaction that causes oxidation of hTR or 
hTERT.  This possibility is currently being investigated.  
 We hypothesize that the ability of Tan II-A to inhibit nucleic acid processing 
enzymes is specific for telomerase, an RNA-dependent DNA Polymerase, as the tanshinones 
failed to significantly affect the activity of T7 RNA Polymerase, M-MLV RT and Klenow 
DNA Polymerase (Figure 4.4).  We did observe a notable increase in activity when Tan II-A 
was added to an M-MLV RT reaction, however, this increase in activity does not influence 
our hypothesis that the compound has inhibitory specificity for telomerase. 
Our cell-based assays demonstrated that Tan II-A is cytotoxic to both telomerase-
positive and telomerase-negative cells, but that telomerase-positive cell lines were more 
sensitive to Tan II-A than telomerase-negative cells (Figure 4.5A).  We also showed that Tan 
II-A decreases telomerase activity in telomerase-positive MCF-7 cells (Figures 4.5B and C).  
Thus, disrupting telomerase assemblage in telomerase-positive cells likely contributes to the 
overall mechanism of Tan II-A-mediated cytotoxicity.  Perhaps in rapidly dividing cells, the 
telomerase complex actively participates in an anti-apoptotic process.  Whereas in 
telomerase-negative cells that are sensitive to Tan II-A, the apoptotic block served by 
telomerase is replaced by other factors.  Tan II-A has several biological effects that are 
consistent with this model.  In cell-based assays, Tan II-A inhibited differentiation of 
precursor cells to osteoclasts and inhibited bone reabsorption by differentiated osteoclasts in 
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cultured mouse cells (Takahashi et al., 2002).  In this case, Tan II-A affected the gene 
expression of proteins required for osteoclast differentiation and activity but did not induce 
apoptosis.  While the telomerase activity of these cells was not examined, human osteoblasts 
and osteoclasts are generally considered telomerase negative (Yudoh et al., 2001; Darimont 
et al., 2002).  Tan II-A-induced apoptosis of human hepatocellular carcinoma cells coincided 
with upregulation of the apoptosis-related genes fas, bax and p53 coincidental with 
downregulation of bcl2 and c-myc (Yuan et al., 2004).  Downregulation of c-myc may also 
contribute to the observed inhibition of telomerase in cultured cells as c-myc appears to 
participate in the regulation of hTERT expression (Horikawa et al., 1999).  These results 
suggest that Tan II-A has variable effects depending on cell type and can affect multiple 
signaling pathways.  These multiple effects of Tan II-A presumably arise from its ability to 
affect several targets, which now includes telomerase.  
 In summary, our results indicate that the tanshinones containing a 1,2-diketone 
provide a unique structural class of telomerase inhibitors that function through a unique 
mechanism, perturbing telomerase assemblage.  Our results demonstrate that cytotoxicity of 
Tan II-A in part correlates with telomerase expression.  Results suggest that the ortho-
quinone moiety of Tan II-A is the important pharmacophore for inhibition of telomerase.  
This suggests that Tan II-A is involved in REDOX cycling that could generate reactive 
oxygen species leading to oxidative damage of telomerase, similar to the polyaromatic 
quinine-mediated catalytic inactivation of protein tyrosine phosphatases observed by Wang et 
al. (Wang, Q. et al., 2004a).  If true, this would explain the broad pharmacological activity of 
Tan II-A and shed light on the REDOX regulation of telomerase (Borras et al., 2004).  
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D. Materials and methods 
 
See Chapter II, section D for information on pET-28c-hTERT and phTR+HH 
expression plasmids and methods for in vitro transcription and purification of hTR, synthesis 
of hTERT, reconstitution of human telomerase, direct telomerase assays and assemblage 
assays.  
 
1. Chemical reagents 
Tanshinones were made available from a previous study and were stored as 5 mM 
stocks in sterile DMSO (Wang, X. et al., 2004b).   
 
2. Cells and cell culture 
The human breast cancer cell line MCF-7 (telomerase-positive adenocarcinoma, from 
ATCC, Manassas, VA) was cultured in αMEM medium (Gibco, Carlsbad, Calif.) 
supplemented with 10% fetal bovine serum (FBS) (Sigma, St. Louis, Mo.), 10µg/ml insulin 
(Gibco) and sodium pyruvate (Gibco).  The human prostate cancer cell line PC-3 
(telomerase-positive adenocarcinoma, from ATCC) was cultured in Dulbecco's modified 
Eagle/F12 medium (DMEM/F12) (Gibco) supplemented with 10% FBS. The human 
osteosarcoma cell line Saos-2 (telomerase-negative, from ATCC) was cultured in McCoy’s 
5A medium supplemented with 15% FBS.  The immortalized fibroblast cell line GM847 
(telomerase-negative) was a gift from Shelia Stewart and Robert Weinberg at the 
Massachusetts Institute of Technology (Cambridge, Mass.) and was cultured in DMEM 
supplemented with 10% FBS (Sigma, St. Louis, Mo.) and 50 µg/ml of gentamycin (Sigma).   
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 3. Telomerase activity of cell extracts 
Telomerase activity in cell extracts was determined by a modified telomeric repeat 
amplification protocol (TRAP assay) (Kim and Wu, 1997).  In short, cell lysates were 
prepared from 4 × 104 cells in 100 µL of lysis buffer (10 mM Tris, pH 7.5, 1 mM MgCl2, 1 
mM EGTA, 0.1 mM benzamidine, 0.5 mM β-mercaptoethanol, 0.5% CHAPS, 10% glycerol) 
by incubating the suspended cells on ice for 30 min followed by three freeze thaw cycles 
using liquid N2 to freeze the samples.  Cell lysates were clarified by centrifugation (10,000g, 
30 min at 4 ºC) and protein levels in the cell extracts were determined by the method of 
Bradford (Bradford, 1976).  Cell extracts (100 ng of total protein) were incubated with 0.1 µg 
TS primer (5′-AATCCGTCGAGCAGAGTT) in a 25 µl reaction containing TRAP buffer (20 
mM Tris-HCl, pH 8.3, 1.5 mM MgCl2, 63 mM KCl, 0.05% Tween20 and 1 mM EGTA) and 
50 µM of each dNTP at 30 ºC for 30 min.  Telomerase extension reactions were then heated 
to 95 ºC for 5 min before the products were amplified by adding 0.1 µg ACX primer (5′-
GCGCGG(CTTACC)3CTAACC), 0.1 µg NT primer (5′-ATCGGCTTCTCGGCCTTTT),  
0.001 amol TSNT template (5′-AATCCGTCGAGCAGAGTTAAAAGGCCGAGAA-
GCGAT, used as a PCR and loading control), 0.5 units HotMaster Taq DNA polymerase 
(Eppendorf), 5 µl of 10× Taq buffer and dNTPs to a final concentration of 50 µM.  The 
reactions were then subjected to 33 PCR cycles at 95 ºC for 30 s, 60 ºC for 30 s, 72 ºC for 60 
s.  Reaction products were separated on a 12.5% nondenaturing polyacrylamide gel, stained 
with SYBR Green I (Molecular Probes) and imaged on a phosphorimager.  Reactions were 
quantified using ImageQuant and the product intensity for each reaction was normalized to 
the TSNT internal control. 
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4. Cytotoxicity assay   
Acute cell growth inhibition by drugs was determined using a sulforhodamine B 
(SRB) assay (Papazisis et al., 1997).   Between 3,000 and 6,000 cells/well were seeded into 
96-well microtiter plates in 0.2 ml of media and allowed to attach overnight.  A range of 
concentrations of Tan II-A was added from a 5 mM stock in DMSO to quadruplicate wells 
and cells were incubated for 96 hr.  Cell numbers of treated and untreated cells were 
compared.  First, cells were fixed by adding 50 µL of cold 50% trichloroacetic acid to the top 
of the 200 µL culture medium and incubated for 30 min at 4 ºC.  Fixed cells were washed 
extensively with deionized water and dried for 2 hr at room temperature.  Cells were stained 
for 20 min in 0.4% SRB, 1% acetic acid, rinsed with 1% acetic acid and air dried.  The bound 
SRB was solubilized with 200 µl 10 mM Tris-base and the absorbance at 562 nm was 
measured.  
 
5.  Testing the effects of Tanshinone II-A on T7 RNA polymerase, M-MLV reverse    
     transcriptase and the Klenow fragment of DNA polymerase I 
 
 To test the effect of 50 µM Tan II-A on T7 RNA Polymerase, the compound was 
added to a reaction transcribing 32P-labeled pseudoknot RNA fragment (see Chapter II).  The 
RNA was resolved on a denaturing gel and compared to RNA transcribed in the presence of 
DMSO as a carrier. 
To determine if 50 µM Tan II-A influences M-MLV reverse transcription, the 
compound was added to a reaction containing 0.5 mM dNTPs, 0.33 µM [α-32P]-dGTP (3000 
Ci/mmol, 10 µCi/µL; Perkin Elmer), 20 units RNasin (Promega), 10 ng RNA template, 1 µM 
primer, 100 units M-MLV reverse transcriptase (Promega) and 1× M-MLV buffer 
(Promega).  The dNTPs, RNA, primer, Tan II-A and buffer were first combined and 
 84
 85
incubated at 95 ºC for 5 min followed by 0 ºC for 3 min.  The [α-32P]-dGTP and enzymes 
were then added and the reaction was incubate at 37 ºC for 2 h followed by 95 ºC for 5 min.  
After passing through a Microspin G-25 column (Amersham), the sample was resolved on a 
denaturing gel and compared to a reaction containing DMSO in place of Tan II-A.   
To test the effect of 50 µM Tan II-A on the Klenow Fragment of DNA Polymerase I, 
we first performed a double digestion on pET-28c using Sal I and Xho I in order to generate 
a 21 base-pair piece of DNA with sticky ends.  About 2 µg pET-28c was combined with 20 
units Sal I (New England Biolabs, NEB), 20 units Xho I (NEB), 100 µg/mL BSA and 1× Sal 
I buffer (NEB) and incubated at 37 ºC for 90 min, followed by 65 ºC for 20 min to heat 
inactivate the enzymes.  ~600 ng of the digested DNA was then combined with 50 µM 
dNTPs, 0.165 µM [α-32P]-dGTP (3000 Ci/mmol, 10 µCi/µL; Perkin Elmer), 5 units Large 
(Klenow) Fragment of DNA Polymerase I (NEB), 1× NEB buffer #2 and Tan II-A to a final 
concentration of 50 µM.  The reaction was incubated at 25 ºC for 30 min followed by 75 ºC 
for 20 min and passed through a Microspin G-25 column.  The degree of Tan II-A-induced 
Klenow inhibition was quantified by resolving the final product on a native gel along side a 
positive control reaction containing DMSO instead of Tan II-A.   
 
 6.  Natural product isolation and derivative synthesis 
 
 These experiments were performed by Xihong Wang in the laboratory of Dr.  
 
Kuo-Hsiung Lee.  
 
 
 
 
 
 
 
Chapter V.  Hsp90 is required to maintain telomerase in an active conformation 
 
 
A. Introduction 
 
The complete subunit composition of the human telomerase ribonucleoprotein (RNP) 
complex has yet to be fully elucidated, but the minimally active enzyme requires the reverse 
transcriptase catalytic subunit (hTERT) and an RNA subunit (hTR), which contains the 
template  (Feng et al., 1995; Kilian et al., 1997; Meyerson et al., 1997; Nakamura et al., 
1997).  Recent findings revealed that chaperone proteins such as Hsp90, p23, Hsp70, p60 and 
Hsp40/ydj are also part of the telomerase RNP, at least during part of the cell cycle (Holt et 
al., 1999; Forsythe et al., 2001).   In fact, these chaperones are required to obtain a 
functionally active telomerase RNP in vitro, though their precise role in telomerase 
assemblage remains enigmatic (Holt et al., 1999; Forsythe et al., 2001).   
Hsp90 is a highly conserved and abundant protein found in all eukaryotic cells (Lai et 
al., 1984; Jolly and Morimoto, 2000) that functions as part of  a “foldosome” complex (Pratt, 
1993; Hutchison et al., 1994).  Together with other chaperones, Hsp90 facilitates the accurate 
arrangement of numerous proteins.  Hsp90 possesses a number of previously identified 
functional domains.  Important for pharmacological concerns are the two ATP-binding sites 
located in both the N-terminus (Grenert et al., 1997; Prodromou et al., 1997) and C-terminus 
(Csermely and Kahn, 1991; Marcu et al., 2000) of the protein.  These sites are essential for 
Hsp90 function because ATP binding and hydrolysis are crucial in the conformational 
regulation of Hsp90 and therefore its affects on client proteins (Prodromou et al., 2000).  It 
has been suggested that the two ATP-binding sites act cooperativity, allowing cross-talk 
mediated by a central charged domain between the two termini (Marcu et al., 2000).  Hsp90 
is a functional homodimer with one homo-dimerization domain in the C-terminus (Nemoto et 
al., 1995) and a second located within the N-terminus (Prodromou et al., 2000).  There are 
also a number of co-chaperone binding domains including one for the acidic phosphoprotein 
p23, which binds to the amino-terminal and central region of Hsp90 in an ATP-dependent 
manner (Johnson and Toft, 1994; Grenert et al., 1997; Sullivan et al., 1997; Bohen, 1998; 
Fang et al., 1998), and one for Hsp70, which binds to the carboxyl terminus of Hsp90 
(Freitag et al., 1997; Young et al., 1998; Carrello et al., 1999; Marcu et al., 2000; Murphy et 
al., 2001).   
The best characterized domain of Hsp90 is undoubtedly the highly conserved, N-
terminal, nucleotide-binding pocket (Grenert et al., 1997; Prodromou et al., 1997; Stebbins et 
al., 1997), which also serves as the binding site for the Hsp90 inhibitor geldanamycin (GA) 
(Whitesell et al., 1994; Grenert et al., 1997).  GA, a benzoquinone ansamycin antibiotic, 
exerts its inhibitory effect by blocking the ATP-dependent binding of p23 to Hsp90 (Grenert 
et al., 1997; Prodromou et al., 1997).  Another Hsp90 inhibitor, the coumarin-type antibiotic 
novobiocin (NB), binds to the C-terminus of Hsp90 and hinders chaperone complex 
formation by blocking its association with both Hsp70 and p23 (Marcu et al., 2000).  Due to 
their antagonizing effects on Hsp90 function, both GA and NB are also inhibitors of proper 
telomerase holoenzyme assembly and therefore telomerase activity (Holt et al., 1999; 
Haendeler et al., 2003). 
The Hsp90 client list, which is constantly being updated, includes various 
transcription factors, polymerases, signaling protein kinases and steroid receptors, as well as 
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other proteins (Pratt and Toft, 2003).  Besides telomerase, Hsp90 has been implicated in 
activating another reverse transcriptase (RT), duck hepatitis B virus (DHBV) RT (Hu and 
Seeger, 1996).  Interestingly, Hu and Seeger demonstrated that the role of Hsp90 in DHBV 
RT activity is to maintain the RT in a “protein-priming” conformation capable of binding to 
the viral pregenomic RNA, which serves as the template for reverse transcription.    
Because we are interested in targeting telomerase assemblage as an anticancer 
approach, it is important to elucidate and understand the role of Hsp90 in telomerase RNP 
assemblage and function.  Here, we show that the addition of GA or NB to a direct 
telomerase assay inhibits telomerase activity independent of the order of inhibitor addition, 
i.e. before or after telomerase assembly.  We also report that hTERT and hTR are capable of 
interacting with each other in the absence of a functional Hsp90-p23 complex, though such a 
complex is inactive.  In these experiments, GA inhibition could only be overcome if 
telomerase was pre-incubated with its primer.  This leads us to propose a model in which the 
maturation of the human telomerase RNP into its final “primer-accepting” conformation 
requires Hsp90 and its co-chaperones.  Hsp90 may therefore play a role in human telomerase 
RNP maturation and ligand binding similar to its role in establishing active DHBV RT (Hu 
and Seeger, 1996) and steroid receptors (Bledsoe et al., 2002). 
 
 
B. Results 
 
     1.  Hsp90 inhibitors affect in vitro reconstituted human telomerase activity           
                both before and after assembly 
 
 To examine the role of Hsp90 in telomerase activation we used two Hsp90 inhibitors: 
GA, which binds to the N-terminal ATP-binding site, and NB, which binds to the C-terminal 
ATP-binding site.  Despite their separate binding sites, both compounds have been reported 
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to inhibit human telomerase (Holt et al., 1999; Haendeler et al., 2003).  In our hands, GA 
inhibited the in vitro reconstitution of telomerase activity when added before assembly with 
an IC50pre of 8.4 µM and NB inhibited with an IC50pre of 148 µM (Figure 5.1).  Notably, the 
concentrations of GA and NB were maintained throughout the assays, including both the 
assemblage and the primer extension reactions.  These findings are consistent with the 
hypothesis that Hsp90 inhibitors exert their effect by preventing Hsp90-dependent 
association between hTR and hTERT.  We further tested the role of Hsp90 by adding the 
Hsp90  inhibitors to  telomerase  that was pre- assembled.    Surprisingly,  we found that both  
 
%
 A
ct
iv
ity
%
 A
ct
iv
ity
Log [GA] Log [NB]
IC50
pre = 8.4 µM
IC50
post = 53 µM
IC50
pre = 148 µM
IC50
post = 408 µM
Α. B.
-12.5 -10.0 -7.5 -5.0 -2.5 0.0
0
50
100
-7.5 -5.0 -2.5
0
50
100
GA and N
respectively
when added
 Figure 5.1  GA and NB inhibit telomerase when added before or after assembly. 
(A) Concentration dependence of GA on telomerase activity in an assemblage assay
(pre-assembly, ■) and a direct assay (post-assembly, ▲). (B) Concentration 
dependence of NB on telomerase activity in an assemblage assay and a direct assay. 
IC50 values were calculated and inhibition curves were plotted as described in the 
Materials and methods.  Error bars indicate standard deviation.  
B inhibited telomerase activity with IC50post values of 53 µM and 408 µM, 
 (Figure 5.1).  Although the IC50 values for GA and NB were slightly higher 
 post-assemblage when compared to their addition pre-assemblage, both drugs 
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were full antagonists of assembled telomerase.  Therefore, we predicted that the effect of the 
Hsp90 inhibitors was not caused by explicitly preventing hTR-hTERT interaction, but 
resulted from an affect on some other aspect of telomerase.  To rule out direct inhibition of 
telomerase, we showed that the addition of p23 suppressed inhibition by GA (Figure 5.2). 
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Figure 5.2  p23 has a slight rescue effect on GA-induced telomerase inhibition. 
Telomerase activity was inhibited in an assembly assay by the addition of 75 µM GA 
(lanes 2 and 3).  p23 was added to the reaction for 30 min prior to the addition of GA 
and hTR at a final concentration of 20 µM (lane 3).  % Activity indicates the amount of 
residual telomerase activity as compared to the positive control (DMSO).  Error bars 
indicate standard deviation. 
 
 
 
 
 
 
2.  Telomerase maintains hTR-hTERT interactions in the presence of   
                 geldanamycin and novobiocin after hTERT translation 
 
Hsp90 was previously shown to be required for reconstituting active recombinant 
telomerase and to be involved in maintaining telomerase activity in cultured human cells 
(Holt et al., 1999; Akalin et al., 2001).  The precise role of Hsp90 in establishing active 
telomerase, however, is not clear from these studies.  To determine if Hsp90 is involved in 
establishing the association of hTR and hTERT during telomerase assembly, we performed 
co-immunoprecipitation assays using T7-tagged [35S]-hTERT and [32P]-RNA in the presence 
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of 300 µM GA or 1 mM NB.  We tested the ability of GA and NB to inhibit hTERT binding 
to full-length hTR as well as the CR4-CR5 and pseudoknot domains, which are two regions 
of hTR previously shown to interact independently with hTERT (Tesmer et al., 1999; 
Mitchell and Collins, 2000; Chen et al., 2002; Chen and Greider, 2003; Keppler and Jarstfer, 
2004).  The CR4-CR5 domain is a structurally conserved domain found in vertebrate 
telomerase RNAs.  In humans, the CR4-CR5 domain is well defined and has been found to 
contain a stem-loop termed P6.1, whose direct interaction with hTERT is required for 
telomerase activity (Tesmer et al., 1999; Mitchell and Collins, 2000; Chen et al., 2002; Chen 
and Greider, 2003).  The pseudoknot domain, which contains the template, also interacts with 
hTERT in a telomerase activity-dependent manner (Tesmer et al., 1999; Mitchell and 
Collins, 2000).  After allowing assembly between the two subunits, hTERT was 
immunopurified, along with bound RNA, and the resulting complexes were analyzed by SDS 
PAGE.  We found that Hsp90 inhibition does not affect the association of hTERT with hTR 
or the two domains of hTR we tested (Figure 5.3A).  This suggests that Hsp90 does not 
facilitate the association of hTR and hTERT.  Clearly, however, the telomerase complex that 
is assembled when Hsp90 is inhibited is dysfunctional.  
  Hsp90 and other chaperones function in part to stabilize peptides during translation to 
prevent improper folding (Wegele et al., 2004).  In the previous experiments, GA and NB 
were added after hTERT had been translated while Hsp90 was presumably active. To 
determine if Hsp90 activity is required to allow the nascent hTERT transcript to assume an 
hTR-binding competent state, we inhibited Hsp90 during hTERT translation. Because 
inhibition of Hsp90 during translation appeared to affect immunoprecipitation efficiency in 
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preliminary studies, we used affinity purification of the RNA subunit to assess hTR-hTERT 
association. 
 To analyze the association of full-length hTR with hTERT, telomerase complexes 
were affinity purified using a biotinylated oligonucleotide that was complimentary to the 
RNA template (Schnapp et al., 1998).  To analyze the association of the CR4-CR5 and 
pseudoknot  domains  with  hTERT,  [35S]-hTERT  was  translated in the presence  of  biotin-  
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Figure 5.3  hTR/hTERT interactions are unaffected by the presence of GA and NB 
after translation of hTERT, but hTR/hTERT interactions are effected by the presence 
of GA and NB during translation.  (A)  [32P]-Pseudoknot RNA fragment (lanes 1-3), [32P]-
CR4-CR5 RNA fragment (lanes 4-6) or [32P]-full-length hTR (lanes 7-9) were incubated 
with T7-tagged [35S]-hTERT either in the presence or absence of 300 µM GA or 1 mM NB. 
The complexes were immunopurified and resolved on an SDS gel.  [35S]-hTERT bands were 
used to normalize [32P]-RNA bands.  (B)  Pseudoknot RNA fragment (lanes 1-2), CR4-CR5 
RNA fragment (lanes 3-4) or full-length hTR (lanes 5-8) were added to TNT Coupled 
Reticulocyte Lysate reactions, which translated T7-tagged [35S]-hTERT in the presence of
100 µM GA or 1 mM NB.  The complexes were affinity purified and resolved on an SDS 
gel.  “% Bound” values indicate the amount of protein bound to the RNA when compared to 
control reactions with no GA or NB.  Gels shown are representative of multiple (2-4) 
experiments.  Independent experiments revealed no significant nonspecific binding (< 5%). 
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labeled RNAs and GA (Keppler and Jarstfer, 2004).   Interestingly, only the interaction of the 
CR4-CR5 domain was dramatically affected by the presence of GA during hTERT 
translation (Figure 5.3B, lanes 3-4), though there was a small decrease in the amount of 
pseudoknot RNA that co-purified with hTERT (Figure 5.3B, lanes 1-2).  The interaction 
between hTERT and full-length hTR was not affected by the presence of GA during 
translation (Figure 5.3B, lanes 5-6).  NB, on the other hand, was found to prevent over 60% 
of the full-length hTR/hTERT interaction when present during translation (Figure 5.3B, lanes 
7-8). 
 
3.  Primer binding overcomes GA, but not NB, inhibition of human telomerase 
 
 If GA does not affect telomerase by preventing the association of hTR with hTERT, 
then how does it inhibit its enzymatic activity?  One possibility is that Hsp90 is involved in 
loading telomerase onto the chromosome end. That is, Hsp90 might be involved in 
telomerase-primer docking.  Hu and Seeger found that Hsp90 maintains the DHBV RT in a 
“protein-priming” conformation capable of binding the RNA template used for reverse 
transcription (Hu and Seeger, 1996).  Similarly, Hsp90 promotes binding of steroid receptor 
complexes to their ligands (Tanenbaum et al., 1998; Williams and Sigler, 1998; Bledsoe et 
al., 2002; Koide et al., 2002).   Thus, it seems  that  Hsp90  can  participate  in  preparing  its 
clients for substrate and ligand binding.  Based on this precedence, we determined if Hsp90 
plays a direct role in telomerase-primer loading. 
We performed direct extension assays in the presence of either GA or NB and 
telomerase or telomerase pre-incubated with a telomeric primer.  We found that pre-
incubation of a telomeric primer with telomerase overcame GA-induced inhibition (Figures 
5.4A and B).  This effect was dependent on a telomeric primer, since a non-telomeric primer 
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did not elicit the rescue effect (Figures 5.4A and B, lane 4).  Because NB, like GA, is an 
Hsp90 inhibitor, we would expect to see a similar rescue effect.  Surprisingly, pre-incubation 
of a telomeric primer with telomerase did not overcome NB inhibition (Figures 5.4C and D).  
This suggests that the different ATP binding sites confer separate telomerase-specific 
functions to Hsp90.  
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 Figure 5.4  Pre-Incubation with primer rescues GA-induced but not NB-induced telomerase 
inhibition.  Pre-assembled telomerase was assayed for activity in the absence (lane 1) or presence (lanes 
2-4) of GA (A) or NB (C).  Pre-assembled telomerase was pre-incubated with primer (primer pre-inc), 
followed by the addition of GA or NB (A and C, lanes 3 and 4).  Lane 3 included a telomeric primer 
while lane 4 included a non-telomeric primer.  Quantified telomerase activity is displayed in (B) and 
(D).  “% Activity” is the amount of residual telomerase activity when compared to the positive control 
(lane 1).  The [32P]-loading control (L.C.) and the human telomere primer-extension products (+4, +10, 
+16, +22, etc. nucleotides added) are indicated.  Lane numbers for (B) and (D) correlate with (A) and 
(C), respectively.  Error bars indicate standard deviation.  
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4.  Hsp90 is associated with hTERT after telomeric primer binding 
 
If Hsp90 is involved in primer loading, then it might be expected to release the 
telomerase complex once docking has occurred, similar to the behavior of Hsp90 in 
facilitating ligand binding to steroid receptors (Bledsoe et al., 2002).  To test this possibility, 
we examined the association of [35S]-hTERT with Hsp90 in the presence or absence of a 
telomeric primer.  The holoenzyme complexes were pre-incubated with a telomeric primer, a 
non-telomeric primer, or in the absence of added DNA.  The resulting complexes were 
immunoprecipitated with an anti-Hsp90 antibody.  We found that the presence of the 
telomeric primer had no significant effect on the interaction between Hsp90 and hTERT 
when compared to the positive control without primer (Figure 5.5).  Similarly, a non-
telomeric primer, which served as a control for specificity, exhibited little effect (Figure 5.5, 
 
Telomeric primer:            - +                     - -
Non-telomeric primer:            - - +                      -
Hsp90 Antibody:           +                    +      +                      -
[35S]-Input
[35S]-Beads
Lane:          1                     2                      3   4
% Bound:       100                   92                   105   8
 
 
Figure 5.5  Hsp90 remains associated with hTERT after primer loading.  [35S]-labeled telomerase was 
incubated alone (lane 1), in the presence of telomeric primer (lane 2) or in the presence of non-telomeric 
primer (lane 3) and immunopurified with an Hsp90 antibody.  “% Bound” values indicate the amount of [35S]-
labeled telomerase bound to Hsp90 when compared to the positive control (lane 1).  Lane 4 is a negative 
control performed with no primer or antibody.  All immunoprecipitations were performed in duplicate and 
representative results are shown.   
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lane 3).  This result is consistent with a previous report that demonstrated the association of 
Hsp90 with active human telomerase (Holt et al., 1999).  A negative control with no primer 
or antibody yielded ≤ 8% nonspecific binding of [35S]-hTERT to the beads (Figure 5.5, lane 
4). 
 
5.  Hsp90 inhibition alters telomerase holoenzyme structure 
 
One possible explanation for the effects of GA and NB on telomerase is that Hsp90 is 
involved in stabilizing hTERT and therefore the telomerase complex.  For example, hTERT 
stability or its conformation could depend on Hsp90 activity.  We used partial proteolysis to 
examine the global structure of hTERT.  Partial proteolysis is a powerful technique used to 
identify substructures and functional domains in various proteins (Konigsberg, 1995) and has 
been used to examine the global structure of Tetrahymena thermophila TERT (Bryan et al., 
2000).  To determine if GA and NB affect hTERT stability, we treated Hsp90-inhibited 
assembly reactions with Lys-C, an endoproteinase that cleaves at K-X bonds.  Following 
proteolysis, the rate of full-length hTERT degradation in the absence and presence of Hsp90 
inhibitors was analyzed over time.  In the absence of Hsp90 inhibitors, hTERT degraded with 
a half-life of ~15 min (Figure 5.6).  Further, several prominent hTERT digestion products 
were observed.  In the presence of GA, the hTERT half-life was similar, and the same 
degradation banding pattern was observed.  In contrast, we found that NB significantly 
affected the rate of full-length hTERT proteolysis by decreasing the half-life to ~5 min.  The 
most obvious difference in hTERT degradation between NB and its control is seen at the 
earliest time point in which there is ~100% hTERT remaining in the control reaction but only 
~50% left when NB is present (Figure 5.6, compare  lane  10  to  lane  14).    Furthermore, 
when  comparing  the amounts  of  truncated  proteolysis  products  at  the 60 min time point, 
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 Figure 5.6  NB, but not GA, increases the proteolysis rate of hTERT.  [35S]-hTERT and hTR were 
assembled in the presence or absence of Hsp90 inhibitor.  Following co-immunopurification, the 
complexes were digested with Lys-C and aliquots were quenched at the indicated time points.  [35S]-
hTERT fragments digested after GA (A) or NB (C) treatment were resolved by SDS PAGE.  The 
amount of full-length [35S]-hTERT proteolysis was quantified and is displayed in (B) and (D).  Error 
bars indicate standard deviation.   NB treated sample has a significantly decreased level of truncated products when 
pared to both the H2O control and the GA-treated sample (Figure 5.6, compare lane 16 to 
s 8 and 12).  This presumably resulted from increased Lys-C digestion of the already 
cated proteolysis products due to decreased hTERT stability.   Further experiments will 
 to be performed in order to determine precisely what domains of hTERT have become 
erable to proteolysis.  The increase in Lys-C degradation in the presence of NB, but not 
 may explain why primer binding does not overcome NB inhibition.   
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 6. NB destabilizes hTERT 
A possible consequence of decreased hTERT stability is a commensurate decrease in 
telomerase complex stability.  Using a pulse-chase experiment, we determined if telomerase 
stability was affected by GA or NB by examining the dissociation rate of the CR4-CR5 and 
pseudoknot RNA domains from hTERT.  We did not detect any change in the dissociation 
rate of  the RNA-protein  complexes  in  our  assay  (Figure 5.7).   However,  we consistently  
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Figure 5.7  hTERT stability, but not RNA/protein complex half-life, is affected by NB.  T7-tagged 
[35S]-hTERT was incubated with [32P]-CR4-CR5 RNA, [32P]-PD RNA and either 100 µM GA (B) or 1 
mM NB (E).  Positive controls contained DMSO (A) or H2O (D).  Following a 90 min incubation at 30 
ºC, 70-fold excess CR4-CR5 and PD RNA were added to the reaction and a 50 µL aliquot was taken 
immediately and placed on ice (Time = 0).  The reaction was incubated at 30 ºC for 4 h and additional 
50 µL aliquots were taken at 30, 60, 120 and 240 min and placed on ice.  Following 
immunopurification, gel analysis and phosphorimaging, the RNA band intensities were quantified, 
normalized to the [35S]-hTERT protein bands and compared to the positive control.  The amount of 
hTERT pulled-down in the presence of GA (C) or NB (F) is displayed.  “% hTERT Pull-Down” 
indicates the amount of [35S]-hTERT immunopurified as compared to Time = 0 for the positive 
controls.  PD indicates the pseudoknot domain and CR4-CR5 indicates the CR4-CR5 domain of hTR. 
All immunoprecipitations were performed at least twice.  Error bars indicate standard deviation. 
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observed a time-dependent decrease in the ability to immunoprecipitate hTERT in the 
presence of NB as compared to the positive control, suggesting that the hTERT structure is 
not stable in the presence of NB owing to the inhibition of Hsp90.  GA also had a slight 
effect on the immunoprecipitation though the effect was much less severe than the NB effect.  
These results are consistent with the conclusion that NB destabilizes hTERT. 
 
 7. Hsp90 is associated with hTERT following geldanamycin or novobiocin treatment 
Yun et al. showed that NB binding to Hsp90 induces a conformational change that 
induces dissociation from client proteins (Yun et al., 2004).  They specifically showed that 
this “client-release” conformation promotes the dissociation of Hsp90 from the heme-
regulated eIF2α kinase.  A similar phenomenon would explain our finding that NB caused 
increased Lys-C proteolysis of hTERT and explain why pre-loading primer does not 
overcome NB inhibition.  Previously, Holt et al. showed that GA has no effect on 
Hsp90/hTERT   interaction   (Holt et al., 1999).    Using   an   anti-Hsp90   antibody  and  co-  
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Figure 5.8  Hsp90/hTERT interactions are unaffected by the presence of 
GA and NB after hTERT translation.  Pre-assembled telomerase was 
combined with GA or NB and immunoprecipitated with an anti-Hsp90 
antibody.  Negative controls using DMSO (lane 1) or H2O (lane 3) were also 
performed.  [35S]-hTERT protein band intensities were quantified and [35S]-
Input values were used to normalize [35S]-Bead values.  All 
immunoprecipitations were performed in duplicate and representative results 
are shown.   
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immunoprecipitating [35S]-hTERT we confirm that GA has no negative affect on 
Hsp90/hTERT interactions and report that NB also caused no decrease in the co-
immunoprecipitation efficiency of hTERT with Hsp90, even at a concentration that caused 
80% inhibition in telomerase activity (Figure 5.8).  Apparently NB-induced dissociation of 
Hsp90 from its clients is dependent on the particular client, and hTERT remains bound to 
Hsp90 even in the presence of NB. 
 
 
C. Discussion 
 
Human telomerase must be properly assembled to produce an active complex.  The 
biogenesis of telomerase has received much attention and appears to be a complex process 
that requires specific pathways for maturation of its RNA subunit (Mitchell et al., 1999; Fu 
and Collins, 2003) as well as assemblage of the holoenzyme complex (Holt et al., 1999; 
Forsythe et al., 2001; Collins and Mitchell, 2002).  It was previously revealed that the Hsp90 
chaperone complex interacts with hTERT and that Hsp90 activity is required for establishing 
active telomerase in both in vitro reconstitution assays and in cultured human cells.  In this 
work, we set out to further expand our understanding of the biochemical role of Hsp90 in 
maintaining telomerase activity and established that the role of Hsp90 in activating 
telomerase is more complex than previously thought.   
We confirmed that Hsp90 inhibitors GA and NB prevent reconstitution of active 
human telomerase (Figure 5.1).  Surprisingly, we found that this inhibition was not the result 
of preventing the interaction between hTERT and hTR or specific domains of hTR (Figure 
5.3A).  On the contrary, we found that hTR and hTERT are capable of interacting in the 
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presence of either GA or NB, even though the RNP complex that is assembled in the 
presence of these Hsp90 inhibitors is inactive.  Interestingly, when added to an assembly 
reaction prior to hTERT translation, NB caused a decrease in the amount of hTERT that co-
immunoprecipitated with full-length hTR, whereas GA only affected the association of the 
CR4-CR5 domain with hTERT (Figure 5.3B).  This suggests that the nascent hTERT 
transcript requires Hsp90 activity to achieve a structure that is fully competent in hTR 
binding and that the NB-targeted C-terminus of Hsp90 may be more important in 
maintaining RNP stability than the GA-targeted N-terminus.  In summary, our results 
indicate that Hsp90 does not chaperone the marriage of hTERT to hTR, per se, but may 
instead be involved in fine-tuning and stabilizing the assembled structure and ensuring that 
the nascent hTERT transcript folds properly.  
When GA or NB was added to pre-assembled telomerase, we observed complete 
inhibition of telomerase activity, albeit with a higher IC50 than when the inhibitors were 
added before assemblage (Figure 5.1).  There are several possible explanations for this result.  
During early work on the mechanism of GA action, it was noted that GA is an inhibitor of 
several nucleotide transferases including DNA Pol α (Yamaki et al., 1982), though it is not 
clear from these studies if the effect is related to Hsp90 inhibition or specific polymerase 
inhibition.  More recently, it was found that while GA inhibits hepatitis B RT, it does so by 
binding Hsp90 and is not an RT inhibitor as GA inhibition could be overcome using a 
synthetic mutant that was Hsp90 independent (Hu and Seeger, 1996; Wang et al., 2003).  
While we cannot entirely rule out direct inhibition of telomerase by GA and NB, the history 
of GA and NB suggests that Hsp90 is the more likely candidate in our studies.  Several 
observations are consistent with this conclusion.  First, GA and NB have different effects on 
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telomerase and are known to bind two distinct sites on Hsp90 that have distinct functions in 
the Hsp90 reaction cycle.  If telomerase were the target, we might expect GA and NB to 
generate more similar effects on telomerase.  Furthermore, the addition of p23, which has an 
overlapping binding site with GA on Hsp90, partially rescued telomerase activity from GA 
inhibition in an assemblage assay (Figure 5.2).  We also showed that NB affects the stability 
of hTERT, consistent with an Hsp90-dependent activity.  Together, the known 
pharmacological effects of GA and NB on Hsp90 and the observations we describe here are 
more consistent with an effect on Hsp90 than a direct inhibitory effect on telomerase.  
Since Hsp90 does not seem to be explicitly required to promote the association of 
hTERT and hTR, we speculated that it might be involved in primer loading.  This hypothesis 
was based on work with DHBV RT, for which Hsp90 removes an autoinhibitory domain 
away from the RT active site to allow primer loading and RNA binding (Hu and Seeger, 
1996; Wang et al., 2003).  We found that pre-incubation of a telomerase primer with pre-
assembled telomerase, prior to the addition of GA, rescued GA-induced telomerase inhibition 
(Figures 5.4A and B).  However, NB-induced telomerase inhibition was not overcome by 
pre-incubating primer (Figures 5.4C and D).  Though it has been suggested that the two 
termini of Hsp90 engage in cooperativity and cross-talk (Marcu et al., 2000), our results 
indicate that GA and NB dissociate different facets of Hsp90 involvement with telomerase 
and implicate different functions of the N- and C-terminal Hsp90 domains in the telomerase 
reaction cycle.   Hsp90 appears to be directly involved in primer binding and stabilizing the 
active telomerase complex as shown in the model presented in Figure 5.9.  In this model, the 
N-terminal ATP binding site functions to maintain telomerase in a primer-binding competent 
state.  The role of the putative C-terminal ATP binding site is to confer Hsp90-dependent  
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stability  to  hTERT.  This proposal  is  consistent with the apparent instability of hTERT in 
the presence of NB and the rescue of GA inhibition by primer.  Furthermore, though GA and 
NB target different ATP-binding sites on Hsp90, they both displace p23 from Hsp90 (Grenert 
et al., 1997; Prodromou et al., 1997; Marcu et al., 2000). This suggests that p23 displacement 
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 Figure 5.9  Conceptual model for Hsp90-mediated human telomerase 
maturation and the effects of GA and NB.  hTR and hTERT assemble after 
translation in the presence of Hsp90/p23 into an active complex that is competent in 
primer binding.  The addition of geldanamycin (GA) or novobiocin (NB) to the 
assembled complex leads to the formation of an inactive complex, in part by 
preventing primer binding and in part by destabilizing the hTERT polypeptide.  The 
addition of primer overcomes inhibition by GA, but not NB.  The CR4-CR5 and 
pseudoknot domains are indicated in their respective dotted boxes.  The N-terminus 
of Hsp90 is shown as the p23- and GA-binding sites.  The Hsp90 C-terminus is 
shown as the NB-binding site.  Note that the sizes of individual proteins are not 
drawn to scale.   d to primer binding.  It therefore remains to be seen whether or not the addition of 
ctive primer-bound telomerase complex will result in the release of p23 (Figure 
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Unlike the transient nature of some chaperones and client proteins, it is clear from our 
studies and those of the Holt lab that Hsp90 is stably associated with the telomerase 
holoenzyme both after hTERT/hTR assembly (Forsythe et al., 2001) and after primer binding 
(Figure 5.5).  To explain this, we propose that Hsp90 remains bound to hTERT in order to 
maintain the holoenzyme in a conformation capable of primer binding and catalysis (Figure 
5.9).  By comparison to the DHBV holoenzyme (Wang et al., 2003), perhaps the role of 
Hsp90 in telomerase holoenzyme maturation may include the manipulation and offsetting of 
an autoinhibitory domain to allow primer binding.  It is not clear if hTERT contains an 
autoinhibitory domain, but it is clear that the presence of functional Hsp90 does allow for 
efficient primer binding and thus increased telomerase activity.  Further studies using 
truncated hTERT mutants will address the existence of an Hsp90-antagonized autoinhibitory 
domain on hTERT. 
The mechanism of Hsp90-targeted inhibition of telomerase in cells appears more 
complex.  Antisense oligonucleotides targeting cellular Hsp90 have been shown to directly 
reduce Hsp90 mRNA expression and decrease telomerase activity (Chang et al., 2002).  
However, Hsp90 plays a significant role in regulating many cellular signaling pathways 
including that for the serine/threonine kinase Akt.  Akt has been found to increase human 
telomerase activity via phosphorylation of hTERT (Kang et al., 1999).  The association with 
Hsp90 is required to maintain Akt in an active state (Sato et al., 2000) and GA- and NB-
mediated Hsp90 inhibition has been found to inhibit the Akt cascade (Haendeler et al., 2003; 
Machida et al., 2003), thus leading to decreased telomerase activity.  Furthermore, GA-
induced Hsp90 inhibition in H1299 cells leads to the ubiquitination and proteosome-
mediated degradation of hTERT (Kim et al., 2005).  These indirect affects on telomerase 
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activity must therefore be taken into account when elucidating the cellular mechanisms of 
GA- and NB-induced telomerase inhibition.  Additionally, these results suggest that Hsp90 
inhibition will not lead to the formation of a dominant negative complex within cells.  
Therefore, though Hsp90 inhibitors do influence telomerase holoenzyme stability and 
primer-binding competence, they do not fit into our defined class of telomerase assemblage 
inhibitors. 
In conclusion, we have found that the role of Hsp90 in the telomerase reaction cycle 
is more complex than expected.  Hsp90 is not involved in allowing hTR to bind hTERT, 
though it may be involved in fine-tuning and stabilizing the structure of the complex.  Active 
Hsp90 seems to be required both during translation of the nascent hTERT transcript and for 
the assembly of active telomerase.  Importantly, Hsp90 appears to be involved in maintaining 
telomerase in a conformation that is competent to bind the telomere.  While it remains to be 
seen if this is true in vivo, it is an attractive model for allowing the Hsp90-dependent 
regulation of telomerase, and is consistent with the role of Hsp90 in facilitating ligand 
binding to other Hsp90 clients.   
 
 
D. Materials and methods 
 
See Chapter II, section D for information on pET-28c-hTERT and phTR+HH 
expression plasmids and methods for synthesis of hTERT, reconstitution of human 
telomerase, direct telomerase assays and assemblage assays.  p23 protein used in the direct 
telomerase assay was generously donated by Dr. David O. Toft. 
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1. Antibodies and chemical reagents 
The anti-Hsp90 mouse monoclonal antibody (H90-10) was a generous gift from Dr. 
David O. Toft (Mayo Clinic, Rochester, MN) (Barent et al., 1998).  GA was purchased from 
Alexis Biochemicals and NB was purchased from MP Biomedicals, Inc.  Before use, GA and 
NB were dissolved in sterile DMSO and H2O, respectively. 
 
2. In vitro transcription and purification of hTR 
Wild-type hTR was in vitro transcribed as described in Chapter II with minor 
modifications.  Briefly, 15 µg of phTR+HH was linearized with the restriction enzyme Fok1 
and added to a 100 µL transcription reaction containing 1× Ampliscribe T7 Reaction Buffer 
(Epicentre Technologies), 7.5 mM each NTP, 10 mM DTT and 10 µL Ampliscribe T7 
Enzyme Solution (containing an RNase inhibitor) (Epicentre Technologies).  The reaction 
was incubated at 37 °C for 4 h.  Hammerhead ribozyme cleavage was initiated by the 
addition of MgCl2 to a final concentration of 12 mM followed by incubation at 45 °C for 1 h. 
The reaction was then treated with 5 µL RNase-Free DNase 1 (Epicentre, 1 MBU/µL), 
incubated at 37 °C for 20 min, extracted with phenol/chloroform/isoamyl alcohol and ethanol 
precipitated in the presence of 0.3 M NaOAc.  The RNA was then resuspended in denaturing 
loading buffer (7 M urea/10% glycerol/1× TBE) and purified by denaturing PAGE.  The 
resulting purified RNA was resuspended in a suitable volume of 1× TE (10 mM Tris-HCl, 
pH 7.5, and 1 mM EDTA) and quantified by UV absorbance. 
 
3. Synthesis of [32P]-labeled pseudoknot and CR4-CR5 RNA fragments and  
      full-length hTR 
 
RNA fragments were generated using a modification of the protocol described in 
Chapter II (Chen and Greider, 2003; Keppler and Jarstfer, 2004).  Briefly, the DNA template 
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required to transcribe the pseudoknot RNA fragment (nucleotides 46-209) and the CR4-CR5 
RNA fragment (nucleotides 243-328) were generated by PCR. The resulting PCR products 
were purified using the Wizard PCR Preps DNA Purification system (Promega).  A 100 µL 
Ampliscribe T7 Transcription reaction contained 1× Ampliscribe T7 Reaction Buffer, 7.5 
mM CTP, 7.5 mM GTP, 7.5 mM UTP, 5.8 mM ATP, ~0.7 µM [α-32P]-ATP (3000 Ci/mmol, 
10 µCi/µL; Perkin-Elmer), 10 mM DTT, 10 µL Ampliscribe T7 Enzyme Solution and the 
required linear template.  Reactions were incubated at 37 °C for 4 h.  For full length hTR, 
hammerhead ribozyme cleavage was initiated as described.  Reactions were treated with 5 
µL RNase-Free DNase 1 (Epicentre, 1 MBU/µL), incubated at 37 °C for 20 min, extracted 
with phenol/chloroform/isoamyl alcohol and ethanol precipitated in the presence of 0.3 M 
NaOAc.  The RNA was resuspended in 1× TE and passed through a Microspin G-25 column 
(Amersham) to remove any remaining unincorporated [α-32P]-ATP. 
 
4.  Synthesis of biotinylated pseudoknot or CR4-CR5 RNA fragment 
A 100 µL Ampliscribe T7 Transcription reaction contained 1× Ampliscribe T7 
Reaction Buffer, 7.5 mM GTP, 7.5 mM UTP, 7.5 mM ATP, 6.25 mM CTP, 1.25 mM bio-11-
CTP (ENZO Life Sciences), 10 mM DTT, 10 µL Ampliscribe T7 Enzyme Solution and the 
appropriate DNA template.  Reactions were incubated for 4 h at 37 °C, treated with DNase, 
extracted with phenol/chloroform/isoamyl alcohol, ethanol precipitated and purified by 
PAGE as described. 
 
5.  Inhibition studies 
Telomerase activity assays, using both pre-assembled telomerase and telomerase 
assembled in the presence of an Hsp90 inhibitor were performed using varying 
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concentrations of inhibitor.  Seven data points were used with GA or NB concentrations 
ranging from 0 to 5 mM.  IC50 values were calculated and inhibition data were plotted as 
described in Chapter II. 
 
6.  Association of hTR and hTERT in the presence of GA and NB 
The ability of hTERT to associate with hTR in the presence of Hsp90 inhibitors was 
determined using a co-immunoprecipitation assay as described in Chapter II with minor 
modifications.  Briefly, a 75 µL reaction contained 50 µL (~250 fmol) of T7-tagged [35S]-
hTERT from a reticulocyte lysate reaction and ~80-800 pmol [32P]-labeled pseudoknot or 
CR4-CR5 RNA fragment or full-length hTR (2.7-3.1 x 106 cpm per reaction).  Inhibition 
studies also included GA (300 µM) or NB (1 mM).  Reactions were incubated at 30 °C for 90 
min.  Each reaction was immunoprecipitated using 25 µL of pre-washed and pre-blocked 
anti-T7 antibody agarose beads (Novagen).  Following incubation on a rotary platform for 2 
h at 4 °C, the beads were washed three times, resuspended in SDS gel loading buffer 
containing 10 mM DTT and resolved on a 4-12% Bis-Tris SDS gel (Invitrogen).  After 
phosphorimaging, the RNA band intensities were quantified, normalized to the [35S]-hTERT 
protein bands and compared to the positive control. 
 
7. Association of hTR and hTERT when GA or NB was present during translation of      
      hTERT   
 
The association of hTERT with hTR when Hsp90 was inhibited during translation of 
hTERT was assayed by affinity purification of full-length hTR using a modification of a 
previously described protocol for purification of human telomerase (Schnapp et al., 1998).  
[35S]-hTERT was synthesized in 50 µL reactions as described in Chapter II in the presence of 
5 pmol hTR and 100 µM GA or 1 mM NB.  Following a 90 min incubation at 30 °C the 
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reactions were combined with 50 µL of UltraLink® Immobilized NeutrAvidinTM Plus beads 
(Pierce) and 50 µL buffer A (20 mM Hepes-KOH, pH 7.9, 1 mM EDTA, 300 mM KCl, 0.5 
mM DTT, 0.5 mM PMSF, 10% glycerol) supplemented with 0.5% Triton X-100, 5 µg yeast 
RNA (50 µg/mL final concentration) and 100 pmol hTRbait, an affinity oligonucleotide 
complimentary to the template of hTR (5’-/biotin/-
CTAGACCTGTCATCAmGmUmUmAmGmGmGmUmUmAmG-3’ where m = 2’ O-methyl 
ribose).  Before use, the beads were washed once with 300 µL buffer A, blocked twice with 
250 µL blocking buffer (buffer A supplemented with 0.5 mg/mL BSA) for 15 min at 4°C and 
then washed with 300 µL buffer A.  The beads were precipitated by centrifugation at 2500g 
for 1.5 min.  The reactions were then incubated for 10 min at room temperature followed by 
2 h at 4°C on a rotary platform.  The resulting bead complexes were washed three times with 
300 µL buffer A supplemented with 0.5% Triton X-100, once with 300 µL buffer A 
supplemented with 300 mM KCl and twice with buffer A alone.  The precipitated bead 
samples were then resuspended in 1× SDS gel loading buffer with 10 mM DTT, heated for 5 
min at 95 °C and loaded onto a tris-glycine SDS gel (6% resolving, 5% stacking).  Dried gels 
were exposed to a phosphorimager screen overnight and the [35S]-hTERT bands were 
quantified, normalized to inputs and compared to the positive control.  Controls containing 
DMSO and H2O were conducted for comparison to GA and NB, respectively.   
Association of the CR4-CR5 and pseudoknot domains of hTR with hTERT was 
determined using biotin-labeled RNA.  [35S]-hTERT was synthesized in 50 µL reactions in 
the presence of ~60 pmol biotinylated pseudoknot RNA fragment or biotinylated CR4-CR5 
RNA fragment and 100 µM GA or DMSO carrier.  Each reaction was then affinity purified 
with 45 µL of pre-blocked MPG® Streptavidin beads (Pure Biotech, LLC).  Beads were 
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washed four times with 400 µL wash buffer 1 and blocked twice with 250 µL blocking buffer 
for 15 min at 4 °C before use as described in Chapter II.  The beads were precipitated by 
centrifugation at 2500g for 2 min between each step.  Each 50 µL reaction was then mixed 
with 50 µL blocking buffer and centrifuged at 17000g for 10 min at 4 °C in order to remove 
any precipitates.  The supernatant was added to the blocked beads and the samples were 
incubated for 45 min at room temperature on a rotary platform.  After washing the beads 
three times with 350 µL wash buffer 2 and once with 350 µL TMG, the samples were 
analyzed by SDS PAGE as described in Chapter II.    
 
8.  Immunoprecipitation of telomerase using an Hsp90 antibody 
Pre-assembled telomerase complexes were immunoprecipitated using a previously 
described protocol (Holt et al., 1999).  Briefly, 75 µL telomerase pre-assembled with [35S]-
hTERT was incubated at 30 °C in the presence of 1 µg human telomeric primer, no telomeric 
primer or 1 µg of non-telomeric primer.  After 90 min, anti-Hsp90 mouse monoclonal 
antibody (H90-10), generously donated by Dr. David O. Toft, was added to a final 
concentration of ~0.5 µg/mL and the samples were placed on ice for 1 h.  A negative control 
with no primer and no antibody added was performed.  Each reaction was 
immunoprecipitated by the addition of 22.5 µL Protein-G Agarose Beads (Roche).  Before 
use, the beads were washed three times with 400 µL PBS.  The reactions were incubated at 4 
°C for 1 h with constant rotation.  The beads were then washed three times with 400 µL 
Wash Buffer (20 mM Hepes, pH 7.6, 20% glycerol, 100 mM NaCl, 0.2 mM EGTA, 1 mM 
MgCl2, 0.1% NP-40, 0.1% BSA).  The precipitated bead samples were analyzed by SDS 
PAGE as described. 
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A similar immunoprecipitation was performed utilizing the H90-10 antibody in which 
pre-assembled, 35S-labeled telomerase was incubated in the presence of 100 µM GA or 500 
µM NB.  Positive controls contained DMSO or H2O.  The remainder of this pull-down was 
performed as above. 
 
9.  Lys-C proteolysis of hTERT 
The stability of hTERT was determined by Lys-C proteolysis using a modification of 
a previously described protocol (Bryan et al., 2000).  ~700 fmol T7-tagged [35S]-hTERT and 
3 µg hTR were allowed to assemble either in the presence or absence of 100 µM 
geldanamycin or 1 mM novobiocin at 30 °C for 90 min.  Each reaction was then 
immunoprecipitated using 30 µL of pre-washed and pre-blocked anti-T7 antibody agarose 
beads (Novagen), as described in Chapter II.  Following immunoprecipitation, the beads 
were washed with and resuspended in 80 µL Digestion Buffer (25 mM Tris-HCl, pH 8.5, 1 
mM EDTA).  Each sample was then treated with ~90 ng endoproteinase Lys-C (Roche, 
sequencing grade) and incubated at 30 °C.  Aliquots were taken out of each reaction at 
various time points and quenched with an equal volume of Laemmli’s sample buffer (125 
mM Tris-Cl, pH 6.8, 4% SDS, 0.005% bromophenol blue, 20% glycerol, 0.72 M β-
mercaptoethanol).  The samples were then heated at 95 °C for 5 min and resolved on a 4-12% 
Bis-Tris SDS gel (Invitrogen).  Following phosphorimaging, the [35S]-hTERT and hTERT 
fragment bands were quantified.   
 
10.  Pulse-chase 
325 µL (~1.625 pmol) T7-tagged [35S]-hTERT was incubated with 16.25 pmol [32P]-
CR4-CR5 RNA (~32 x 106 cpm), 16.25 pmol [32P]-PD RNA (~24 x 106 cpm) and either 100 
 111
 112
µM GA or 1 mM NB.  Positive controls contained DMSO or H2O.  Following a 90 min 
incubation at 30 ºC, 70-fold excess (~1137 pmol) CR4-CR5 and PD RNA were added to the 
reaction.  A 50 µL aliquot was taken immediately and placed on ice (Time = 0).  The reaction 
was incubated at 30 ºC for 4 h and additional 50 µL aliquots were taken at 30, 60, 120 and 
240 min and placed on ice.  Each 50 µL sample was then immunopurified via a T7-tag on 
hTERT and resolved on 4-12% Bis-Tris SDS gels (Invitrogen) as described in Chapter II 
(Keppler and Jarstfer, 2004).  Following phosphorimaging, the RNA band intensities were 
quantified, normalized to the [35S]-hTERT protein bands and compared to the positive 
control.  Pulse-chase experiments were performed in partnership with Allen T. Grady. 
 
 
 
 
 
 
 
 
Chapter VI.  Development of a high-throughput screen capable of identifying novel   
                       inhibitors of a specific hTERT/hTR interaction 
 
 
Adapted from:  Keppler, B. R. and Jarstfer, M. B. (2005) A High-Throughput Screen 
Capable of Identifying Novel Inhibitors of Human Telomerase Assemblage, accepted to 
Analytical Biochemistry. 
 
 
A.  Introduction 
 
Although active telomerase is naturally present in only select, non-somatic cells, the 
vast majority of cancer cell types also express active telomerase in order to maintain genetic 
stability throughout their infinite lifespan.  The loss of telomerase activity in a telomerase-
dependent cancer cell adversely affects telomeric integrity and results in senescence or cell 
death, thus making telomerase an appealing drug target.  In fact, the telomerase inhibitor 
GRN163L has entered phase I/II clinical trials for the treatment of chronic lymphocytic 
leukemia (Djojosubroto et al., 2005).  Past approaches towards manipulating telomerase 
activity include, but are not limited to, targeting hTERT, hTR, telomerase enzymatic activity 
or the telomere (White et al., 2001; Saretzki, 2003).  The use of dominant negative mutants 
(Hahn et al., 1999; Zhang, X. et al., 1999b) or ribozymes (Yokoyama et al., 2000; Qu et al., 
2002) are the most common methods of hTERT-targeted telomerase inhibition, and hTERT-
targeted immunotherapy is a more recent approach that is showing great promise (Shay and 
Wright, 2002).  Targeting hTR is carried out mainly through antisense interactions using 
various modified oligonucleotides including phosphorothioate (Pitts and Corey, 1998; 
Elayadi et al., 2001), 2'-O-methyl (Pitts and Corey, 1998), 2'-O-(2-methoxyethyl) (2'-MOE) 
(Elayadi et al., 2001), N3'→P5' thio-phosphoramidate (NPS) (Asai et al., 2003) and peptide 
nucleic acids (PNA) (Norton et al., 1996).  The most potent antisense oligonucleotide 
inhibitors found to date target the telomerase RNA template (Elayadi et al., 2001; Corey, 
2002; Asai et al., 2003).  Targeting the telomere as an anti-telomerase approach has been 
achieved using compounds that bind and stabilize G-quadruplexes at the end of the telomere.  
This class of telomerase inhibitors, which includes various derivatives of anthraquinones 
(Sun et al., 1997; Read, M. A. et al., 1999; Read, M. et al., 2001), acridines (Harrison et al., 
1999), porphyrins (Han et al., 2001; Shi et al., 2001), perylenes (Fedoroff et al., 1998; Han et 
al., 1999; Rangan et al., 2001) and ethidium (Koeppel et al., 2001), inhibits telomerase 
activity by preventing its access to the telomere.  Recently, our laboratory demonstrated that 
preventing proper telomerase holoenzyme assemblage is a viable approach to inhibiting the 
telomere-extension capabilities of telomerase (Keppler and Jarstfer, 2004).  We have 
advanced this approach by confirming that small molecules such as known nucleic acid-
binding compounds can also adversely affect telomerase assembly and thus its activity 
(Dominick et al., 2004).  Because the identification of an ideal, efficacious telomerase 
inhibitor has the potential to be a universal anticancer drug, there lies a need to develop rapid 
methods to identify novel inhibitors of telomerase.     
Several high-throughput methods to identify inhibitors of telomerase have been 
developed.  Originally, telomerase activity was detected using a direct assay that required 
large amounts of reagents including partially purified telomerase from cell extracts and 
radioactive substrates.  Issues related to the minute amounts of telomerase available from 
cultured cells were partially overcome by a PCR-based telomerase assay called the Telomeric 
Repeat Amplification Protocol (TRAP) (Kim et al., 1994).  By amplifying the telomerase 
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extension products, the TRAP assay allows detection of very small amounts of telomerase 
activity, though without the proper controls the TRAP assay is liable to yield problems such 
as false positives due to Taq DNA polymerase inhibition (Wright et al., 1995).  Both the 
direct telomerase assay and the TRAP assay, however, require gel analysis in order to 
visualize and quantify activity.  In order to bypass the requirement for gel electrophoresis, 
Francis and Friedman used a biotinylated primer that was bound to streptavidin-coated 96-
well plates after extension by telomerase with radioactive nucleotides (Francis and Friedman, 
2002).  Subsequent washing steps in the plate precluded the need for gel analysis.  Francis 
and Freidman also developed a modification of this assay that utilized PCR and PicoGreen to 
detect the amplification of double-stranded DNA (Francis and Friedman, 2003).  Their use of 
streptavidin-coated 96-well PCR plates allowed for rapid screening and inhibitor removal to 
prevent false positives resulting from inhibition of Taq polymerase during PCR (Francis and 
Friedman, 2003).  Kha et al. developed a similar high-throughput screen using streptavidin-
coated plates, however, this assay quantified activity using ELISA-based chemiluminescence 
and therefore did not require the use of radioactivity or electrophoresis (Kha et al., 2004).  
Atha et al. developed a high-throughput method to detect telomerase activity using a 
fluorescent-labeled primer, PCR-amplified products and capillary electrophoresis (Atha et 
al., 2003).  Savoysky et al. developed a screen utilizing both TRAP and scintillation 
proximity assay (SPA) technology (Bosworth and Towers, 1989; Savoysky et al., 1996).  A 
biotinylated primer was used to amplify telomerase extension products with [3H]-thymidine 
as one of the dNTPs.  Following extension and amplification, the products were captured on 
fluorophore-containing streptavidin-coated beads (Savoysky et al., 1996).  Notably, each of 
these screens reports directly on the enzymatic activity of telomerase.   
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We previously showed that hTRas010, a 2’-O-methyl modified oligonucleotide that 
targets nucleotides 301-322 of hTR and envelops the entire P6.1 stem-loop (targets nt’s 301-
322 of hTR), inhibits telomerase activity when added prior to hTR/hTERT assembly 
(Keppler and Jarstfer, 2004).  By using a co-immunoprecipitation assay, we determined that 
this inhibition was the result of blocking the association between hTERT and the CR4-CR5 
portion of hTR (Keppler and Jarstfer, 2004).  With this in mind, we developed a high-
throughput screen proficient in identifying telomerase assemblage modulators that 
specifically affected the interaction of hTERT with the CR4-CR5 domain of hTR.  Using 
SPA technology, we were able to develop a robust assay using a biotin-labeled derivative of 
the CR4-CR5 domain of hTR to capture [35S]-hTERT.     
 
 
B.  Results 
 
1.  Biotin-labeled CR4-CR5 domain binds hTERT 
 
Previously, we identified oligonucleotide hTRas010 as a nM telomerase inhibitor that 
functions by blocking the interaction between the CR4-CR5 domain of hTR and hTERT and 
therefore preventing assemblage of active telomerase (Keppler and Jarstfer, 2004).  This 
highly conserved RNA domain contains a short stem-loop, termed P6.1, that was identified 
by Chen and Greider (Chen et al., 2002) and subsequently characterized by NMR (Leeper 
and Varani, 2005) (Figure 6.1A, inset).  To facilitate the identification of small molecules 
that block this critical interaction we developed a high-throughput screen.  Due to the 
established use and commercial support of the streptavidin-biotin interaction for monitoring 
biomolecular interactions, we chose to use biotin-labeled CR4-CR5 domain RNA to capture 
hTERT on streptavidin beads.  Before developing the high-throughput screen, we first 
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confirmed that biotin labeled CR4-CR5 domain RNA could associate with hTERT.  The 
ability to capture [35S]-labeled hTERT with biotin-labeled CR4-CR5 RNA was determined 
biochemically using MPG streptavidin-coated beads (~20% efficiency).  We confirmed that 
biotin-labeled CR4-CR5 domain RNA could associate with hTERT and demonstrated that 
the addition of the known telomerase inhibitor hTRas010 inhibited the interaction when 
added prior to RNA/protein association (Figure 6.1B).  Importantly, negative controls with 
unbiotinylated RNA were unable to efficiently capture hTERT on the streptavidin beads (< 
5%). 
 
 
 
CR4-CR5
Domain
Template (CR1)
CR4-CR5 RNA Fragment
(nucleotides 243-328)
243 328
322
301P6
P6.1
35S-hTERT
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hTRas010 (µM):            0                          1
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 Figure 6.1  Structure and hTERT-binding inhibition of the CR4-CR5 domain of 
hTR.  (A) Proposed secondary structure of hTR.  The template and CR4-CR5 domain 
are indicated.  Inset: the P6.1 stem-loop-containing CR4-CR5 RNA fragment 
(nucleotides 243-328) used in the SPA.  Structure modified from Chen et al., 2002. 
(B)  Effect of 1 µM hTRas010 on the affinity purification of [35S]-hTERT using 
biotinylated CR4-CR5 RNA when added prior to protein/RNA association.    117
 
2.  A Scintillation Proximity Assay for hTERT-hTR interactions 
 
We examined several analytical techniques that are compatible with the demands of a 
high-throughput screen.  Filter binding assays were limited by the high background and 
fluorescence-based assays were incompatible with our current source of recombinant 
hTERT.  We therefore settled on and developed a SPA.  For the SPA, the same affinity 
purification principle as described above was used, except the readout was by scintillation 
counting as opposed to phosphorimaging.  In the absence of inhibitor, [35S]-hTERT can bind 
biotinylated RNA.  Upon the addition of streptavidin-coated SPA beads (Amersham 
Biosciences), the RNA can bring the [35S]-hTERT into close proximity with the fluorophore 
contained in the bead, thus eliciting a signal (Figure 6.2).  
Streptavidin SPA bead
hTERT
CR4-CR5
RNA
β emissions
35S
Signal produced 
by scintillant
Biotin
 
Figure 6.2  Assay schematics for scintillation proximity assay.  Biotinylated CR4-
CR5 RNA and radio-labeled hTERT associate.  The addition of streptavidin-SPA 
beads brings the [35S]-hTERT into close proximity to the beads and produces a 
scintillant signal. 
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3.  Validation of SPA 
 
Initially, prior to assay optimization, the SPA was run in concert with a low-
throughput affinity purification using a range of concentrations of hTRas010 to determine if 
the two assays reported similar results.  We found that the addition of hTRas010 to both the 
affinity purification and the SPA impeded the RNA/protein interaction in a concentration 
dependent manner yielding IC50 values of 0.89 µM and 1.22 µM, respectively (Figure 6.3).  
Notably, high concentration of hTRas010 completely impeded RNA/protein binding in the 
SPA.  The close comparison to the biochemical assay validated the SPA approach.  
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 Figure 6.3  Concentration dependence of hTRas010 in an affinity purification 
and a scintillation proximity assay.  Each concentration of hTRas010 was assayed 
in duplicate (A) or triplicate (B).  “% Activity” indicates the amount of residual 
activity as compared to the positive control.  IC50 curves and values were obtained as 
described in the Materials and methods.  Error bars indicate standard deviation and 
IC50 error indicates standard error. 
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4.  Optimization of SPA 
 
Several aspects of the CR4-CR5-hTERT SPA were optimized to ensure its efficient 
and accurate application for high-throughput data collection.  Various assay conditions were 
compared by calculating the Z-factor for each.  The Z-factor, first defined by Zhang et al., is 
a statistical parameter used to evaluate the robustness and usefulness of an assay (Zhang, J. 
H. et al., 1999a).  Generally, a Z-factor value between 0.5 and 1 is considered an excellent 
assay, whereas one between zero and 0.5 is marginal (Zhang, J. H. et al., 1999a).  
Optimizations included varying amount of biotin-labeled RNA, amounts of protein, bead 
concentration, blocking buffer components and concentrations, incubation time and order of 
addition.  Components were titrated and the amounts yielding the best Z-factor were 
implemented.  The optimum conditions are those listed in the Materials and methods section.  
Notably, the use and optimization of blocking buffer was a key step in the development of 
this assay as the absence of a blocking step resulted in both increased background signal and 
decreased RNA-bead interaction.  Furthermore, using a blocking buffer that contained 
herring sperm DNA and BSA yielded an assay with a better Z-factor when compared to 
assays containing yeast RNA and Casein as the blocking reagents.  Cross-talk between 
adjacent wells was also determined and found to be negligible.   
To demonstrate assay specificity, hTRas010MM, a modified mismatch 
oligonucleotide that is complimentary to the CR4-CR5 domain at 15 of its 22 nucleotides, 
was added to the SPA in place of hTRas010.  At 10 µM, the concentration at which 
hTRas010 inhibited  the SPA by  ~70%,  hTRas010MM had a negligible effect  (Figure 6.4,  
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 Figure 6.4  Effects of hTRas010 and hTRas010MM on the interaction between hTERT and 
the CR4-CR5 fragment of hTR.  “Pre-assembled” refers to hTERT and CR4-CR5 RNA pre-
assembled prior to oligonucleotide addition.  hTERT pre-assembled with RNA was prepared by 
adding 855 ng of in vitro transcribed biotinylated CR4-CR5 RNA to a 100 µL reticulocyte lysate 
reaction during translation of hTERT.  “% Activity” indicates the amount of residual activity as 
compared to the positive control.  Error bars indicate standard deviation  3).  Negative controls using unbiotinylated RNA, no RNA or an empty vector control 
 performed with no significant increase in signal.  We also performed a control in which 
RT and the CR4-CR5 RNA were pre-assembled prior to the addition of hTRas010.  
risingly, we found that the oligonucleotide was equally effective at preventing the 
/protein interaction in this instance as it is when added prior to assembly (Figure 6.4, 
pare lane 4 to lane 2).  This suggests that other hTR/hTERT contacts, such as those 
tified in the pseudoknot domain (Tesmer et al., 1999; Mitchell and Collins, 2000; 
pler and Jarstfer, 2004), affect the affinity or dissociation rate of the CR4-CR5 domain. 
Over a span of 11 days, the SPA was tested for inter-day and intra-column variability.  
obtained a positive signal of 251.2 x 103 cpm and a background signal of 77.6 x 103 cpm, 
 a Z-factor of 0.6 (Figure 6.5).  Due to 35S nuclide decay and the use of different [35S]-
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Met batches to translate hTERT, the scintillant signals from different assays were normalized 
to the background signals. 
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Figure 6.5  Precision of scintillation proximity assay for assembly of hTERT with CR4-CR5 
RNA under optimal conditions.  Inter-day and intra-column assay variation is represented.    
 
 
C.  Discussion 
 
There are many approaches used to detect telomerase activity.  Direct assays, PCR-
based TRAP assays and bead-based assays have all been adapted to high-throughput 
protocols with the goal of identifying novel, efficacious telomerase inhibitors (Bosworth and 
Towers, 1989; Savoysky et al., 1996; Francis and Friedman, 2002; Francis and Friedman, 
2003).  To date, however, there is presently no gold-standard FDA-approved anti-telomerase 
drug.  The identification of such a compound would have dramatic implications on cancer 
therapy as telomerase is found almost universally in cancer cells and its activity is required 
for cancer cell proliferation.  Therefore, there lies a need for the identification of a specific, 
high affinity telomerase inhibitor. To facilitate the discovery of such compounds, we 
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considered blocking telomerase-specific protein-RNA interactions.  Towards this end, the 
SPA described here was developed. 
Rather than screening for compounds which directly affect the enzymatic activity of 
telomerase, i.e. telomere extension, we set out to develop a high-throughput method to screen 
for compounds that inhibit proper telomerase assemblage.  We choose to target the CR4-CR5 
domain of hTR (Figure 6.1A) because it is a well-defined and structurally conserved region 
that has received much attention (Chen et al., 2000; Chen et al., 2002; Chen and Greider, 
2003).  Screening with full-length hTR was not performed because there are multiple 
hTR/hTERT contact sites that preclude the use of simplistic analytic methods required for 
high-throughput screening (Tesmer et al., 1999; Mitchell and Collins, 2000; Chen et al., 
2002; Chen and Greider, 2003; Keppler and Jarstfer, 2004).  The identification of a 
compound that perturbs all of these required contacts is unlikely, and the disruption of the 
CR4-CR5 domain binding to hTERT has been shown to be all that is needed to disrupt 
reconstituted telomerase activity (Chen et al., 2002; Keppler and Jarstfer, 2004).  
Furthermore, the NMR structure of the CR4-CR5 domain has been solved by Leeper and 
Varani, foreshadowing structural studies on CR4-CR5 domain-ligand complexes (Leeper and 
Varani, 2005).  Here we describe a method to rapidly identify novel inhibitors of telomerase 
assemblage in high-throughput format using scintillation proximity assay technology.   
Prior to SPA development, we confirmed that [35S]-hTERT could be affinity purified 
using biotinylated CR4-CR5 RNA and streptavidin beads (Figure 6.1B).  The same 
methodology was implemented for the SPA (Figure 6.2).  In the absence of inhibitor, the 
RNA/protein complex forms and binds to the streptavidin-coated SPA beads.  The close 
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proximity of the radio-labeled hTERT to the bead generates a positive signal when read on a 
microplate scintillation counter.   
The SPA was validated using a modified oligonucleotide previously shown to 
completely inhibit the association of hTERT with the CR4-CR5 portion of hTR (Keppler and 
Jarstfer, 2004).  Biochemical affinity purifications and scintillation proximity assays were 
performed concurrently to determine the concentration dependence of hTRas010 using these 
different methods.  Both techniques generated IC50’s in the 1 µM range thus validating the 
SPA (Figure 6.3).  The proven ability to completely eradicate binding in the SPA at high 
concentration of hTRas010 is important for the usefulness and quality of the assay.  
Noticeably there is a much greater error associated with the biochemical affinity purification 
than the SPA, particularly with the intermediate concentrations of hTRas010 (Figure 6.3A).  
This deviation is most likely due to human error during the many handling steps required for 
this procedure.  The error in the SPA data (Figure 6.3B), however, is minimal as the beads 
are handled only once and the filter plate washing steps are not prone to loss of beads, as is 
common in centrifugation-mediated affinity purifications.  Thus, the SPA could also find 
applications in biochemical-binding studies of the telomerase complex.  
SPA optimization was performed in order to increase the speed and sensitivity of the 
assay while decreasing nonspecific binding and cost.  The amounts of RNA, protein and 
beads were minimized as much as possible without greatly affecting signal strength.  Various 
common blocking buffer components were used in different combinations and concentrations 
in order to decrease the background signal and increase the Z-factor of the screen.  The order 
of addition was also optimized.  Ultimately, the delayed addition of the beads to the samples 
allowed for optimum RNA/protein association.  Importantly, this screen generated a Z-factor 
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value of 0.6, which is within the defined range of an “excellent assay,” as described by 
Zhang et al. (Zhang, J. H. et al., 1999a).  To determine assay specificity, we used a mismatch 
oligonucleotide.  hTRas010MM was found to have little effect on the SPA (Figure 6.4, lane 
3), indicating that the decrease in signal in the presence of hTRas010 is due to specific 
targeting and not a nonspecific effect of 2’-O-methyl RNA.  
The SPA described here has several advantages over other high-throughput screens in 
that there is no false positive-laden PCR step, a lower energy radionuclide (35S) is used when 
compared to 32P and the use of scintillation proximity beads negates the need for a 
scintillation cocktail.  Furthermore, by detecting changes in telomerase assemblage rather 
than changes in activity, this screen will identify telomerase inhibitors that would be missed 
by activity screens that use full-length hTR pre-assembled with hTERT.  For example, 
previous reports have shown that the addition of hTRas010 to a direct telomerase assay with 
pre-assembled telomerase has little effect on activity, whereas telomerase assembled in the 
presence of hTRas010 is inactive (Keppler and Jarstfer, 2004).  This is because hTRas010, 
when targeting the association between hTERT and full-length hTR, is only effective at 
inhibiting telomerase activity when added prior to hTERT interaction with the CR4-CR5 
domain of hTR.  The inhibitory potential of hTRas010, when targeting the association 
between hTERT and the CR4-CR5 domain only, however, is effective both before and after 
protein/RNA assembly (Figure 6.4, lanes 2 and 4).  This is presumably because when using 
full-length hTR, other hTR/hTERT contact points, such as those identified in the pseudoknot 
domain (Tesmer et al., 1999; Mitchell and Collins, 2000; Keppler and Jarstfer, 2004), hold 
the CR4-CR5 domain in place, thus preventing hTRas010 from inhibiting.  Because of the 
rapid rate at which hTERT-positive cancer cells divide, the high transcription rate of hTR (Yi 
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et al., 1999) and thus the likely high turnover rate of telomerase complexes, the identification 
of compounds that can only perturb hTR/hTERT interactions prior to telomerase assembly is 
therapeutically relevant. Additionally, we have shown that hTRas010 inhibits telomerase in 
cultured cells (unpublished data), which is not surprising as a PNA that binds to a similar 
region of hTR has been reported to inhibit cellular telomerase (Hamilton et al., 1999).  
Therefore, our assay will identify highly specific compounds that inhibit telomerase 
assemblage and therefore its enzymatic activity.  By conducting the assay with hTERT 
translated in rabbit reticulocyte lysates, the assay will identify compounds with greater 
selectivity than compounds identified in screens using purified materials. 
In comparison to performing direct activity assays or affinity purifications, our 
method greatly reduces both assay time and cost.  One 96-well SPA plate can be assayed in 4 
h, whereas it takes 10 h plus an overnight gel exposure for up to 25 samples in a direct assay 
or 6 h plus an overnight gel exposure for up to 25 samples when using affinity purification.  
Presently, our screen can be run at a cost of about $1 per compound.  Despite these 
advancements to past high-throughput assays, there obviously remains room for 
improvement particularly in decreasing the cost.   
Unlike the typical SPA protocol, our procedure does involve the removal of unbound 
ligand.  This is not due to non-proximity effects from the [35S]-hTERT, but because the 
protein is translated in rabbit reticulocyte lysates and the scintillant signal could not be 
detected through such a medium.  Though this necessitates an extra step, the use of 96-well 
filter plates to remove the surrounding medium allows for rapid simultaneous analysis of a 
large number of samples and greatly reduces assay time as compared to individual affinity 
purification washes.  However, it would be beneficial to express hTERT in a different 
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heterologous system other than reticulocyte lysates to remove this step and improve the cost 
effectiveness.  Unfortunately, hTERT expression in baculovirus is not trivial and bacterial 
expression systems are unable to translate hTERT, owing to its size (~127 kDa), poor 
solubility and other issues related to the complexity of this polypeptide.  Elucidation of RNA 
binding sites on hTERT could allow bacterial expression of smaller hTERT fragments that 
bind the CR4-CR5 domain of hTR.  In fact, this SPA is adaptable to the high-throughput 
characterization of hTERT point and truncation mutants that are capable of binding hTR, 
thus potentially revealing as yet undiscovered RNA-binding domains in the protein. 
 
 
D.  Materials and methods 
 
See Chapter II, section D for information on the pET-28c-hTERT expression plasmid 
and synthesis of hTERT.  See Chapter V, section D for a protocol for the synthesis of 
biotinylated CR4-CR5 RNA fragment.  We thank Dr. Gary M. Pollack for use of the 
TopCount™ NXT scintillation counter. 
 
1. Oligonucleotides.   
Modified oligonucleotides were purchased from Integrated DNA Technologies (IDT, 
Coralville, Iowa).  Concentrations were determined by UV absorbance at 260 nm using the 
molar extinction coefficient supplied by the manufacturer.  The sequence of hTRas010 is 
CGGCUGACAGAGCCCAACUCUU and the sequence of hTRas010MM is 
CGGCUCAGACACGGGAACUCUU.  All bases are 2’-O-methyl modified and underlined 
bases indicate phosphorothioate linkages.  
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2. Biochemical assay for the interaction between hTERT and the CR4-CR5 domain 
of hTR.    
 
Biotinylated RNA was used to capture [35S]-hTERT.  75 µL reactions contained 50 
µL (250 fmol) of 35S-labeled hTERT from a reticulocyte lysate reaction and 29 pmol of 
biotinylated CR4-CR5 RNA.  Inhibition studies also included varying amounts of hTRas010.  
Reactions were incubated at 30 °C for 90 min to allow assembly between the RNA and the 
protein. Each reaction was affinity purified using 50 µL of MPG® Streptavidin beads (Pure 
Biotech, LLC).  Prior to use, the beads were washed and blocked as described in Chapters II 
and V.  The beads were precipitated by centrifugation at 1500g for 30 sec.  The 75 µL 
assembly reaction was combined with 75 µL blocking buffer and centrifuged at 17000g for 
10 min at 4 °C to remove any precipitates. The assembly reaction was then added to the 
blocked beads and the samples were mixed on a rotary platform for 30 min at room 
temperature.  The beads were then washed and processed as described in Chapters II and V. 
 
3.  Scintillation Proximity Assay 
Each 15 µL assembly reaction contained 10 µL (50 fmol) [35S]-hTERT from an in 
vitro translation reaction and 2.9 pmol biotinylated CR4-CR5 RNA.  Negative controls 
contained either unbiotinylated RNA, no RNA or 10 µL of a translation reaction using an 
empty vector (pET-28c) in place of pET-28c-hTERT.  Inhibition-control reactions also 
included varying concentrations of hTRas010.  Prior to use, all reticulocyte lysate reactions 
were centrifuged at 17000g for 10 min at 4 °C to remove any precipitates.  Protein/RNA 
assembly reactions were incubated at 30 °C for 90 min in 96-well polystyrene microplates 
(OptiPlate-96, Packard).  For each SPA reaction, 0.4 mg Streptavidin PVT-SPA beads 
(Amersham Biosciences, Cat. # RPNQ0006) were used.  Prior to use, beads were washed 
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four times with 200 µL SPA buffer 1 (10 mM Tris-acetate, pH 7.5, 5% glycerol, 0.5 mM 
EDTA, 2.5 mM MgCl2, 50 mM potassium glutamate, 0.05% IGEPAL, 0.5 mM DTT) and 
blocked twice for 15 min at 4 °C with 200 µL of SPA blocking buffer (20 mM Tris-acetate, 
pH 7.5, 10% glycerol, 1 mM EDTA, 5 mM MgCl2, 100 mM potassium glutamate, 0.1% 
IGEPAL, 1 mM DTT, 0.05 mg/mL lysozyme, 0.5 mg/mL BSA, 0.05 mg/mL glycogen, 0.1 
mg/mL herring sperm DNA (Promega)).  The beads were precipitated by centrifugation at 
4000g for 2 min.  Precipitating the beads from the SPA blocking buffer first required the 
addition of an equal volume of H2O in order to prevent bead buoyancy due to high glycerol 
concentrations.  Large batch preparations of beads were possible by scaling up the above 
procedure.  To initiate the SPA, 15 µL assembly reactions were combined with 15 µL 
blocking buffer and 0.4 mg blocked beads and incubated for 30 min at room temperature.  
Reactions were transferred to a 96-well MultiScreen® HTS filter plate (Millipore, Cat. 
#MSDNV6B) that had been pre-wet with 200 µL SPA buffer 2 (10 mM Tris-acetate, pH 7.5, 
5% glycerol, 0.5 mM EDTA, 2.5 mM MgCl2, 150 mM potassium glutamate, 0.05% 
IGEPAL, 0.5 mM DTT).  Samples were filtered using a MultiScreen® Resist Vacuum 
Manifold (Millipore, Cat. #MAVM0960R).  The trapped beads were washed four times with 
200 µL of SPA buffer 2, ceasing the vacuum pressure in between each wash.  Once 
completed, the underdrain was removed from the filter plate and the top and bottom of the 
plate were covered with clear and opaque tape, respectively, per the manufacturer’s 
instructions.  The plate was then read on a TopCount™ NXT scintillation counter (Packard, 
version 1.06).  TopCount™ instrument settings used can be found at 
www.amershambiosciences.com/spa.  After subtracting the background signal (negative 
control with no RNA), the SPA signals for the experimental samples were compared to that 
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for the positive control.  Unused beads were stored in SPA buffer 1 (minus the DTT) at 4 °C 
and were used within 10 days.  All liquid transfer steps could be conducted with multi-
channel pipettors or robotic liquid handling devices. 
 
4.  Inhibition studies 
Affinity purifications and SPA assays were conducted as described above with 
varying concentrations of hTRas010.  Five data points were used with oligonucleotide 
concentrations ranging from 10 nM to 100 µM.  IC50 values were calculated and inhibition 
data were plotted as described in Chapter II. 
 
5.  Z-factor determination  
The Z-factor (Z’), first described by Zhang et al. (Zhang, J. H. et al., 1999a), was 
calculated using the following equation 
Z’ = 1-
(3σmax + 3σmin)
( |SPAmax – SPAmin| )
 
where σmax is the standard deviation of the maximum signal (positive control), σmin is the 
standard deviation of the minimum signal (negative control), SPAmax is the mean of the 
maximum signal and SPAmin is the mean of the minimum signal. 
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Chapter VII.  Conclusions and future directions of this research 
 
 
 This research describes the design, development and validation of a new mode of 
human telomerase inhibition.  Through the use of oligonucleotides and known nucleic-
binding compounds, it was shown that this methodology of perturbing proper telomerase 
assemblage represents an innovative modality for inhibiting telomerase.  The screening of a 
small library of compounds and identification of a structurally related group of natural 
products and derivatives as telomerase inhibitors further solidified this approach.  This work 
has also further elucidated the roles of hsp90 in maintaining an active telomerase complex for 
the purpose of understanding telomerase holoenzyme assemblage requirements. It was shown 
that hsp90 is involved in both telomerase primer-binding competence and holoenzyme 
stability.  In order to adapt this method of telomerase inhibition to a high-throughput 
approach a scintillation proximity assay screen was initiated.  The development of this screen 
is the first step toward identifying a new class of telomerase inhibitor. 
Recently, other functions of telomerase besides DNA synthesis have been suggested 
to contribute to the survival of cancer cells (Stewart et al., 2002).  Notably, telomerase 
appears capable of inhibiting apoptosis by a mechanism that is independent of telomere 
maintenance (Cao et al., 2002; Rahman et al., 2004).  Some believe that this is achieved via 
telomerase’s potential involvement in capping and protecting the telomere (Blackburn, E., 
1999; Blackburn, E. H., 2000; Blackburn, E. H., 2001; Masutomi et al., 2003).  This suggests 
that simply targeting its enzymatic activity may not achieve the maximum potential of 
telomerase-targeted therapeutics.  It is believed that the method of telomerase inhibition 
described in this thesis will be a more effective approach in the abrogation of cancer cells as 
telomerase assemblage inhibitors may have the potential to not only perturb telomerase’s 
ability to maintain telomere length, but also its anti-apoptotic role in tumorigenesis.  
Preventing the proper assemblage of the holoenzyme could seize telomerase in an inactive 
state by preventing the dissociation of hTR and hTERT, thus generating an in situ dominant 
negative complex that is incapable of performing its telomere capping function or other 
functions unrelated to DNA synthesis.   
The identification of potent telomerase assemblage inhibitors will likely have a 
profound impact on the relentless fight against cancer.  Future clinically approved telomerase 
inhibitors will almost certainly be used as an adjuvant to increase the efficacy of additional 
chemotherapeutics as a two-pronged approach toward cancer cell attack. 
Future studies in the field of telomerase assembly inhibition will focus on the 
characterization of hTR binding sites on hTERT and the determination of compound target 
sites on telomerase, as well as cellular in vivo experiments.  Presently, not much is known 
about the structure of hTERT due to the inability to completely purify it to homogeneity.  
Additionally, large scale translation of recombinant wild-type hTERT with commonly used 
viral and bacterial expression systems has proven to be an arduous task.  Recently, however, 
the Cech laboratory has used high-throughput methods to characterize portions of the 
telomerase catalytic protein from Tetrahymena by identifying and over-expressing soluble 
truncated tTERT fragments in E. coli (Jacobs et al., 2005).  Analysis of these fragments, 
which can be purified to homogeneity, revealed the presence of an independently folded 
domain at the N-terminus of tTERT.  This approach is also adaptable to hTERT structural 
 132
identification, which, along with other studies such as limited proteolytic digestion, NMR 
spectroscopy and hTR binding studies, will ultimately reveal the specific hTERT amino acids 
involved in hTR/hTERT assembly.  Furthermore, once soluble hTERT fragments are 
expressed, the scintillation proximity assay screen described in Chapter VI can also be 
adapted identify the region(s) of hTERT that interact with the CR4-CR5 domain of hTR.  
Subsequently, additional RNA-binding domains of hTERT can then be identified by 
replacing the biotinylated CR4-CR5 RNA fragment in the SPA with other biotinylated hTR 
domains known to independently bind hTERT. 
 Surface Plasmon Resonance (SPR) can be utilized to determine if a compound binds 
to either hTR or hTERT.  SPR involves the immobilization of a target on a sensor chip and 
the measurement of the change in the angle of polarized reflected light off of the chip as the 
compound is passed over the target (Biacore website: 
http://www.biacore.com/technology/spr_technology.lasso#).  This technique yields real-time 
measurements and allows for the determination of stoichiometry and on/off rates for the 
binding between target and compound.  Determination of compound binding to hTERT, 
however, will have to await the development of a high-yield hTERT expression protocol as 
the use of a protein as the target in SPR requires more purified material than is presently 
reasonably able to be expressed.  Alternatively, verification of compound/target interaction 
can be accomplished using amine-reactive fluorescent dyes such as 5-
carboxytetramethylrhodamine, succinimidyl ester (5-TAMRA, SE) or 5-carboxyfluorescein, 
succinimidyl ester (5-FAM, SE) (Molecular Probes).  After allowing fluorescent 
compound/target association, detection of the relative fluorescence on various independent 
domains of hTR for example should shed light on the compound’s specific target site(s).  The 
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protocols for conjugation and measuring the change in fluorescent absorbance are relatively 
simple, however, this method can only be used to test amine-containing compounds.     
Following the identification and binding characterization of telomerase assemblage 
inhibitors in vitro, cellular studies should be performed to confirm that the compound not 
only inhibits enzymatic activity, but also decreases telomere length, limits proliferation and 
induces apoptosis.  Compound-induced inhibition of activity will typically be detected by the 
PCR-based TRAP assay since the low levels of telomerase expressed in cancer cells are 
difficult to detect using a direct assay.  Changes in telomere length upon inhibitor treatment 
should be performed by restriction digest of genomic DNA followed by Southern blot 
analysis using a telomeric probe, for example.  Proliferation rates can be determined using 
basic cell culture and counting methods while the induction of apoptosis can be monitored by 
terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL).  
Furthermore, in terms of compound specificity for telomerase, the time is takes a cell to 
senesce after being treated with a telomerase assemblage inhibitor should be proportional to 
the initial telomere length of the cell (White et al., 2001). 
Cellular studies to define the mechanism(s) of compound-induced telomerase 
inhibition should also be performed.  Even if a compound is shown to bind to hTR or hTERT 
in vivo, it may also interact with other cellular entities (enzymes, nucleic acids, etc.) resulting 
in decreased proliferation and/or cell death if it is promiscuous and has low specificity for 
telomerase.  Prior to cell studies, therefore, compounds should be screened in vitro for their 
specificity toward telomerase versus other polymerases, for example (see Figure 4.4).  
Compound-induced cytotoxicity should also be assayed in multiple cells lines, including 
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those that are hTERT-negative, in order to determine if the toxicity is telomerase-dependent 
(see Figure 4.5A).   
Additionally, cellular studies to test the hypothesis that telomerase assemblage 
inhibitors induce the formation of an in vivo dominant negative complex will also further 
define and advance the field of telomerase assemblage inhibition.  Most screened compounds 
identified as telomerase assemblage inhibitors are expected to affect only a single hTR-
hTERT contact point, which will continue to allow the two subunits to associate, however in 
an inactive and misshapen form that is unable to bind and maintain telomere length or 
telomere structure.  Therefore, this could possibly be achieved by first treating a cancer cell 
line with a defined telomerase assemblage inhibitor and affinity purifying hTR from cells to 
detect the presence of hTERT via Western blot.  The continued association of hTERT with 
hTR would suggest that the inhibitor paralyzes the complex, thus perturbing activity and 
preventing hTR/hTERT dissociation.  This, however, would not decidedly reveal if the 
inactive telomerase complex was incapable of binding the telomere.  This feat could be 
approached with electron microscopy, though large amounts of the enzyme purified to 
homogeneity would most likely be required.  Alternatively, affecting this secondary role of 
telomerase in tumorigenesis has been shown to lead to apoptosis without affecting telomere 
length or inducing senescence (Hao et al., 2005).  Telomerase assemblage inhibitors eliciting 
this same behavior would thus be evidence that they also have adverse effects on the anti-
apoptotic role of telomerase. 
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